Hologic (HOLX) 10-K 16 Nov 21 2021 FY Annual report Financial data

Cover Page

Cover Page - USD ($)	12 Months Ended
	Sep. 25, 2021	Nov. 11, 2021	Mar. 27, 2021
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Sep. 25, 2021
Document Transition Report	false
Entity File Number	1-36214
Entity Registrant Name	HOLOGIC, INC
Entity Central Index Key	0000859737
Current Fiscal Year End Date	--09-25
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-2902449
Entity Address, Address Line One	250 Campus Drive
Entity Address, City or Town	Marlborough
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01752
City Area Code	508
Local Phone Number	263-2900
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	HOLX
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 18,639,078,720
Entity Common Stock, Shares Outstanding		251,420,529
Documents Incorporated by Reference	Portions of the registrant’s Proxy Statement for the registrant’s annual meeting of stockholders to be filed within 120 days of the end of its fiscal year ended September 25, 2021 are incorporated into Part III (Items 10, 11, 12, 13 and 14) of this Annual Report on Form 10-K where indicated.

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Revenues:
Revenue from product and services	$ 5,632.3	$ 3,776.4	$ 3,367.3
Costs of revenues:
Amortization of acquired intangible assets	276.7	253.2	318.5
Impairment of intangible assets and equipment	0	25.8	578.7
Gross Profit	3,795.8	2,227.5	1,170.9
Operating expenses:
Research and development	276.3	222.5	232.2
Selling and marketing	561.2	484.6	564.9
General and administrative	433.2	355.7	332.3
Amortization of acquired intangible assets	42.2	39.7	52
Impairment of intangible assets and equipment	0	4.4	106.7
Contingent consideration – fair value adjustments	(6.7)	0.3	0
Restructuring and divestiture charges	9.3	15.3	6.6
Operating expenses	1,315.5	1,122.5	1,294.7
Income (loss) from operations	2,480.3	1,105	(123.8)
Interest income	1.4	4.3	4.6
Interest expense	(93.6)	(116.5)	(140.8)
Debt extinguishment losses	(21.6)	0	(0.8)
Other income (expense), net	(5.4)	9.1	3.1
Income (loss) before income taxes	2,361.1	1,001.9	(257.7)
Provision (benefit) for income taxes	491.4	(108.6)	(54.1)
Net income (loss)	1,869.7	1,110.5	(203.6)
Net loss attributable to noncontrolling interest	(1.8)	(4.7)
Net income (loss) attributable to Hologic	$ 1,871.5	$ 1,115.2	$ (203.6)
Net income (loss) per common share attributable to Hologic:
Basic (in dollars per share)	$ 7.28	$ 4.24	$ (0.76)
Diluted (in dollars per share)	$ 7.21	$ 4.21	$ (0.76)
Weighted average number of shares outstanding:
Basic (in shares)	257,046	262,727	269,413
Diluted (in shares)	259,706	264,613	269,413
Product
Revenues:
Revenue from product and services	$ 4,967.3	$ 3,227	$ 2,771.3
Costs of revenues:
Cost of goods and services sold	1,205.1	953.7	948.7
Service
Revenues:
Revenue from product and services	665	549.4	596
Costs of revenues:
Cost of goods and services sold	$ 354.7	$ 316.2	$ 350.5

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Net income (loss)	$ 1,869.7	$ 1,110.5	$ (203.6)
Changes in foreign currency translation adjustment	(20.2)	18.5	(14.8)
Changes in pension plans, net of taxes of $0.2 in 2021, $0.1 in 2020, and $0.3 in 2019	0.5	(0.1)	(0.6)
Other comprehensive loss	(9.4)	(7.4)	(16.8)
Comprehensive income (loss)	1,860.3	1,103.1	(220.4)
Comprehensive loss attributable to noncontrolling interest	1.8	4.7	0
Comprehensive income (loss) attributable to Hologic	1,862.1	1,107.8	(220.4)
Interest rate caps - derivative
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax	0.4	(0.5)	(8)
Loss reclassified from accumulated other comprehensive loss to the statement of operations, net	(0.5)	(2.3)	(3.1)
Interest Rate Swap [Member]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax	$ 9.4	$ (27.6)	$ 3.5

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Change in pension plans, tax	$ 0.2	$ 0.1	$ 0.3
tax on interest rate swap	2.5	(8.3)	1.2
Interest rate caps - derivative
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax	$ 0.2	$ 0.5	$ 1.1

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 25, 2021	Sep. 26, 2020
Current assets:
Cash and cash equivalents	$ 1,170.3	$ 701
Accounts receivable	942.7	1,028.9
Inventory	501.2	395.1
Prepaid income taxes	25.7	38.8
Prepaid expenses and other current assets	528.8	58.5
Total current assets	3,168.7	2,222.3
Property, plant and equipment, net	564.7	491.5
Intangible assets, net	1,659.2	1,307.5
Goodwill	3,281.6	2,657.9
Other assets	245.7	516.6
Total assets	8,919.9	7,195.8
Current liabilities:
Current portion of long-term debt	313	324.9
Accounts payable	215.9	178.8
Accrued expenses	596.2	547.6
Deferred revenue	198	186.1
Finance lease liabilities (current)	3.7	1.9
Total current liabilities	1,326.8	1,239.3
Long-term debt, net of current portion	2,712.2	2,713.9
Finance lease liabilities (non-current)	22.8	17.4
Deferred income tax liabilities	250.5	201.8
Deferred revenue, net of current portion	20.3	12.9
Other long-term liabilities	368.7	303.2
Commitments and contingencies (Note 13 and 14)
Stockholders’ equity:
Preferred stock, $0.01 par value – 1,623 shares authorized; 0 shares issued	0	0
Common stock, $0.01 par value – 750,000 shares authorized; 297,306 and 295,107 shares issued, respectively	3	2.9
Additional paid-in-capital	5,965.8	5,904.8
Accumulated earnings (deficit)	298.3	(1,573.2)
Treasury stock, at cost – 43,653 and 37,609 shares, respectively	(1,989.4)	(1,579.6)
Accumulated other comprehensive loss	(59.1)	(49.7)
Total Hologic's stockholders’ equity	4,218.6	2,705.2
Noncontrolling interest	0	2.1
Total stockholders' equity	4,218.6	2,707.3
Total liabilities and stockholders’ equity	$ 8,919.9	$ 7,195.8

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 25, 2021	Sep. 26, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,623,000	1,623,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	750,000,000	750,000,000
Common stock, shares issued (in shares)	297,306,000	295,107,000
Treasury stock (in shares)	43,653,000	37,609,000

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands	Total	Share Repurchase Program [Member]	Common Stock [Member]	Additional Paid-in-Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income [Member]	Treasury Stock [Member]	Treasury Stock [Member]Share Repurchase Program [Member]	Noncontrolling Interest
Balance (in shares) at Sep. 29, 2018			289,900				19,812
Balance at Sep. 29, 2018	$ 2,428,800,000		$ 2,900,000	$ 5,671,300,000	$ (2,494,000,000)	$ (25,500,000)	$ (725,900,000)		$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting standard transition adjustment - ASC 606	6,400,000				6,400,000
Accounting standard transition adjustment - ASU 2016-16	2,500,000				2,500,000
Exercise of stock options (in shares)			1,304
Stock Issued During Period, Value, Stock Options Exercised	32,800,000			32,800,000
Vesting of restricted stock units, net of shares withheld for employee taxes (in shares)			645
Restricted Stock, Value, Shares Issued Net of Tax Withholdings	(12,800,000)			(12,800,000)
Common stock issued under the employee stock purchase plan (in shares)			474
Stock Issued During Period, Value, Employee Stock Purchase Plan	16,500,000			16,500,000
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	62,000,000			62,000,000
Repurchase of common stock (in shares)							4,826
Treasury Stock, Value, Acquired, Par Value Method	(200,100,000)						$ (200,100,000)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent	(14,800,000)					(14,800,000)
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent	(600,000)					(600,000)
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax	(8,000,000)					(8,000,000)
Unrealized gain on interest rate swap	3,500,000					3,500,000
Net income (loss) attributable to Hologic	(203,600,000)				(203,600,000)
Balance (in shares) at Sep. 28, 2019			292,323				24,638
Balance at Sep. 28, 2019	2,115,700,000		$ 2,900,000	5,769,800,000	(2,688,700,000)	(42,300,000)	$ (926,000,000)		0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax						3,100,000
Exercise of stock options (in shares)			1,761
Stock Issued During Period, Value, Stock Options Exercised	48,300,000			48,300,000
Vesting of restricted stock units, net of shares withheld for employee taxes (in shares)			611
Restricted Stock, Value, Shares Issued Net of Tax Withholdings	(14,200,000)			(14,200,000)
Common stock issued under the employee stock purchase plan (in shares)			412
Stock Issued During Period, Value, Employee Stock Purchase Plan	17,600,000			17,600,000
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	83,300,000			83,300,000
Repurchase of common stock (in shares)							9,064	3,907
Treasury Stock, Value, Acquired, Par Value Method	(448,600,000)	$ (205,000,000)					$ (448,600,000)	$ (205,000,000)
Unrealized gain (loss) on interest rate cap, net of taxes	(500,000)					(500,000)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent	18,500,000					18,500,000
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent	(100,000)					(100,000)
Unrealized gain on interest rate swap	(27,600,000)					(27,600,000)
Net income (loss) attributable to Hologic	1,110,500,000				1,115,200,000				(4,700,000)
Noncontrolling Interest, Increase from Business Combination	8,600,000								8,600,000
Accounting standard transition adjustment - ASC 842 | Accounting Standards Update 2018-01 [Member]					300,000
Balance (in shares) at Sep. 26, 2020			295,107				37,609
Balance at Sep. 26, 2020	$ 2,707,300,000		$ 2,900,000	5,904,800,000	(1,573,200,000)	(49,700,000)	$ (1,579,600,000)		2,100,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax						2,300,000
Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests									1,800,000
Exercise of stock options (in shares)	800		857
Stock Issued During Period, Value, Stock Options Exercised	$ 32,900,000			32,900,000
Vesting of restricted stock units, net of shares withheld for employee taxes (in shares)			980
Restricted Stock, Value, Shares Issued Net of Tax Withholdings	(47,500,000)			(47,600,000)
Common stock issued under the employee stock purchase plan (in shares)			362
Stock Issued During Period, Value, Employee Stock Purchase Plan	18,900,000			18,900,000
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	65,000,000			65,000,000
Repurchase of common stock (in shares)							6,044
Treasury Stock, Value, Acquired, Par Value Method	(409,800,000)						$ (409,800,000)
Unrealized gain (loss) on interest rate cap, net of taxes	400,000					400,000
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent	(20,200,000)					(20,200,000)
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent	500,000					500,000
Unrealized gain on interest rate swap	9,400,000					9,400,000
Net income (loss) attributable to Hologic	1,869,700,000				1,871,500,000				(1,800,000)
Balance (in shares) at Sep. 25, 2021			297,306				43,653
Balance at Sep. 25, 2021	4,218,600,000		$ 3,000,000	5,965,800,000	$ 298,300,000	(59,100,000)	$ (1,989,400,000)		0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Purchase of non-controlling interest reclassified to APIC				$ (8,200,000)
Change in par value	100,000
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax						$ 500,000
Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests	$ 8,500,000								$ (300,000)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
OPERATING ACTIVITIES
Net income (loss)	$ 1,869,700,000	$ 1,110,500,000	$ (203,600,000)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation	88,000,000	83,100,000	92,500,000
Amortization	318,900,000	292,900,000	370,600,000
Stock-based compensation expense	65,000,000	83,300,000	62,000,000
Deferred income taxes and other non-cash taxes	(70,100,000)	(94,400,000)	(235,700,000)
Impairment of intangible assets and equipment	0	30,200,000	685,400,000
Debt extinguishment loss	21,600,000	0	800,000
Other adjustments and non-cash items	24,300,000	27,300,000	33,800,000
Changes in operating assets and liabilities, excluding the effect of acquisitions and dispositions:
Accounts receivable	110,900,000	(427,100,000)	(76,500,000)
Inventory	(84,100,000)	(25,300,000)	(63,000,000)
Prepaid income taxes	13,000,000	(3,800,000)	(3,200,000)
Prepaid expenses and other assets	(56,300,000)	(286,200,000)	(6,000,000)
Accounts payable	20,400,000	(4,900,000)	(5,500,000)
Accrued expenses and other liabilities	(4,900,000)	96,000,000	(16,500,000)
Deferred revenue	14,000,000	15,000,000	14,400,000
Net cash provided by operating activities	2,330,400,000	896,600,000	649,500,000
INVESTING ACTIVITIES
Acquisition of businesses, net of cash acquired	(1,164,700,000)	(119,400,000)	(110,600,000)
Net proceeds from sale of business	0	139,300,000	0
Payments to Acquire Equity Method Investments	0	0	(18,200,000)
Loans to SSI	0	0	(28,400,000)
Purchase of property and equipment	(96,800,000)	(98,300,000)	(57,000,000)
Increase in equipment under customer usage agreements	(59,400,000)	(58,100,000)	(52,100,000)
Payments to Acquire in Process Research and Development	6,500,000	0	4,500,000
Other activity	(2,200,000)	(5,100,000)	(9,900,000)
Net cash used in investing activities	(1,329,600,000)	(141,600,000)	(280,700,000)
FINANCING ACTIVITIES
Proceeds from long-term debt, net of issuance costs	0	0	1,497,300,000
Repayment of long-term debt	(75,000,000)	(45,800,000)	(1,465,000,000)
Proceeds from Senior Notes	936,300,000	0	0
Repayment of Senior Notes	(970,800,000)	0	0
Proceeds from revolving credit line	0	750,000,000	480,000,000
Repayments under revolving credit line	(250,000,000)	(500,000,000)	(780,000,000)
Proceeds from accounts receivable securitization agreement	320,000,000	16,000,000	43,000,000
Repayments under accounts receivable securitization agreement	(71,500,000)	(250,000,000)	(34,000,000)
Payments to Noncontrolling Interests	(8,500,000)	(1,800,000)	0
Repurchases of common stock	(409,800,000)	(653,600,000)	(200,100,000)
Payments for Previous Acquisition	1,900,000	24,300,000	6,500,000
Purchase of interest rate caps	0	0	(1,500,000)
Net proceeds from issuance of common stock under employee stock plans	51,300,000	65,600,000	49,800,000
Payment of minimum tax withholdings on net share settlements of equity awards	(47,500,000)	(14,300,000)	(12,800,000)
Payments under finance lease obligations	2,400,000	1,700,000	1,700,000
Net cash used in financing activities	(529,800,000)	(659,900,000)	(431,500,000)
Effect of exchange rate changes on cash and cash equivalents	(1,700,000)	4,100,000	(2,200,000)
Net increase (decrease) in cash and cash equivalents	469,300,000	99,200,000	(64,900,000)
Cash and cash equivalents, beginning of period	701,000,000	601,800,000	666,700,000
Cash and cash equivalents, end of period	$ 1,170,300,000	$ 701,000,000	$ 601,800,000

Operations

Operations	12 Months Ended
	Sep. 25, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Operations	Operations Hologic, Inc. (the “Company” or “Hologic”) develops, manufactures and supplies premium diagnostics products, medical imaging systems, and surgical products with an emphasis on women's health and well-being through early detection and treatment. Until December 30, 2019, the Company's product portfolio included light-based aesthetic and medical treatment systems sold by its former Medical Aesthetics business. The Company completed the sale of its Medical Aesthetics segment on December 30, 2019 (the first day of the second quarter of fiscal 2020). COVID-19 Considerations The global COVID-19 pandemic has created significant volatility, uncertainty, and economic disruption in the markets the Company sells its products into, primarily the U.S., Europe and Asia-Pacific. Starting in the second quarter of fiscal 2020, the spread of COVID-19 negatively impacted business and healthcare activity globally. In particular, due to government measures, elective procedures and exams were delayed or cancelled, there were significant reductions in physician office visits, and hospitals postponed or canceled capital purchases as well as limited or eliminated services; however, in the second half of the third quarter of fiscal 2020, the Company started to see a recovery of elective procedures and exams as economies were opened back up and restrictions eased, which has continued through the fourth quarter of fiscal 2021. The reductions in testing and procedures had a negative impact on the Company's operating results and cash flows in fiscal 2020, however, the impact of the commercial release of its COVID-19 assays more than offset those negative impacts as the Company generated significant revenue from the sales of these assays starting in the third quarter of fiscal 2020 through the fourth quarter of fiscal 2021. While the Company's results of operations and cash flows since the third quarter of fiscal 2020 have been positively impacted by the sale of its COVID-19 assays as well the continued recovery of its other primary product lines and businesses to pre-COVID levels, the COVID-19 pandemic could have an adverse impact on its operating results, cash flows and financial condition in the future. The factors that could create such adverse impact include: reduced demand for COVID-19 testing; competition from existing and new COVID-19 testing technologies and products as well as the timing and effectiveness of distributing vaccines; the severity and duration of the COVID-19 pandemic; the resurgence of COVID-19 infections; the emergence of new COVID strain variants; the COVID-19 pandemic's impact on the U.S. and international healthcare systems, the U.S. economy and worldwide economy; and the timing, scope and effectiveness of U.S. and international governmental, regulatory, fiscal, monetary and public health responses to the COVID-19 pandemic and associated economic disruptions. The Company expects that as the current COVID-19 pandemic subsides, there may be a significantly reduced demand for ongoing testing, and thus, for its COVID-19 assays. As expected in the third quarter of fiscal 2021, revenues generated from the sale of its COVID-19 assays decreased significantly in the U.S. compared to the prior year period and the first and second quarters of fiscal 2021 as the population of vaccinated people continues to grow in the U.S. In the fourth quarter of fiscal 2021, COVID-19 assay revenues increased compared to the preceding quarter primarily due to the impact of the delta strain of COVID-19 resulting in higher demand for testing, however COVID-19 assay revenues decreased compared to the corresponding prior year period. In response to the negative impact of COVID-19 on the Company's business, in April 2020, the Company initiated cost-cutting measures, which included not only reducing discretionary and variable spend, such as travel, marketing programs and the use of contractors, consultants and temporary help, but the Company also implemented employee furloughs, salary cuts primarily in the U.S., reduced hours and in certain instances, effected employee terminations. Further in April 2020, the Company shut down certain manufacturing facilities temporarily and implemented reduced work-week schedules in response to lower near-term demand for many of its products. As of the end of the third quarter of fiscal 2020, substantially all of the Company's employee cost-cutting measures ceased During fiscal 2021, the majority of the impacted manufacturing facilities were back to pre-COVID levels. The Company has also taken and continue to take measures to ensure the safety of its employees and to comply with governmental orders. These measures could require that the Company's employees continue to work remotely or otherwise refrain from reporting to their normal workplace for extended periods of time, which in turn could result in a decrease in the Company's commercial and marketing activities. In addition, complying with government and customer vaccine mandates that apply to the Company may lead to employee attrition, disruption to the Company's workforce and result in additional costs associated with implementation and on-going compliance, which could have an adverse impact on the Company's operating results, cash flows and financial condition.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Sep. 25, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The Company’s fiscal year ends on the last Saturday in September. Fiscal 2021, 2020 and 2019 ended on September 25, 2021, September 26, 2020 and September 28, 2019, respectively. Fiscal 2021, 2020 and 2019 were 52-week years. Subsequent Events Consideration The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence for certain estimates or to identify matters that may require additional disclosure. Subsequent events have been evaluated as required. There were no material recognized or unrecognized subsequent events, except as described below, recorded in the consolidated financial statements as of and for the year ended September 25, 2021. On September 27, 2021, the Company refinanced its term loan and revolving credit facility. For additional information, refer to Note 7. On October 14, 2021, the Company announced that it had entered into an agreement to acquire Bolder Surgical, Inc. ("Bolder Surgical") for a purchase price of approximately $160.0 million. The closing is subject to certain regulatory approvals, but the Company expects to close this acquisition by the end of calendar 2021. Bolder Surgical, located in Louisville, CO, is a developer and manufacturer of energy vessel sealing surgical devices in both laparoscopic and open procedures. Management’s Estimates and Uncertainties The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions by management affect the Company’s revenue recognition for multiple performance obligation arrangements, valuations, purchase price allocations and contingent consideration related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets and goodwill, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, restructuring and other related charges, contingent liabilities, tax reserves, deferred tax rates and recoverability of the Company’s net deferred tax assets and related valuation allowances, and stock-based compensation. Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. The Company is subject to a number of risks similar to those of other companies of similar size in its industry, including dependence on third-party reimbursements to support the markets of the Company’s products, early stage of development of certain products, rapid technological changes, recoverability of long-lived assets (including intangible assets and goodwill), competition, stability of world financial markets, ability to obtain regulatory approvals, changes in the regulatory environment, limited number of suppliers, customer concentration, integration of acquisitions, substantial indebtedness, government regulations, management of international activities, protection of proprietary rights, patent and other litigation, dependence on contract manufacturers and dependence on key individuals. Cash Equivalents Cash equivalents are highly liquid investments with insignificant interest rate risk and maturities of three months or less at the time of acquisition. Concentrations of Credit Risk Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents, cost-method investments and trade accounts receivable. The Company invests its cash and cash equivalents with high credit quality financial institutions. The Company’s customers are principally located in the U.S., Europe and Asia. The Company performs ongoing credit evaluations of the financial condition of its customers and generally does not require collateral. Although the Company is directly affected by the overall financial condition of the healthcare industry, as well as global economic conditions, management does not believe significant credit risk exists as of September 25, 2021. The Company generally has not experienced any material losses related to receivables from individual customers or groups of customers in the healthcare industry. The Company maintains an allowance for doubtful accounts based on accounts past due and historical collection experience. There were no customers with a balance greater than 10% of accounts receivable as of September 25, 2021. There was one customer with a balance greater than 10% of accounts receivable as of September 26, 2020, at 11.9%. There were no customers that represented greater than 10% of consolidated revenues for fiscal years 2021, 2020 and 2019. Concentration of Suppliers The Company purchases certain components of its products from a single or small number of suppliers. A change in or loss of these suppliers could cause a delay in filling customer orders and a possible loss of sales, which could adversely affect results of operations. Supplemental Cash Flow Statement Information Years ended September 25, 2021 September 26, 2020 September 28, 2019 Cash paid during the period for income taxes $ 615.1 $ 265.9 $ 180.6 Cash paid during the period for interest $ 93.2 $ 109.5 $ 132.5 Non-Cash Financing Activities: Fair value of contingent consideration at acquisition $ — $ 82.7 $ — Inventories Inventories are valued at the lower of cost or market on a first in, first out basis. Work-in-process and finished goods inventories consist of materials, labor and manufacturing overhead. The valuation of inventory requires management to estimate excess and obsolete inventory. The Company employs a variety of methodologies to determine the net realizable value of its inventory. Provisions for excess and obsolete inventory are primarily based on management’s estimates of forecasted sales, usage levels and expiration dates, as applicable for certain disposable products. A significant change in the timing or level of demand for the Company’s products compared to forecasted amounts may result in recording additional charges for excess and obsolete inventory in the future. The Company records charges for excess and obsolete inventory within cost of product revenues. Inventories consisted of the following: September 25, 2021 September 26, 2020 Raw materials $ 163.3 $ 152.3 Work-in-process 53.0 46.5 Finished goods 284.9 196.3 $ 501.2 $ 395.1 Property, Plant and Equipment Property, plant and equipment is recorded at cost less allowances for depreciation and impairments. The straight-line method of depreciation is used for all property and equipment. Property, plant and equipment consisted of the following: Estimated Useful Life September 25, 2021 September 26, 2020 Equipment 3–10 years $ 467.1 $ 460.7 Equipment under customer usage agreements 3–8 years 484.6 456.8 Buildings and improvements 20–35 years 191.2 167.3 Leasehold improvements Shorter of the Original Term of Lease or Estimated Useful Life 49.7 44.3 Land 41.3 40.7 Furniture and fixtures 5–7 years 16.8 16.1 Finance lease right-of-use asset 9.9 — 1,260.6 1,185.9 Less - accumulated depreciation and amortization (695.9) (694.4) $ 564.7 $ 491.5 Equipment under customer usage agreements primarily consists of diagnostic instrumentation and imaging equipment located at customer sites but owned by the Company. Generally, the customer has the right to use the equipment for a period of time provided they meet certain agreed to conditions. The Company recovers the cost of providing the equipment from the sale of disposables, primarily assays, tests and handpieces. The depreciation costs associated with equipment under customer usage agreements are charged to cost of product revenues over the estimated useful life of the equipment. The costs to maintain the equipment in the field are charged to cost of product revenue as incurred. In September 2020 and October 2020, the Company was awarded grants of $7.6 million and $119.3 million, respectively, from the Department of Defense Joint Acquisition Task Force ("DOD") to expand production capacity for the Company's two SARS-CoV-2 assays. These grants are specifically to fund the capital equipment and labor investments needed to increase manufacturing capacity to enable the Company to provide a certain amount of COVID-19 tests per month for the U.S. market. The Company is accounting for the funds received under these grants as a reimbursement of the purchased capital equipment. The Company procures and pays for the capital equipment and necessary resources to build out its facility and construct the manufacturing lines to meet the requirements specified in the grant agreement. Subsequent to paying for the capital equipment, the DOD will reimburse the Company upon it meeting certain requirements However, the DOD retains title to assets purchased under the agreement, and title is transferred to the Company upon meeting certain milestones of the manufacturing efforts. As of September 25, 2021, the Company had $95.2 million of capital equipment related to the DOD grant that was awaiting approval. In fiscal 2021, the Company received $21.2 million from the DOD under these grants which has been recorded as a reduction of the cost basis of the purchased equipment. Payments under these grants are subject to satisfaction of the conditions of the grants. Long-Lived Assets The Company reviews its long-lived assets, which includes property, plant and equipment and identifiable intangible assets (see below for discussion of intangible assets), for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable in accordance with ASC 360-10-35-15, Property, Plant and Equipment—Impairment or Disposal of Long-Lived Assets (ASC 360). Recoverability of these assets is evaluated by comparing the carrying value of the assets to the undiscounted cash flows estimated to be generated by those assets over their remaining economic life. If the undiscounted cash flows are not sufficient to recover the carrying value of the assets, the assets are considered impaired. The impairment loss is measured by comparing the fair value of the assets to their carrying value. Fair value is determined by either a quoted market price, if any, or a value determined by a discounted cash flow technique. Business Combinations and Acquisition of Intangible Assets The Company accounts for the acquisition of a business in accordance with ASC 805, Business Combinations (ASC 805). Amounts paid to acquire a business are allocated to the assets acquired and liabilities assumed based on their fair values at the date of acquisition. Contingent consideration not deemed to be linked to continuing employment is recorded at fair value as measured on the date of acquisition. The value recorded is based on estimates of future financial projections under various potential scenarios using a Monte Carlo simulation. These cash flow projections are discounted with an appropriate risk adjusted rate. Each quarter until such contingent amounts are earned, the fair value of the liability is remeasured at each reporting period and adjusted as a component of operating expenses based on changes to the underlying assumptions. The estimates used to determine the fair value of the contingent consideration liability are subject to significant judgment and actual results are likely to differ from the amounts originally recorded. The Company determines the fair value of acquired intangible assets based on detailed valuations that use certain information and assumptions provided by management. The Company allocates any excess purchase price over the fair value of the net tangible and intangible assets acquired to goodwill. The Company uses the income approach to determine the fair value of developed technology and in-process research and development ("IPR&D") acquired in a business combination. This approach determines fair value by estimating the after-tax cash flows attributable to the respective asset over its useful life and then discounting these after-tax cash flows back to a present value. The Company bases its revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected product introductions by competitors. Developed technology represents patented and unpatented technology and know-how. The value of the in-process projects is based on the project's stage of completion, the complexity of the work completed as of the acquisition date, the projected costs to complete, the contribution of core technologies and other acquired assets, the expected introduction date, the estimated cash flows to be generated upon commercial release and the estimated useful life of the technology. The Company believes that the estimated developed technology and IPR&D amounts represent the fair value at the date of acquisition and do not exceed the amount a third-party would pay for the assets. The significant assumptions used to estimate the fair value of intangible assets include discount rates and certain assumptions that form the basis of the forecasted results specifically revenue growth rates. These significant assumptions are forward looking and could be affected by future economic and market conditions. The Company also uses the income approach, as described above, to determine the estimated fair value of certain other identifiable intangible assets including customer relationships, trade names and business licenses. Customer relationships represent established relationships with customers, which provide a ready channel for the sale of additional products and services. Trade names represent acquired company and product names. Intangible Assets and Goodwill Intangible Assets Intangible assets are initially recorded at fair value and stated net of accumulated amortization and impairments. The Company amortizes its intangible assets that have finite lives using either the straight-line method, or if reliably determinable, based on the pattern in which the economic benefit of the asset is expected to be utilized. Amortization is recorded over the estimated useful lives ranging from 2 to 30 years. The Company evaluates the recoverability of its definite lived intangible assets whenever events or changes in circumstances or business conditions indicate that the carrying value of these assets may not be recoverable based on expectations of future undiscounted cash flows for each asset group. If the carrying value of an asset or asset group exceeds its undiscounted cash flows, the Company estimates the fair value of the assets, generally utilizing a discounted cash flow analysis based on the present value of estimated future cash flows to be generated by the assets using a risk-adjusted discount rate. To estimate the fair value of the assets, the Company uses market participant assumptions pursuant to ASC 820, Fair Value Measurements . Indefinite lived intangible assets, such as IPR&D assets, are required to be tested for impairment annually, or more frequently if indicators of impairment are present. The Company’s annual impairment test date is as of the first day of its fourth quarter. Intangible assets consisted of the following: September 25, 2021 September 26, 2020 Description Gross Accumulated Gross Accumulated Acquired intangible assets: Developed technology $ 4,597.7 $ 3,184.2 $ 4,054.0 $ 2,907.2 In-process research and development 71.6 — — — Customer relationships 591.7 510.1 549.1 477.8 Trade names 268.1 191.8 245.5 181.2 Non-competition agreements 1.5 1.5 1.5 1.3 Business licenses 2.5 2.5 2.4 2.3 Total acquired intangible assets $ 5,533.1 $ 3,890.1 $ 4,852.5 $ 3,569.8 Internal-use software 23.5 17.2 51.8 43.2 Capitalized software embedded in products 25.5 15.6 26.8 10.6 Total intangible assets $ 5,582.1 $ 3,922.9 $ 4,931.1 $ 3,623.6 Medical Aesthetics Impairment In the first quarter of fiscal 2020, the Company's Medical Aesthetics business met the criteria to be designated as assets held-for-sale. As a result, the Company recorded a $30.2 million charge to record the asset group at fair value less costs to sell. See Note 15 for additional information. During fiscal 2019, the Company identified indicators of impairment for its Medical Aesthetics reporting unit as a result of reductions in forecasts during the year, and in connection with the Company’s efforts to sell the business that began prior to the end of fiscal 2019. In performing the undiscounted cash flow analysis pursuant to ASC 360, the expected undiscounted cash flows of the asset group were determined using a probability-weighted approach taking into consideration the planned disposition, which was deemed to be highly probable as of the balance sheet date. Based on this analysis, the undiscounted cash flows were not sufficient to recover the carrying value of the asset group. As a result, the Company was required to perform Step 3 of the impairment test and determine the fair value of the asset group. The Company executed a definitive agreement on November 20, 2019 to sell the business. Although this agreement was signed subsequent to the balance sheet date, the Company concluded that it provided evidence regarding the estimate of fair value of the asset group at September 28, 2019 and that there were no events that occurred between September 28, 2019 and the date the Company entered into the definitive agreement that would significantly affect the fair value of the asset group. As a result, the Company recorded total impairment charges of $685.4 million in fiscal 2019. The impairment charge was allocated to the long-lived assets as follows: $576.9 million to developed technology, $22.4 million to customer relationships, $48.6 million to trade names, $27.7 million to distribution agreements and $9.8 million to equipment. On November 20, 2019, this asset group met the assets held-for-sale criteria and was recorded at fair value less the costs to sell as noted above. Other Activity During the third quarter of fiscal 2021, the Company acquired Mobidiag Oy and recorded $285.0 million of developed technology, $74.0 million of in-process research and development, $20.9 million of customer relationships and $20.0 million of trade names based on its preliminary purchase accounting. During the second quarter of fiscal 2021, the Company acquired Biotheranostics, Inc. and recorded $160.3 million of developed technology and $2.1 million of trade names based on its preliminary purchase accounting. During the second quarter of fiscal 2021, the Company acquired Diagenode SA and recorded $69.8 million of developed technology and $9.2 million of customer relationships based on its preliminary purchase accounting. During the second quarter of fiscal 2021, the Company acquired Somatex Medical Technologies GmbH and recorded $38.0 million of developed technology, $1.2 million of customer relationships and $0.9 million of trade names based on its preliminary purchase accounting. During the fourth quarter of fiscal 2020, the Company acquired Acessa Health, Inc. and recorded $127.0 million of developed technology and $1.2 million of trade names. Amortization expense related to developed technology is classified as cost of product revenues—amortization of intangible assets. Amortization expense related to customer relationships, contracts, trade names, and business licenses is classified as a component of amortization of intangible assets within operating expenses. The estimated amortization expense at September 25, 2021 for each of the five succeeding fiscal years was as follows: Fiscal 2022 $ 326.5 Fiscal 2023 $ 231.3 Fiscal 2024 $ 222.3 Fiscal 2025 $ 208.9 Fiscal 2026 $ 178.1 Goodwill In accordance with ASC 350, Intangibles—Goodwill and Other (ASC 350), the Company tests goodwill for impairment annually at the reporting unit level and between annual tests if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying value. Events that could indicate impairment and trigger an interim impairment assessment include, but are not limited to, current economic and market conditions, including a decline in market capitalization, a significant adverse change in legal factors, business climate, operational performance of the business or key personnel, and an adverse action or assessment by a regulator. In performing the impairment test, the Company utilizes the single-step approach prescribed under Accounting Standards Update No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (ASU 2017-04). This approach requires a comparison of the carrying value of each reporting unit to its estimated fair value and to the extent the carrying value exceeds the fair value a charge is recorded up to the amount of goodwill in the reporting unit. To estimate the fair value of its reporting units, the Company primarily utilizes the income approach. The income approach is based on a DCF analysis and calculates the fair value by estimating the after-tax cash flows attributable to a reporting unit and then discounting the after-tax cash flows to present value using a risk-adjusted discount rate. Assumptions used in the DCF require significant judgment, including judgment about appropriate discount rates and terminal values, growth rates, and the amount and timing of expected future cash flows. The forecasted cash flows are based on the Company’s most recent budget and strategic plan and for years beyond this period, the Company’s estimates are based on assumed growth rates expected as of the measurement date. The Company believes its assumptions are consistent with the plans and estimates used to manage the underlying businesses. The discount rates used are intended to reflect the risks inherent in future cash flow projections and are based on estimates of the weighted-average cost of capital (“WACC”) of market participants relative to each respective reporting unit. The market approach considers comparable market data based on multiples of revenue or earnings before interest, taxes, depreciation and amortization (“EBITDA”) and is primarily used as a corroborative analysis to the results of the DCF analysis. The Company believes its assumptions used to determine the fair value of its reporting units are reasonable. If different assumptions were used, particularly with respect to forecasted cash flows, terminal values, WACCs, or market multiples, different estimates of fair value may result and there could be the potential that an impairment charge could result. Actual operating results and the related cash flows of the reporting units could differ from the estimated operating results and related cash flows. The Company conducted its fiscal 2021 impairment test for its reporting units on the first day of the fourth quarter, and as noted above used DCF and market approaches to estimate the fair value of its reporting units as of June 27, 2021, and ultimately used the fair value determined by the DCF approach in making its impairment test conclusions. The Company believes it used reasonable estimates and assumptions about future revenue, cost projections, cash flows, market multiples and discount rates as of the measurement date. As a result of completing this analysis, all of the Company's reporting units had fair values exceeding their carrying values. At September 25, 2021, the Company believes that its reporting units, with goodwill aggregating $3.3 billion, were not at risk of failing the goodwill impairment test based on its current forecasts and qualitative assessment. The Company conducted its fiscal 2020 impairment test for its reporting units on the first day of the fourth quarter, and as noted above used DCF and market approaches to estimate the fair value of its reporting units as of June 28, 2020, and ultimately used the fair value determined by the DCF approach in making its impairment test conclusions. The Company believes it used reasonable estimates and assumptions about future revenue, cost projections, cash flows, market multiples and discount rates as of the measurement date. As a result of completing this analysis, all of the Company's reporting units had fair values exceeding their carrying values. For illustrative purposes, had the fair value of each of the reporting units been lower by 10%, all of the reporting units would still have passed the goodwill impairment test. A rollforward of goodwill activity by reportable segment from September 26, 2020 to September 25, 2021 is as follows: Diagnostics Breast Health GYN Surgical Skeletal Health Total Balance at September 26, 2020 $ 821.6 $ 764.8 $ 1,063.4 $ 8.1 $ 2,657.9 Mobidiag acquisition 432.6 — — — 432.6 Diagenode acquisition 83.5 — — — 83.5 Biotheranostics acquisition 80.9 — — — 80.9 Somatex acquisition — 32.4 — — 32.4 Foreign currency and other adjustments (7.8) (0.1) 2.2 — (5.7) Balance at September 25, 2021 $ 1,410.8 $ 797.1 $ 1,065.6 $ 8.1 $ 3,281.6 Other Assets Other assets consisted of the following: September 25, 2021 September 26, 2020 Other Assets Tax receivable $ 24.7 $ 325.7 Right of use assets 83.6 80.7 Life insurance contracts 64.3 49.3 Deferred tax assets 21.9 15.5 Cost-method equity investments 9.5 11.4 Other 41.7 34.0 $ 245.7 $ 516.6 The tax receivable in fiscal 2020 primarily related to a discrete tax benefit from the sale of Cynosure in the second quarter of fiscal 2020. This receivable was reclassified to a current asset in fiscal 2021 as the Company filed the carryback claim and expects to receive the refund within the next twelve months, subject to Internal Revenue Service processing times. The right of use assets were recorded in connection with the adoption of ASC 842, Leases , and pertains to operating leases. Life insurance contracts were purchased in connection with the Company’s Nonqualified Deferred Compensation Plan (“DCP”) and are recorded at their cash surrender value (see Note 12 for further discussion). Research and Software Development Costs Costs incurred for the research and development of the Company’s products are expensed as incurred. Nonrefundable advance payments for goods or services to be received in the future by the Company for use in research and development activities are deferred. The deferred costs are expensed as the related goods are delivered or the services are performed. The Company accounts for the development costs of software embedded in the Company’s products in accordance with ASC 985, Software. Costs incurred in the research, design and development of software embedded in products to be sold to customers are charged to expense until technological feasibility of the ultimate product to be sold is established. The Company’s policy is that technological feasibility is achieved when a working model, with the key features and functions of the product, is available for customer testing. Software development costs incurred after the establishment of technological feasibility and until the product is available for general release are capitalized, provided recoverability is reasonably assured. Capitalized software development costs are amortized over their estimated useful life and recorded within cost of revenues - product. Foreign Currency Translation The financial statements of the Company’s foreign subsidiaries are translated in accordance with ASC 830, Foreign Currency Matters. The reporting currency for the Company is the U.S. dollar. The functional currency of the Company’s foreign subsidiaries is determined based on the guidance in ASC 830. The majority of the Company's foreign subsidiaries' functional currency is the applicable local currency, although certain of the Company's foreign subsidiaries' functional currency is the U.S. dollar based on the nature of their operations or functions. Assets and liabilities of subsidiaries whose functional currency is the local currency are translated at the exchange rate in effect at each balance sheet date. Before translation, the Company re-measures foreign currency denominated assets and liabilities, including inter-company accounts receivable and payable, into the functional currency of the respective entity, resulting in unrealized gains or losses recorded in other income (expense), net in the Consolidated Statements of Operations. Revenues and expenses are translated using average exchange rates during the respective period. Foreign currency translation adjustments are accumulated as a component of other comprehensive income (loss), which is a separate component of stockholders’ equity. Gains and losses arising from transactions denominated in foreign currencies are included in other income (expense), net in the Consolidated Statements of Operations and were not significant in any of the reporting periods presented. Accumulated Other Comprehensive Income (Loss) Other comprehensive income (loss) includes certain transactions that have generally been reported in the statement of stockholders’ equity. The following tables summarize the components and changes in accumulated balances of other comprehensive loss for the periods presented: Year Ended September 25, 2021 Year Ended September 26, 2020 Foreign Currency Translation Pension Plans Hedged Interest Rate Caps Hedged Interest Rate Swaps Total Foreign Currency Translation Pension Plans Hedged Interest Rate Caps Hedged Interest Rate Swaps Total Beginning Balance $ (22.9) $ (1.8) $ (0.9) $ (24.1) $ (49.7) $ (41.4) $ (1.7) $ (2.7) $ 3.5 $ (42.3) Other comprehensive income (loss) before reclassifications (20.2) 0.5 0.4 9.4 (9.9) 18.5 (0.1) (0.5) (27.6) (9.7) Charges (gains) reclassified to statement of operations — — 0.5 — 0.5 — — 2.3 — 2.3 Ending Balance $ (43.1) $ (1.3) $ — $ (14.7) $ (59.1) $ (22.9) $ (1.8) $ (0.9) $ (24.1) $ (49.7) Derivatives Interest Rate Cap - Cash Flow Hedge The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company manages its exposure to some of its interest rate risk through the use of interest rate caps, which are derivative financial instruments. The Company does not use derivatives for speculative purposes. For a derivative that is designated as a cash flow hedge, changes in the fair value of the derivative are recognized in accumulated other comprehensive income ("AOCI") to the extent the derivative is effective at offsetting the changes in the cash flows being hedged until the hedged item affects earnings. To the extent there is any hedge ineffectiveness, changes in fair value relating to the ineffective portion are immediately recognized in earnings in other income (expense), net in the Consolidated Statements of Operations. During fiscal 2018, the Company entered into separate interest rate cap agreements with multiple counter-parties to mitigate the interest rate volatility associated with the variable interest rate on its amounts borrowed under the term loan feature of its credit facilities (see Note 7). Interest rate cap agreements provide the right to receive cash if the reference interest rate rises above a contractual rate. The aggregate premium paid for these interest rate cap agreements was $3.7 million, which was the initial fair value of the instruments recorded in the Company's financial statements. During fiscal 2019, the Company entered into additional separate interest rate cap agreements with multiple counter-parties to extend the expiration date of its hedges by an additional year. The aggregate premium paid for these interest cap agreements was $1.5 million, which was the initial fair value of the instruments recorded in the Company’s financial statements. The critical terms of the interest rate caps were designed to mirror the terms of the Company’s LIBOR

Revenue (Notes)

Revenue (Notes)	12 Months Ended
	Sep. 25, 2021
Revenue from Contract with Customer [Abstract]
Revenue	Revenue The Company accounts for revenue pursuant to ASC Update No. 2014-09, Revenue from Contracts with Customer (ASC 606) and generates revenue from the sale of its products, primarily medical imaging systems and related components and software, diagnostic tests and assays and surgical disposable products, and related services, which are primarily support and maintenance services on its medical imaging systems, and to a lesser extent installation, training and repairs. Prior to the Cynosure divestiture, the Company also generated revenue from the sale and service of medical aesthetic treatment systems. The Company's products are sold primarily through a direct sales force, and within international markets, there is more reliance on distributors and resellers. Revenue is recorded net of sales tax. The following table provides revenue from contracts with customers by business and geographic region on a disaggregated basis: Years Ended September 25, 2021 September 26, 2020 September 28, 2019 Business (in millions) United States Intl. Total United States Intl. Total United States Intl. Total Diagnostics: Cytology & Perinatal $ 304.6 $ 169.3 $ 473.9 $ 266.3 $ 143.8 $ 410.1 $ 312.9 $ 159.1 $ 472.0 Molecular Diagnostics 2,038.9 1,132.6 3,171.5 1,272.5 375.9 1,648.4 549.9 125.1 675.0 Blood Screening 49.6 — 49.6 43.6 — 43.6 58.5 — 58.5 Total 2,393.1 1,301.9 3,695.0 1,582.4 519.7 2,102.1 921.3 284.2 1,205.5 Breast Health: Breast Imaging 830.4 253.0 1,083.4 722.0 231.6 953.6 853.1 241.5 1,094.6 Interventional Breast Solutions 221.4 47.5 268.9 166.6 31.7 198.3 184.8 34.8 219.6 Total 1,051.8 300.5 1,352.3 888.6 263.3 1,151.9 1,037.9 276.3 1,314.2 GYN Surgical 396.4 91.7 488.1 310.1 66.0 376.1 362.8 74.4 437.2 Skeletal Health 61.0 35.9 96.9 51.2 29.8 81.0 58.6 36.2 94.8 Medical Aesthetics — — — 30.9 34.4 65.3 155.4 160.2 315.6 Total $ 3,902.3 $ 1,730.0 $ 5,632.3 $ 2,863.2 $ 913.2 $ 3,776.4 $ 2,536.0 $ 831.3 $ 3,367.3 Years Ended Geographic Regions ( in millions ) September 25, 2021 September 26, 2020 September 28, 2019 United States $ 3,902.3 $ 2,863.2 $ 2,536.0 Europe 1,201.8 569.8 396.0 Asia-Pacific 365.0 226.8 286.0 Rest of World 163.2 116.6 149.3 $ 5,632.3 $ 3,776.4 $ 3,367.3 The following table provides revenue recognized by source: Years Ended Revenue by type ( in millions ) September 25, 2021 September 26, 2020 September 28, 2019 Disposables $ 4,198.2 $ 2,561.1 $ 1,786.4 Capital equipment, components and software 769.1 665.9 984.9 Service 598.1 516.6 568.3 Other 66.9 32.8 27.7 $ 5,632.3 $ 3,776.4 $ 3,367.3 The Company considers revenue to be earned when all of the following criteria are met: the Company has a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the amount the Company expects to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable; and the Company has transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in the contract. The transaction price for the contract is measured as the amount of consideration the Company expects to receive in exchange for the goods and services expected to be transferred. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, control of the distinct good or service is transferred. Transfer of control for the Company's products is generally at shipment or delivery, depending on contractual terms, but occurs when title and risk of loss transfers to the customer which represents the point in time when the customer obtains the use of and substantially all of the remaining benefit of the product. As such, the Company's performance obligation related to product sales is satisfied at a point in time. Revenue from support and maintenance contracts, extended warranty and professional services for installation, training and repairs is recognized over time based on the period contracted or as the services are performed as these methods represent a faithful depiction of the transfer of goods and services. The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction and is most often equal to the transaction price in the contract. Payment terms are typically 30 days in the U.S. but may be longer in international markets. The Company treats shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and records these costs within costs of product revenue when the corresponding revenue is recognized. The Company also places instruments (or equipment) at customer sites but retains title to the instrument. The customer has the right to use the instrument for a period of time, and the Company recovers the cost of providing the instrument through the sales of disposables, namely tests and assays in Diagnostics and handpieces in GYN Surgical. These types of agreements include an embedded lease, which is generally an operating lease, for the right to use an instrument and no instrument revenue is recognized at the time of instrument delivery. The Company recognizes a portion of the revenue allocated to the embedded lease concurrent with the sale of disposables over the term of the agreement. Some of the Company's contracts have multiple performance obligations. For contracts with multiple performance obligations, the Company allocates the transaction price to each performance obligation using its best estimate of the standalone selling price of each distinct good or service in the contract. The Company determines its best estimate of standalone selling price using average selling prices over 3- to 12-month periods of data depending on the products or nature of the services coupled with current market considerations. If the product or service does not have a history of sales or if sales volume is not sufficient, the Company relies on prices set by its pricing committees or applicable marketing department adjusted for expected discounts. Variable Consideration The Company exercises judgment in estimating variable consideration, which includes volume discounts, sales rebates, product returns and other adjustments. These amounts are recorded as a reduction to revenue and classified as a current liability. The Company bases its estimates for volume discounts and sales rebates on historical information to the extent it is reasonable to be used as a predictive tool of expected future rebates. To the extent the transaction price includes variable consideration, the Company applies judgment in constraining the estimated variable consideration due to factors that may cause reversal of revenue recognized. The Company evaluates constraints based on its historical and projected experience with similar customer contracts. The Company's contracts typically do not provide the right to return product. In general, estimates of variable consideration and constraints are not material to the Company's financial statements. Remaining Performance Obligations As of September 25, 2021, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was approximately $830.6 million. These remaining performance obligations primarily relate to extended warranty and support and maintenance obligations in the Company's Breast Health and Skeletal Health reportable segments. The Company expects to recognize approximately 40% of this amount as revenue in 2022, 27% in 2023, 18% in 2024, 10% in 2025, and 5% thereafter. The Company has applied the practical expedient to not include remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above. Contract Assets and Liabilities The Company discloses accounts receivable separately in the Consolidated Balance Sheets at their net realizable value. Contract assets primarily relate to the Company's conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were immaterial. Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. The Company records a contract liability, or deferred revenue, when it has an obligation to provide service, and to a much lesser extent product, to the customer and payment is received or due in advance of performance. Deferred revenue primarily relates to support and maintenance contracts and extended warranty obligations within the Company's Breast Health and Skeletal Health reportable segments. Contract liabilities are classified as other current liabilities and other long-term liabilities on the Consolidated Balance Sheets. The Company recognized revenue of $112.1 million and $106.2 million in the years ended September 25, 2021 and September 26, 2020, respectively, that was included in the contract liability balance at September 26, 2020 and September 28, 2019, respectively. Practical Expedients The Company applies a practical expedient to expense costs to obtain a contract with a customer as incurred when the amortization period would have been one year or less. These costs solely comprise sales commissions and typically the commissions are incurred at the time of shipment of product and upon billings for support and maintenance contracts.

Leases

Leases	12 Months Ended
	Sep. 25, 2021
Leases [Abstract]
Leases	Leases In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) , referred to as ASC 842. The purpose of ASU 2016-02 was to increase the transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet, including those previously classified as operating leases under GAAP, and disclosing key information about leasing arrangements. ASC 842, as amended, was effective for the Company in fiscal 2020. The Company adopted the standard using the transition method provided by ASC Update No. 2018-11, Leases (Topic 842): Targeted Improvements . Under this method, the Company applied the new lease standard on September 29, 2019, rather than at the earliest comparative period presented in the financial statements. Upon transition, the Company applied the package of practical expedients permitted under ASC 842 transition guidance to its entire lease portfolio at September 29, 2019. As a result, the Company was not required to reassess (i) whether any expired or existing contracts are or contain leases, (ii) the classification of any expired or existing leases, and (iii) initial direct costs for any existing leases. Furthermore, as a lessee the Company elected to combine lease and non-lease components together for the majority of its leases. As a result, for these applicable classes of underlying assets, the Company accounted for each separate lease component and the non-lease components associated with that lease component as a single lease component. Under ASC 842 as a lessor, in instances where the Company places instruments (or equipment) at customer sites as part of its reagent rental contracts, certain of the Company's reagent rental contracts could be classified as sales-type leases. Under sales-type leases, there is accelerated expense recognition for the cost of the placed equipment and potentially up-front revenue in the event there are fixed rental payments, a portion of which would be allocated to the equipment. The Company does not have a significant amount of sales-type leases. Prior to the adoption of ASC 842, all instruments placed under the Company's reagent rental programs were classified as operating leases and instrument revenue and cost were recognized over the term of the contract. Upon adoption of the new lease standard, the Company recognized operating lease right-of-use assets and finance lease right-of-use assets of $91.7 million and $10.2 million, respectively, and corresponding operating lease liabilities and finance lease liabilities of $ 96.6 million 21.0 million Lessee Activity - Leases where Hologic is the Lessee The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the term of the lease, and some of which include options to terminate the lease within one year. The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of one year to approximately 14 years, some of which may include options to extend the leases for up to 10 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees. The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the consolidated balance sheet as of September 25, 2021. Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating and finance lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the estimated rate that would be incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of September 25, 2021 was 2.25%. The following table presents supplemental balance sheet information related to the Company's operating and finance leases: September 25, 2021 September 26, 2020 Balance Sheet Location Operating Leases Finance Leases Operating Leases Finance Leases Assets Lease right-of-use assets Other assets $ 83.6 $ — $ 80.7 $ — Finance lease right-of-use assets (non-current) Property, plant and equipment, net $ — $ 9.3 $ — $ — Liabilities Operating lease liabilities (current) Accrued expenses $ 26.8 $ — $ 23.5 $ — Finance lease liabilities (current) Finance lease obligations - short term $ — $ 3.7 $ — $ 1.9 Operating lease liabilities (non-current) Other long-term liabilities $ 66.1 $ — $ 65.6 $ — Finance lease liabilities (non-current) Finance lease obligations - long term $ — $ 22.8 $ — $ 17.4 In connection with the Diagenode SA acquisition, the Company acquired two finance leases. The Company accounted for these lease agreements pursuant to ASC 842 and ASC 805 and recorded both an asset and liability at the present value of future lease payments as part of the purchase accounting. The finance leases are for two facilities with remaining lease terms of 7 and 11 years and contain a bargain purchase option of 3% at the end of the lease term. The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases: As of September 25, 2021 As of September 26, 2020 Operating Leases Finance Lease Operating Leases Finance Lease Weighted average remaining lease term 4.95 7.52 5.58 7.64 Weighted average discount rate 1.6 % 4.3 % 2.0 % 5.1 % The following table provides information related to the Company’s operating and finance leases: Year Ended September 25, 2021 Year Ended September 26, 2020 Operating lease cost (a) $ 30.1 $ 27.5 Finance lease cost - amortization of right-of-use assets $ 0.6 $ 0.3 Finance lease cost - interest cost $ 1.0 $ 1.0 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 1.0 $ 1.0 Operating cash flows from operating leases $ 28.2 $ 23.9 Financing cash flows from finance leases $ 2.4 $ 1.7 Total cash paid for amounts included in the measurement of lease liabilities $ 31.6 $ 26.6 ROU assets arising from entering into new operating lease obligations $ 28.6 $ 13.3 ROU assets arising from entering into new finance lease obligations $ 9.1 $ — (a) Includes short-term lease expense and variable lease costs, which were immaterial for the year ended September 25, 2021. Rent expense under FASB ASC Topic 840 was $23.1 million for fiscal 2019. The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of September 25, 2021: Fiscal Year Operating Leases Finance Lease 2022 $ 28.2 $ 4.4 2023 22.0 4.2 2024 16.4 3.9 2025 11.8 3.9 2026 7.4 3.9 Thereafter 11.7 10.2 Total future minimum lease payments 97.5 30.5 Less: imputed interest (4.6) (4.0) Present value of lease liabilities $ 92.9 $ 26.5 Lessor Activity - Leases where Hologic is the Lessor Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating lease and performance obligations for disposables, reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. Sales-type leases are immaterial. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented less than 5% of the Company’s consolidated revenue for all periods presented. In connection with the disposition of the Medical Aesthetics business in fiscal 2020, the Company entered into an agreement to sublease to Cynosure its U.S. headquarters and manufacturing location. As such, the Company derecognized $10.2 million for the right-of-use asset for the finance lease and recorded a lease receivable, which is $17.4 million as of September 25, 2021. The Company leases a portion of a building it owns and subleases some of its rented facilities and has received aggregate rental income of $2.6 million, $2.0 million and $2.7 million in fiscal 2021, 2020 and 2019, respectively, which has been recorded as an offset to operating lease costs. The future minimum annual rental income payments under these lease and sublease agreements at September 25, 2021 are as follows: Fiscal 2022 $ 3.1 Fiscal 2023 3.0 Fiscal 2024 3.0 Fiscal 2025 2.0 Fiscal 2026 0.9 Thereafter 2.3 Total $ 14.3
Leases	Leases In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) , referred to as ASC 842. The purpose of ASU 2016-02 was to increase the transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet, including those previously classified as operating leases under GAAP, and disclosing key information about leasing arrangements. ASC 842, as amended, was effective for the Company in fiscal 2020. The Company adopted the standard using the transition method provided by ASC Update No. 2018-11, Leases (Topic 842): Targeted Improvements . Under this method, the Company applied the new lease standard on September 29, 2019, rather than at the earliest comparative period presented in the financial statements. Upon transition, the Company applied the package of practical expedients permitted under ASC 842 transition guidance to its entire lease portfolio at September 29, 2019. As a result, the Company was not required to reassess (i) whether any expired or existing contracts are or contain leases, (ii) the classification of any expired or existing leases, and (iii) initial direct costs for any existing leases. Furthermore, as a lessee the Company elected to combine lease and non-lease components together for the majority of its leases. As a result, for these applicable classes of underlying assets, the Company accounted for each separate lease component and the non-lease components associated with that lease component as a single lease component. Under ASC 842 as a lessor, in instances where the Company places instruments (or equipment) at customer sites as part of its reagent rental contracts, certain of the Company's reagent rental contracts could be classified as sales-type leases. Under sales-type leases, there is accelerated expense recognition for the cost of the placed equipment and potentially up-front revenue in the event there are fixed rental payments, a portion of which would be allocated to the equipment. The Company does not have a significant amount of sales-type leases. Prior to the adoption of ASC 842, all instruments placed under the Company's reagent rental programs were classified as operating leases and instrument revenue and cost were recognized over the term of the contract. Upon adoption of the new lease standard, the Company recognized operating lease right-of-use assets and finance lease right-of-use assets of $91.7 million and $10.2 million, respectively, and corresponding operating lease liabilities and finance lease liabilities of $ 96.6 million 21.0 million Lessee Activity - Leases where Hologic is the Lessee The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the term of the lease, and some of which include options to terminate the lease within one year. The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of one year to approximately 14 years, some of which may include options to extend the leases for up to 10 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees. The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the consolidated balance sheet as of September 25, 2021. Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating and finance lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the estimated rate that would be incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of September 25, 2021 was 2.25%. The following table presents supplemental balance sheet information related to the Company's operating and finance leases: September 25, 2021 September 26, 2020 Balance Sheet Location Operating Leases Finance Leases Operating Leases Finance Leases Assets Lease right-of-use assets Other assets $ 83.6 $ — $ 80.7 $ — Finance lease right-of-use assets (non-current) Property, plant and equipment, net $ — $ 9.3 $ — $ — Liabilities Operating lease liabilities (current) Accrued expenses $ 26.8 $ — $ 23.5 $ — Finance lease liabilities (current) Finance lease obligations - short term $ — $ 3.7 $ — $ 1.9 Operating lease liabilities (non-current) Other long-term liabilities $ 66.1 $ — $ 65.6 $ — Finance lease liabilities (non-current) Finance lease obligations - long term $ — $ 22.8 $ — $ 17.4 In connection with the Diagenode SA acquisition, the Company acquired two finance leases. The Company accounted for these lease agreements pursuant to ASC 842 and ASC 805 and recorded both an asset and liability at the present value of future lease payments as part of the purchase accounting. The finance leases are for two facilities with remaining lease terms of 7 and 11 years and contain a bargain purchase option of 3% at the end of the lease term. The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases: As of September 25, 2021 As of September 26, 2020 Operating Leases Finance Lease Operating Leases Finance Lease Weighted average remaining lease term 4.95 7.52 5.58 7.64 Weighted average discount rate 1.6 % 4.3 % 2.0 % 5.1 % The following table provides information related to the Company’s operating and finance leases: Year Ended September 25, 2021 Year Ended September 26, 2020 Operating lease cost (a) $ 30.1 $ 27.5 Finance lease cost - amortization of right-of-use assets $ 0.6 $ 0.3 Finance lease cost - interest cost $ 1.0 $ 1.0 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 1.0 $ 1.0 Operating cash flows from operating leases $ 28.2 $ 23.9 Financing cash flows from finance leases $ 2.4 $ 1.7 Total cash paid for amounts included in the measurement of lease liabilities $ 31.6 $ 26.6 ROU assets arising from entering into new operating lease obligations $ 28.6 $ 13.3 ROU assets arising from entering into new finance lease obligations $ 9.1 $ — (a) Includes short-term lease expense and variable lease costs, which were immaterial for the year ended September 25, 2021. Rent expense under FASB ASC Topic 840 was $23.1 million for fiscal 2019. The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of September 25, 2021: Fiscal Year Operating Leases Finance Lease 2022 $ 28.2 $ 4.4 2023 22.0 4.2 2024 16.4 3.9 2025 11.8 3.9 2026 7.4 3.9 Thereafter 11.7 10.2 Total future minimum lease payments 97.5 30.5 Less: imputed interest (4.6) (4.0) Present value of lease liabilities $ 92.9 $ 26.5 Lessor Activity - Leases where Hologic is the Lessor Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating lease and performance obligations for disposables, reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. Sales-type leases are immaterial. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented less than 5% of the Company’s consolidated revenue for all periods presented. In connection with the disposition of the Medical Aesthetics business in fiscal 2020, the Company entered into an agreement to sublease to Cynosure its U.S. headquarters and manufacturing location. As such, the Company derecognized $10.2 million for the right-of-use asset for the finance lease and recorded a lease receivable, which is $17.4 million as of September 25, 2021. The Company leases a portion of a building it owns and subleases some of its rented facilities and has received aggregate rental income of $2.6 million, $2.0 million and $2.7 million in fiscal 2021, 2020 and 2019, respectively, which has been recorded as an offset to operating lease costs. The future minimum annual rental income payments under these lease and sublease agreements at September 25, 2021 are as follows: Fiscal 2022 $ 3.1 Fiscal 2023 3.0 Fiscal 2024 3.0 Fiscal 2025 2.0 Fiscal 2026 0.9 Thereafter 2.3 Total $ 14.3
Leases	Leases In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) , referred to as ASC 842. The purpose of ASU 2016-02 was to increase the transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet, including those previously classified as operating leases under GAAP, and disclosing key information about leasing arrangements. ASC 842, as amended, was effective for the Company in fiscal 2020. The Company adopted the standard using the transition method provided by ASC Update No. 2018-11, Leases (Topic 842): Targeted Improvements . Under this method, the Company applied the new lease standard on September 29, 2019, rather than at the earliest comparative period presented in the financial statements. Upon transition, the Company applied the package of practical expedients permitted under ASC 842 transition guidance to its entire lease portfolio at September 29, 2019. As a result, the Company was not required to reassess (i) whether any expired or existing contracts are or contain leases, (ii) the classification of any expired or existing leases, and (iii) initial direct costs for any existing leases. Furthermore, as a lessee the Company elected to combine lease and non-lease components together for the majority of its leases. As a result, for these applicable classes of underlying assets, the Company accounted for each separate lease component and the non-lease components associated with that lease component as a single lease component. Under ASC 842 as a lessor, in instances where the Company places instruments (or equipment) at customer sites as part of its reagent rental contracts, certain of the Company's reagent rental contracts could be classified as sales-type leases. Under sales-type leases, there is accelerated expense recognition for the cost of the placed equipment and potentially up-front revenue in the event there are fixed rental payments, a portion of which would be allocated to the equipment. The Company does not have a significant amount of sales-type leases. Prior to the adoption of ASC 842, all instruments placed under the Company's reagent rental programs were classified as operating leases and instrument revenue and cost were recognized over the term of the contract. Upon adoption of the new lease standard, the Company recognized operating lease right-of-use assets and finance lease right-of-use assets of $91.7 million and $10.2 million, respectively, and corresponding operating lease liabilities and finance lease liabilities of $ 96.6 million 21.0 million Lessee Activity - Leases where Hologic is the Lessee The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the term of the lease, and some of which include options to terminate the lease within one year. The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of one year to approximately 14 years, some of which may include options to extend the leases for up to 10 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees. The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the consolidated balance sheet as of September 25, 2021. Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating and finance lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the estimated rate that would be incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of September 25, 2021 was 2.25%. The following table presents supplemental balance sheet information related to the Company's operating and finance leases: September 25, 2021 September 26, 2020 Balance Sheet Location Operating Leases Finance Leases Operating Leases Finance Leases Assets Lease right-of-use assets Other assets $ 83.6 $ — $ 80.7 $ — Finance lease right-of-use assets (non-current) Property, plant and equipment, net $ — $ 9.3 $ — $ — Liabilities Operating lease liabilities (current) Accrued expenses $ 26.8 $ — $ 23.5 $ — Finance lease liabilities (current) Finance lease obligations - short term $ — $ 3.7 $ — $ 1.9 Operating lease liabilities (non-current) Other long-term liabilities $ 66.1 $ — $ 65.6 $ — Finance lease liabilities (non-current) Finance lease obligations - long term $ — $ 22.8 $ — $ 17.4 In connection with the Diagenode SA acquisition, the Company acquired two finance leases. The Company accounted for these lease agreements pursuant to ASC 842 and ASC 805 and recorded both an asset and liability at the present value of future lease payments as part of the purchase accounting. The finance leases are for two facilities with remaining lease terms of 7 and 11 years and contain a bargain purchase option of 3% at the end of the lease term. The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases: As of September 25, 2021 As of September 26, 2020 Operating Leases Finance Lease Operating Leases Finance Lease Weighted average remaining lease term 4.95 7.52 5.58 7.64 Weighted average discount rate 1.6 % 4.3 % 2.0 % 5.1 % The following table provides information related to the Company’s operating and finance leases: Year Ended September 25, 2021 Year Ended September 26, 2020 Operating lease cost (a) $ 30.1 $ 27.5 Finance lease cost - amortization of right-of-use assets $ 0.6 $ 0.3 Finance lease cost - interest cost $ 1.0 $ 1.0 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 1.0 $ 1.0 Operating cash flows from operating leases $ 28.2 $ 23.9 Financing cash flows from finance leases $ 2.4 $ 1.7 Total cash paid for amounts included in the measurement of lease liabilities $ 31.6 $ 26.6 ROU assets arising from entering into new operating lease obligations $ 28.6 $ 13.3 ROU assets arising from entering into new finance lease obligations $ 9.1 $ — (a) Includes short-term lease expense and variable lease costs, which were immaterial for the year ended September 25, 2021. Rent expense under FASB ASC Topic 840 was $23.1 million for fiscal 2019. The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of September 25, 2021: Fiscal Year Operating Leases Finance Lease 2022 $ 28.2 $ 4.4 2023 22.0 4.2 2024 16.4 3.9 2025 11.8 3.9 2026 7.4 3.9 Thereafter 11.7 10.2 Total future minimum lease payments 97.5 30.5 Less: imputed interest (4.6) (4.0) Present value of lease liabilities $ 92.9 $ 26.5 Lessor Activity - Leases where Hologic is the Lessor Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating lease and performance obligations for disposables, reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. Sales-type leases are immaterial. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented less than 5% of the Company’s consolidated revenue for all periods presented. In connection with the disposition of the Medical Aesthetics business in fiscal 2020, the Company entered into an agreement to sublease to Cynosure its U.S. headquarters and manufacturing location. As such, the Company derecognized $10.2 million for the right-of-use asset for the finance lease and recorded a lease receivable, which is $17.4 million as of September 25, 2021. The Company leases a portion of a building it owns and subleases some of its rented facilities and has received aggregate rental income of $2.6 million, $2.0 million and $2.7 million in fiscal 2021, 2020 and 2019, respectively, which has been recorded as an offset to operating lease costs. The future minimum annual rental income payments under these lease and sublease agreements at September 25, 2021 are as follows: Fiscal 2022 $ 3.1 Fiscal 2023 3.0 Fiscal 2024 3.0 Fiscal 2025 2.0 Fiscal 2026 0.9 Thereafter 2.3 Total $ 14.3
Leases	Leases In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) , referred to as ASC 842. The purpose of ASU 2016-02 was to increase the transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet, including those previously classified as operating leases under GAAP, and disclosing key information about leasing arrangements. ASC 842, as amended, was effective for the Company in fiscal 2020. The Company adopted the standard using the transition method provided by ASC Update No. 2018-11, Leases (Topic 842): Targeted Improvements . Under this method, the Company applied the new lease standard on September 29, 2019, rather than at the earliest comparative period presented in the financial statements. Upon transition, the Company applied the package of practical expedients permitted under ASC 842 transition guidance to its entire lease portfolio at September 29, 2019. As a result, the Company was not required to reassess (i) whether any expired or existing contracts are or contain leases, (ii) the classification of any expired or existing leases, and (iii) initial direct costs for any existing leases. Furthermore, as a lessee the Company elected to combine lease and non-lease components together for the majority of its leases. As a result, for these applicable classes of underlying assets, the Company accounted for each separate lease component and the non-lease components associated with that lease component as a single lease component. Under ASC 842 as a lessor, in instances where the Company places instruments (or equipment) at customer sites as part of its reagent rental contracts, certain of the Company's reagent rental contracts could be classified as sales-type leases. Under sales-type leases, there is accelerated expense recognition for the cost of the placed equipment and potentially up-front revenue in the event there are fixed rental payments, a portion of which would be allocated to the equipment. The Company does not have a significant amount of sales-type leases. Prior to the adoption of ASC 842, all instruments placed under the Company's reagent rental programs were classified as operating leases and instrument revenue and cost were recognized over the term of the contract. Upon adoption of the new lease standard, the Company recognized operating lease right-of-use assets and finance lease right-of-use assets of $91.7 million and $10.2 million, respectively, and corresponding operating lease liabilities and finance lease liabilities of $ 96.6 million 21.0 million Lessee Activity - Leases where Hologic is the Lessee The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the term of the lease, and some of which include options to terminate the lease within one year. The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of one year to approximately 14 years, some of which may include options to extend the leases for up to 10 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees. The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the consolidated balance sheet as of September 25, 2021. Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating and finance lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the estimated rate that would be incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of September 25, 2021 was 2.25%. The following table presents supplemental balance sheet information related to the Company's operating and finance leases: September 25, 2021 September 26, 2020 Balance Sheet Location Operating Leases Finance Leases Operating Leases Finance Leases Assets Lease right-of-use assets Other assets $ 83.6 $ — $ 80.7 $ — Finance lease right-of-use assets (non-current) Property, plant and equipment, net $ — $ 9.3 $ — $ — Liabilities Operating lease liabilities (current) Accrued expenses $ 26.8 $ — $ 23.5 $ — Finance lease liabilities (current) Finance lease obligations - short term $ — $ 3.7 $ — $ 1.9 Operating lease liabilities (non-current) Other long-term liabilities $ 66.1 $ — $ 65.6 $ — Finance lease liabilities (non-current) Finance lease obligations - long term $ — $ 22.8 $ — $ 17.4 In connection with the Diagenode SA acquisition, the Company acquired two finance leases. The Company accounted for these lease agreements pursuant to ASC 842 and ASC 805 and recorded both an asset and liability at the present value of future lease payments as part of the purchase accounting. The finance leases are for two facilities with remaining lease terms of 7 and 11 years and contain a bargain purchase option of 3% at the end of the lease term. The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases: As of September 25, 2021 As of September 26, 2020 Operating Leases Finance Lease Operating Leases Finance Lease Weighted average remaining lease term 4.95 7.52 5.58 7.64 Weighted average discount rate 1.6 % 4.3 % 2.0 % 5.1 % The following table provides information related to the Company’s operating and finance leases: Year Ended September 25, 2021 Year Ended September 26, 2020 Operating lease cost (a) $ 30.1 $ 27.5 Finance lease cost - amortization of right-of-use assets $ 0.6 $ 0.3 Finance lease cost - interest cost $ 1.0 $ 1.0 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 1.0 $ 1.0 Operating cash flows from operating leases $ 28.2 $ 23.9 Financing cash flows from finance leases $ 2.4 $ 1.7 Total cash paid for amounts included in the measurement of lease liabilities $ 31.6 $ 26.6 ROU assets arising from entering into new operating lease obligations $ 28.6 $ 13.3 ROU assets arising from entering into new finance lease obligations $ 9.1 $ — (a) Includes short-term lease expense and variable lease costs, which were immaterial for the year ended September 25, 2021. Rent expense under FASB ASC Topic 840 was $23.1 million for fiscal 2019. The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of September 25, 2021: Fiscal Year Operating Leases Finance Lease 2022 $ 28.2 $ 4.4 2023 22.0 4.2 2024 16.4 3.9 2025 11.8 3.9 2026 7.4 3.9 Thereafter 11.7 10.2 Total future minimum lease payments 97.5 30.5 Less: imputed interest (4.6) (4.0) Present value of lease liabilities $ 92.9 $ 26.5 Lessor Activity - Leases where Hologic is the Lessor Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating lease and performance obligations for disposables, reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. Sales-type leases are immaterial. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented less than 5% of the Company’s consolidated revenue for all periods presented. In connection with the disposition of the Medical Aesthetics business in fiscal 2020, the Company entered into an agreement to sublease to Cynosure its U.S. headquarters and manufacturing location. As such, the Company derecognized $10.2 million for the right-of-use asset for the finance lease and recorded a lease receivable, which is $17.4 million as of September 25, 2021. The Company leases a portion of a building it owns and subleases some of its rented facilities and has received aggregate rental income of $2.6 million, $2.0 million and $2.7 million in fiscal 2021, 2020 and 2019, respectively, which has been recorded as an offset to operating lease costs. The future minimum annual rental income payments under these lease and sublease agreements at September 25, 2021 are as follows: Fiscal 2022 $ 3.1 Fiscal 2023 3.0 Fiscal 2024 3.0 Fiscal 2025 2.0 Fiscal 2026 0.9 Thereafter 2.3 Total $ 14.3

Business Combinations

Business Combinations	12 Months Ended
	Sep. 25, 2021
Business Combinations [Abstract]
Business Combinations	Business Combinations During fiscal 2021, 2020, and 2019, the Company completed several business combinations for a total consideration of $1,178.9 million, $269.0 million and $120.1 million, respectively. The business combinations resulted in the recognition of intangible assets, goodwill and other assets and liabilities summarized below. During 2021, the Company also completed an asset acquisition of customer relationship assets of $5.6 million. Mobidiag Oy On June 17, 2021, the Company completed the acquisition of Mobidiag Oy ("Mobidiag"), for a purchase price of $729.6 million. Mobidiag, located in Finland, manufactures molecular diagnostic solutions for gastrointestinal infections, antimicrobial resistance management and other infections. Mobidiag's results of operations are reported in the Company's Diagnostics reportable segment from the date of acquisition. The total purchase price was allocated to Mobidiag's preliminary tangible and identifiable intangible assets and liabilities based on the estimated fair values as of June 17, 2021, as set forth below. Cash $ 7.0 Accounts receivable 4.2 Inventory 13.7 Other assets 29.6 Accounts payable and accrued expenses (19.1) Other liabilities (11.7) Identifiable intangible assets: Developed technology 285.0 In-process research and development 74.0 Customer relationships 20.9 Trade names 20.0 Current debt (66.1) Deferred income taxes, net (60.5) Goodwill 432.6 Purchase Price $ 729.6 In performing the preliminary purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of Mobidiag's business. The allocation of the purchase price is preliminary as the Company continues to gather information supporting the acquired assets and liabilities, primarily related to deferred income taxes. As part of the preliminary purchase price allocation, the Company determined the identifiable intangible assets are development technology, in-process research and development ("IPR&D"), customer relationships and trade names. The preliminary fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using rates ranging from 15.0% to 19.0%. The cash flows were based on estimates used to price the transaction, and the discount rates applied were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The developed technology assets are comprised of know-how, patents and technologies embedded in Mobidiag's products and relate to currently marketed products. The developed technology assets comprise the primary product families under the Novodiag and Amplidiag technology platforms. The IPR&D project relates to an in-process project that has not reached technological feasibility as of the acquisition date and has no alternative future use. The primary basis for determining technological feasibility of the project is obtaining regulatory approval to market the underlying product. The asset recorded relates to one project, and the Company expects to complete the project over the next three years. In the fourth quarter of fiscal 2021, the Company updated its valuation of IPR&D assets based on facts that existed at the date of acquisition and recorded a $29.0 million decrease to the IPR&D intangible asset value. Given the uncertainties inherent with product development and introduction, there can be no assurance that the Company's product development efforts will be successful, completed on a timely basis or within budget, if at all. The IPR&D asset was valued using the income approach. The preliminary estimate of the weighted average life for the developed technology assets range from 8 to 12 years, customer relationships range from 5 to 10 years, and tradenames range from 8 to 12 years. The preliminary calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. Factors contributing to the recognition of the preliminary amount of goodwill were primarily based on anticipated strategic and synergistic benefits that are expected to be realized from the Mobidiag acquisition. These benefits include expanding the Company's molecular diagnostics portfolio into the near-patient testing market and utilizing the Diagnostic's commercial sales, manufacturing and regulatory expertise to drive adoption and revenue growth. None of the goodwill is expected to be deductible for income tax purposes. Biotheranostics On February 22, 2021, the Company completed the acquisition of Biotheranostics, Inc. ("Biotheranostics"), for a purchase price of $231.3 million. Biotheranostics, located in San Diego, California, manufactures molecular diagnostic tests for breast and metastatic cancers and performs the lab testing procedures at its facility. Biotheranostics' results of operations are reported in the Company's Diagnostics reportable segment from the date of acquisition and its revenues are reported within service and other revenue in the Company's consolidated statement of income and within service revenue in the disclosure of disaggregated revenue in Note 3. The total purchase price was allocated to Biotheranostics' preliminary tangible and identifiable intangible assets and liabilities based on the estimated fair values as of February 22, 2021, as set forth below. Cash $ 9.6 Accounts receivable 6.6 Other assets 6.5 Accounts payable and accrued expenses (8.2) Other liabilities (8.1) Identifiable intangible assets: Developed technology 160.3 Trade names 2.1 Deferred income taxes, net (18.4) Goodwill 80.9 Purchase Price $ 231.3 In performing the preliminary purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of Biotheranostics' business. The allocation of the purchase price is preliminary as the Company continues to gather information supporting the acquired assets and liabilities. As part of the preliminary purchase price allocation, the Company determined the identifiable intangible assets are developed technology and trade names. The preliminary fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using a 18.0% rate. The cash flows were based on estimates used to price the transaction, and the discount rate applied was benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The weighted average life of developed technology and trade names is 10 years. The preliminary calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. Factors contributing to the recognition of the preliminary amount of goodwill were primarily based on anticipated synergistic benefits of adding Biotheranostics' Clinical Laboratory Improvement Amendments (CLIA) lab to the Company's portfolio of offerings and of utilizing Diagnostic's marketing and regulatory expertise to drive adoption and revenue growth. None of the goodwill is expected to be deductible for income tax purposes. Diagenode On March 1, 2021, the Company completed the acquisition of Diagenode SA ("Diagenode") for a purchase price of $155.1 million. Diagenode, located in Belgium, is a developer and manufacturer of molecular diagnostic assays based on PCR (polymerase chain reaction) technology to detect infectious diseases of bacterial, viral or parasite origin. Diagenode's results of operations are reported in the Company's Diagnostics reportable segment from the date of acquisition. The total purchase price was allocated to Diagenode's preliminary tangible and identifiable intangible assets and liabilities based on the estimated fair values as of March 1, 2021, as set forth below. Cash $ 5.6 Accounts receivable 9.3 Inventory 9.0 Other assets 13.9 Accounts payable and accrued expenses (16.7) Other liabilities (9.2) Identifiable intangible assets: Developed technology 69.8 Customer relationships 9.2 Deferred income taxes, net (19.3) Goodwill 83.5 Purchase Price $ 155.1 In performing the preliminary purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of Diagenode's business. The allocation of the purchase price is preliminary as the Company continues to gather information supporting the acquired assets and liabilities, primarily related to deferred income taxes. As part of the preliminary purchase price allocation, the Company determined the identifiable intangible assets are developed technology and customer relationships. The preliminary fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using a 14.5% rate for developed technology and a 13.5% rate for customer relationships. The cash flows were based on estimates used to price the transaction, and the discount rate applied was benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The weighted average life of developed technology and customer relationships is 10 years. The preliminary calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. Factors contributing to the recognition of the preliminary amount of goodwill were based on anticipated synergistic benefits of Diagenode's products broadening the Diagnostics portfolio of molecular diagnostics products primarily in the transplant and acute care gastrointestinal and respiratory space as customers seek a broader menu of tests, utilizing Diagnostic's sales force to drive menu expansion and revenue growth and gaining additional PCR assay development expertise. None of the goodwill is expected to be deductible for income tax purposes. Somatex Medical Technologies On December 30, 2020, the Company completed the acquisition of Somatex Medical Technologies GmbH ("Somatex") for a purchase price of $62.9 million. Somatex, located in Germany, is a manufacturer of biopsy site markers, including the Tumark product line of tissue markers, which were distributed by the Company in the U.S. prior to the acquisition. The allocation of the purchase price is based on the Company's preliminary valuation, and it allocated $38.0 million to the preliminary value of developed technology, $1.2 million to customer relationships, $0.9 million to trade names and $32.4 million to goodwill. The remaining $9.6 million of the purchase price was allocated to the net acquired tangible assets and liabilities. The allocation of the purchase price is preliminary as the Company continues to gather information supporting the acquired assets and liabilities, primarily related to deferred income taxes. Somatex' results of operations are reported in the Company's Breast Health reportable segment from the date of acquisition. None of the goodwill is expected to be deductible for income tax purposes. NXC Imaging On September 28, 2020, the Company completed the acquisition of assets from NXC Imaging for a purchase price of $5.6 million. NXC Imaging was a long-standing distributor of the Company's Breast and Skeletal Health products in the U.S. The majority of the purchase price was allocated to a customer relationships intangible asset with a useful life of 5 years. Acessa Health On August 23, 2020, the Company completed the acquisition of Acessa Health, Inc. ("Acessa") for a purchase price of $162.0 million, which included a hold-back of $3.0 million that was paid in January 2021, and contingent consideration, which the Company estimated the fair value to be $81.8 million as of the measurement date. Acessa, located in Austin, Texas, manufactures and markets its ProVu system, a laparoscopic radio frequency ablation system for use in treatment of uterine fibroids. Acessa's results of operations are reported in the Company's GYN Surgical reportable segment from the date of acquisition. The contingent payments are based on a multiple of annual incremental revenue growth over a three-year period ending annually in December. There is no maximum earnout. Pursuant to ASC 805, Business Combinations, the Company recorded its estimate of the fair value of the contingent consideration liability utilizing the Monte Carlo simulation based on future revenue projections of Acessa, comparable companies revenue growth rates, implied volatility and applying a risk adjusted discount rate. Each quarter the Company is required to remeasure the fair value of the liability as assumptions change and such adjustments will be recorded in operating expenses. This fair value measurement was based on significant inputs not observable in the market and thus represented a Level 3 measurement as defined in ASC 820, Fair Value Measurements . This fair value measurement is directly impacted by the Company's estimate of future incremental revenue growth of the business. Accordingly, if actual revenue growth is higher or lower than the estimates within the fair value measurement, the Company would record additional charges or benefits, respectively. For the year ended September 25, 2021, the Company remeasured the contingent consideration liability and recorded a gain of $6.7 million to record the liability at fair value. The reduction in fair value was primarily due to a decrease in forecasted revenues over the measurement period, partially offset by a lower discount rate and accretion of the liability based on the passage of time. As of September 25, 2021, the Company’s contingent consideration liability was $75.1 million, $16.3 million of which was recorded within accrued expenses and $58.8 million was recorded within other long-term liabilities. The total purchase price was allocated to Acessa's tangible and identifiable intangible assets and liabilities based on the estimated fair values of those assets as of August 23, 2020, as set forth below. Cash $ 1.2 Inventory 4.0 Other assets 4.4 Accounts payable and accrued expenses (4.7) Identifiable intangible assets: Developed Technology 127.0 Trade names 1.2 Deferred income taxes, net (20.2) Goodwill 49.1 Purchase Price $ 162.0 In performing the purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of Acessa's business. As part of the purchase price allocation, the Company determined the identifiable intangible assets were developed technology and trade names. The fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using an 18.0% rate. The cash flows were based on estimates used to price the transaction, and the discount rate applied was benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The weighted average life of developed technology and trade names is 10 years. The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. Factors contributing to the recognition of the amount of goodwill were based on synergistic benefits of Acessa's products being complementary to the GYN Surgical portfolio of products and utilizing the GYN Surgical sales force to drive adoption and revenue growth. None of the goodwill is expected to be deductible for income tax purposes. Health Beacons On February 3, 2020, the Company completed the acquisition of Health Beacons, Inc. ("Health Beacons") for a purchase price of $19.7 million, which included hold-backs of $2.3 million that are payable up to eighteen months from the date of acquisition. Health Beacons manufactures the LOCalizer product. Based on the Company's valuation, it allocated $10.7 million to developed technology and $6.2 million to goodwill. The remaining $2.8 million of the purchase price was allocated to acquired tangible assets and liabilities. Health Beacons' results of operations are reported in the Company's Breast Health reportable segment from the date of acquisition. Alpha Imaging On December 30, 2019, the Company completed the acquisition of assets from Alpha Imaging, LLC ("Alpha Imaging") for a purchase price of $18.0 million, which included a hold-back of $1.0 million and contingent consideration which the Company estimated at $0.9 million. The contingent consideration was payable upon shipment of backlog orders entered into by Alpha Imaging prior to the acquisition. Alpha Imaging was a long-standing distributor of the Company's Breast and Skeletal Health products in the U.S. The majority of the purchase price was allocated to a customer relationships intangible asset with a useful life of 5 years. SuperSonic Imagine On August 1, 2019, the Company purchased 46% of the outstanding shares of SuperSonic Imagine SA ("SSI") for $18.2 million. SSI was a public company located in Aix-en-Provence, France that manufactures and markets ultrasound medical imaging equipment. In September 2019, the Company launched a cash tender offer to acquire the remaining outstanding shares for a price of €1.50 per share in cash. The Company determined that SSI was a Variable Interest Entity (“VIE”) but it was not the primary beneficiary as it was not a party to the initial design of the entity nor did it have control over SSI's operations until November 21, 2019 when the Company's ownership of SSI's voting stock exceeded 50%. Accordingly, the Company initially accounted for this investment under the equity method of accounting and included its proportionate share of SSI's net loss of $3.3 million for the two months ended September 28, 2019 within Other income (expense), net. On November 21, 2019, the Company acquired an additional 7.6 million of SSI's common shares for $12.6 million. As a result, the Company owned approximately 78% of the outstanding common shares at November 21, 2019, and controlled SSI's voting interest and operations. The Company performed purchase accounting as of November 21, 2019 and beginning on that date the financial results of SSI are included within the Company's consolidated financial statements, specifically the Breast Health reportable segment. The Company remeasured the initial investment of 46% of the outstanding shares of SSI to its fair value at the acquisition date, resulting in a gain of $3.2 million recorded to other income (expense), net in the first quarter of fiscal 2020. The total accounting purchase price was $69.3 million, which consisted of $17.9 million for the equity method investment in SSI, $12.6 million for shares acquired on November 21, 2019, $30.2 million for loans the Company provided to SSI prior to the acquisition to pay-off pre-existing loans and fund operations that are considered forgiven, and $8.6 million representing the fair value of the noncontrolling interest as of November 21, 2019. The Company purchased an additional 1.1 million outstanding shares in fiscal 2020 for $1.8 million. In the third quarter of fiscal 2021, the Company purchased the remaining 4.8 million shares outstanding for $8.5 million and as of September 25, 2021, the Company owned 100% of the outstanding shares of SSI. The total purchase price was allocated to SSI's tangible and identifiable intangible assets and liabilities based on the estimated fair values of those assets as of November 21, 2019, as set forth below. Cash $ 2.6 Accounts receivable 7.1 Inventory 10.0 Property, plant and equipment 6.5 Other assets 4.3 Accounts payable and accrued expenses (24.5) Deferred revenue (1.8) Short and long-term debt (8.8) Other liabilities (3.8) Identifiable intangible assets: Developed technology 38.3 Customer relationships 4.0 Trade names 3.0 Deferred income taxes, net (1.9) Goodwill 34.3 Purchase Price $ 69.3 In performing the purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of SSI's business. As part of the purchase price allocation, the Company determined the identifiable intangible assets were developed technology, customer relationships, and trade names. The fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using a 12.0% rate. The cash flows were based on estimates used to price the transaction, and the discount rates applied were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The weighted average life for the developed technology is 9 years, customer relationships is 9 years and trade names is 8.6 years. The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. Factors contributing to the recognition of the amount of goodwill were based on anticipated synergistic benefits of SSI's products being complementary to Breast Health's 3D mammography systems and using the Company's existing U.S. sales force as SSI's presence in the U.S. is limited. None of the goodwill is expected to be deductible for income tax purposes. Focal Therapeutics On October 1, 2018, the Company completed the acquisition of Focal Therapeutics, Inc. ("Focal") for a purchase price of $120.1 million, which included hold-backs of $14.0 million payable up to one year from the date of acquisition. In the second quarter of fiscal 2019, $1.5 million of the hold-back was paid, and the remaining $12.5 million was paid in the first quarter of fiscal 2020. Focal, headquartered in California, manufactures and markets its BioZorb marker, which is an implantable three-dimensional marker that helps clinicians overcome certain challenges in breast conserving surgery. Focal's results of operations are reported in the Company's Breast Health reportable segment from the date of acquisition. The total purchase price was allocated to Focal's tangible and identifiable intangible assets and liabilities based on the estimated fair values of those assets as of October 1, 2018, as set forth below: Cash $ 2.2 Accounts receivable 2.0 Inventory 7.9 Other assets 0.5 Accounts payable and accrued expenses (5.6) Long-term debt (2.5) Identifiable intangible assets: Developed technology 83.1 In-process research and development 11.4 Trade names 2.7 Deferred income taxes, net (12.7) Goodwill 31.1 Purchase Price $ 120.1 In performing the purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of Focal's business. As part of the purchase price allocation, the Company determined the identifiable intangible assets were developed technology, in-process research and development, and trade names. The fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using rates ranging from 15.5% to 16.5%. The cash flows were based on estimates used to price the transaction, and the discount rates applied were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The weighted average life of developed technology and trade names was 11 years and 13 years, respectively. The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. The factors contributing to the recognition of the amount of goodwill were based on synergistic benefits that are expected to be realized from this acquisition. Benefits include the expectation of broadening the Company's Breast Health portfolio of products and technology. None of the goodwill is expected to be deductible for income tax purposes.

Restructuring Charges

Restructuring Charges	12 Months Ended
	Sep. 25, 2021
Restructuring and Related Activities [Abstract]
Restructuring Charges	Restructuring and Divestiture Charges The Company evaluates its operations for opportunities to improve operational effectiveness and efficiency, including facility and operations consolidation, and to better align expenses with revenues. As a result of these assessments, the Company has undertaken various restructuring actions which are described below. The following table displays charges taken related to restructuring actions in fiscal 2021, 2020 and 2019 and a rollforward of the charges to the accrued balances as of September 25, 2021: Fiscal 2021 Actions Fiscal 2020 Actions Fiscal 2019 Actions Other Total Restructuring Charges Fiscal 2019 charges: Workforce reductions $ — $ — $ 4.0 $ 1.4 $ 5.4 Facility closure costs — — — 1.2 1.2 Fiscal 2019 restructuring charges $ — $ — $ 4.0 $ 2.6 $ 6.6 Fiscal 2020 charges: Workforce reductions $ — $ 13.2 $ 0.3 $ (0.1) $ 13.4 Facility closure costs — 1.9 — — 1.9 Fiscal 2020 restructuring charges $ — $ 15.1 $ 0.3 $ (0.1) $ 15.3 Fiscal 2021 charges: Workforce reductions $ 8.7 $ 0.6 $ — $ — $ 9.3 Fiscal 2021 restructuring charges $ 8.7 $ 0.6 $ — $ — $ 9.3 Fiscal 2021 Actions Fiscal 2020 Actions Fiscal 2019 Actions Fiscal 2018 Actions Previous Other Charges Total Rollforward of Accrued Restructuring Balance as of September 29, 2018 $ — $ — $ — $ 4.3 $ 4.8 $ 9.1 Fiscal 2019 restructuring charges $ — $ — $ 4.0 $ 1.2 $ 1.4 $ 6.6 Severance payments and adjustments — — (3.0) (3.9) (0.8) (7.7) Other payments — — — (0.5) (1.6) (2.1) Balance as of September 28, 2019 $ — $ — $ 1.0 $ 1.1 $ 3.8 $ 5.9 Fiscal 2020 restructuring charges $ — $ 15.1 $ 0.3 $ (0.1) $ — $ 15.3 Stock-based compensation — (7.5) — — — (7.5) Severance payments and adjustments — (4.4) (1.3) (0.2) — (5.9) Other payments and adjustments (1) — 0.5 — — (3.8) (3.3) Balance as of September 26, 2020 $ — $ 3.7 $ — $ 0.8 $ — $ 4.5 Fiscal 2021 restructuring charges $ 8.7 $ 0.6 $ — $ — $ — $ 9.3 Stock-based compensation (0.9) — — — — (0.9) Severance payments and adjustments (4.6) (3.4) — (0.8) — (8.8) Balance as of September 25, 2021 $ 3.2 $ 0.9 $ — $ — $ — $ 4.1 (1) In fiscal 2020, as part of the adoption of ASC 842, the Company reclassified $3.8 million from a lease liability to offset the right of use asset on the Company's consolidated balance sheet. Fiscal 2021 Actions During fiscal 2021, the Company made various decisions to terminate certain individuals across all divisions in multiple departments and close certain manufacturing facilities for minor product lines. The Company recorded $8.7 million for severance and benefits related to these actions, which occurred in the U.S. and various international locations. The charges were recorded pursuant to ASC 712, Compensation-Nonretirement Postemployment Benefits (ASC 712) or ASC 420, Exit or Disposal Cost Obligations (ASC 420), depending on the employee. Fiscal 2020 Actions During fiscal 2020, the Company made various decisions to terminate certain personnel across all divisions in multiple departments, transfer production and close certain manufacturing facilities for minor product lines. The Company recorded charges totaling $13.4 million for severance and benefits related to these actions. The charges were recorded pursuant to ASC 712 or ASC 420, depending on the employee. Included within this charge was $5.0 million related to the modification of equity awards for a certain executive. These actions are complete. During the second quarter of fiscal 2020, the Company recorded net divestiture charges of $1.9 million. The charge included $1.3 million to dispose of the Company's life sciences testing business located in the UK, which performed research testing for pharmaceutical companies. Separately, in connection with the Cynosure divestiture, the Company accelerated stock compensation expense and other benefits of $2.6 million, partially offset by other adjustments of $2.0 million. Fiscal 2019 Actions During fiscal 2019, the Company decided to transfer certain shared services positions to its Costa Rica facility from its Marlborough location and announced the termination of certain personnel and implemented other employee termination actions. The charges for these actions were recorded pursuant to ASC 420 for one-time termination benefits. The Company recorded severance benefits charges of $4.0 million in fiscal 2019 related to these actions and this action was completed in the first quarter of fiscal 2020. The Company also recorded $1.0 million of severance charges in fiscal 2019 related to 2018 actions that were recorded pursuant to ASC 420. Other In connection with the closure of the Bedford location during the first quarter of fiscal 2017, the Company recorded $3.5 million for lease obligation charges related to the first floor of the facility as the Company determined it had met the cease-use date criteria. The Company made certain assumptions regarding the time period it would take to obtain a subtenant and the sublease rates it could obtain. During the third quarter of fiscal 2017, the Company updated its assumption regarding the time period it would take to obtain a subtenant at the Bedford location and as a result recorded an additional $1.3 million lease obligation charge. During the third quarter of fiscal 2018, the Company further adjusted its assumptions and lowered the estimate of the sublease income rate and extended the time period to obtain a sub-tenant. As a result, the Company recorded an additional charge of $1.6 million. During the third quarter of fiscal 2019, the Company further updated its assumption regarding its ability to sublet the first floor and recorded an additional lease obligation charge of $1.4 million. These estimates may vary from the actual sublease agreements executed, if any, resulting in an adjustment to the charge. The Company has vacated other portions of the building but not the entire facility, and at this time does not meet the cease-use date criteria to record additional restructuring charges. In connection with the adoption of ASC 842, the Company reclassified the remaining accrued lease balance of $3.8 million from restructuring to offset the right of use assets on the consolidated balance sheet.

Borrowings and Credit Arrangeme

Borrowings and Credit Arrangements	12 Months Ended
	Sep. 25, 2021
Debt Disclosure [Abstract]
Borrowings and Credit Agreements	Borrowings and Credit Agreements The Company’s borrowings consisted of the following: September 25, September 26, Current debt obligations, net of debt discount and deferred issuance costs: Term Loan $ — $ 74.9 Revolver — 250.0 Securitization Program 248.5 — Other 64.5 — Total current debt obligations $ 313.0 $ 324.9 Long-term debt obligations, net of debt discount and issuance costs: Term Loan 1,382.3 1,379.9 2025 Senior Notes — 939.4 2028 Senior Notes 395.4 394.6 2029 Senior Notes 934.5 — Total long-term debt obligations 2,712.2 2,713.9 Total debt obligations $ 3,025.2 $ 3,038.8 The debt maturity schedule for the Company’s obligations as of September 25, 2021 was as follows: 2022 2023 2024 2025 2026 2027 and Thereafter Total Term Loan* $ 75.0 $ 112.5 $ 1,200.0 $ — $ — $ — $ 1,387.5 Securitization Program 248.5 — — — — — 248.5 2028 Senior Notes — — — — — 400.0 400.0 2029 Senior Notes — — — — — 950.0 950.0 Other 64.5 — — — — — 64.5 $ 388.0 $ 112.5 $ 1,200.0 $ — $ — $ 1,350.0 $ 3,050.5 *The Term Loan debt maturity schedule herein represents the 2018 Credit Agreement as of September 25, 2021. The Company amended the credit agreement on September 27, 2021, which resulted in a change in the principal maturity schedule. 2018 Amended and Restated Credit Agreement On December 17, 2018, the Company and certain of its subsidiaries refinanced its term loan and revolving credit facility by entering into an Amended and Restated Credit and Guaranty Agreement as of December 17, 2018 (the "2018 Credit Agreement") with Bank of America, N.A. in its capacity as Administrative Agent, Swing Line Lender and L/C Issuer, and certain other lenders. The 2018 Credit Agreement amended and restated the Company's prior credit and guaranty agreement as of October 3, 2017 ("2017 Credit Agreement"). The credit facilities under the 2018 Credit Agreement consisted of: • A $1.5 billion secured term loan ("2018 Term Loan") with a maturity date of December 17, 2023; and • A secured revolving credit facility ("2018 Revolver") under which the Company could borrow up to $1.5 billion, subject to certain sublimits, with a maturity date of December 17, 2023. Borrowings under the 2018 Credit Agreement bore interest, at the Company's option and in each case plus an applicable margin as follows: • 2018 Term Loan : at the Base Rate, Eurocurrency Rate or LIBOR Daily Floating Rate, • 2018 Revolver : if funded in U.S. dollars, the Base Rate, Eurocurrency Rate, or LIBOR Daily Floating Rate, and, if funded in an alternative currency, the Eurocurrency Rate; and if requested under the swing line sublimit, the Base Rate. As of September 25, 2021, the Company had no amounts outstanding under the 2018 Revolver and the interest rate under the 2018 Term Loan was 1.08%. The applicable margin to the Base Rate, Eurocurrency Rate, or LIBOR Daily Floating Rate was subject to specified changes depending on the total net leverage ratio as defined in the 2018 Credit Agreement. The borrowings of the 2018 Term Loan initially bore interest at an annual rate equal to the Eurocurrency Rate (i.e., the LIBOR rate) plus an Applicable Rate equal to 1.00%. The borrowings of the 2018 Revolver initially bore interest at a rate equal to the LIBOR Daily Floating Rate plus an Applicable Rate, which was 1.00% at September 25, 2021. The Company was also required to pay a quarterly commitment fee calculated on the undrawn committed amount available under the 2018 Revolver. The Company was required to make scheduled principal payments under the 2018 Term Loan in increasing amounts ranging from $9.375 million per three-month period commencing with the three-month period ending on December 27, 2019 to $28.125 million per three-month period commencing with the three-month period ending on December 29, 2022 and ending on September 29, 2023. The remaining balance of the 2018 Term Loan after the scheduled principal payments, which was $1.2 billion, and any amounts outstanding under the 2018 Revolver were due at maturity. In addition, subject to the terms and conditions set forth in the 2018 Credit Agreement, the Company could have been required to make certain mandatory prepayments from the net proceeds of specified types of asset sales (subject to certain reinvestment rights), debt issuances and insurance recoveries (subject to certain reinvestment rights). These mandatory prepayments were required to be applied by the Company, first, to the 2018 Term Loan, second, to any outstanding amount under any Swing Line Loans, third, to the 2018 Revolver, fourth to prepay any outstanding reimbursement obligations with respect to Letters of Credit and fifth, to cash collateralize any Letters of Credit. Subject to certain limitations, the Company could have voluntarily prepaid any of the 2018 Credit Facilities without premium or penalty. The 2018 Credit Agreement contained affirmative and negative covenants customarily applicable to senior secured credit facilities, including covenants restricting the ability of the Company, subject to negotiated exceptions, to incur additional indebtedness and grant additional liens on its assets, engage in mergers or acquisitions or dispose of assets, enter into sale-leaseback transactions, pay dividends or make other distributions, voluntarily prepay other indebtedness, enter into transactions with affiliated persons, make investments, and change the nature of their businesses. In addition, the 2018 Credit Agreement required the Company to maintain certain financial ratios. The 2018 Credit Agreement also contained customary representations and warranties and events of default, including payment defaults, breach of representations and warranties, covenant defaults, cross defaults and an event of default upon a change of control of the Company. Borrowings were secured by first-priority liens on, and a first-priority security interest in, substantially all of the assets of the Company and its U.S. subsidiaries, with certain exceptions. The 2018 Credit Agreement contained total net leverage ratio and interest coverage ratio financial covenants measured as of the last day of each fiscal quarter. The total net leverage ratio covenant was 5.00:1.00 beginning on the Company's fiscal quarter ended December 29, 2018, and would have remained as such until it decreased to 4.50:1.00 for the quarter ending June 25, 2022. The interest coverage ratio covenant was 3.75:1.00 beginning on the Company's fiscal quarter ended December 29, 2018, and remained as such for each quarter thereafter. The total net leverage ratio was defined as the ratio of the Company's consolidated net debt as of the quarter end to its consolidated adjusted EBITDA (as defined in the 2018 Credit Agreement) for the four-fiscal quarter period ending on the measurement date. The interest coverage ratio was defined as the ratio of the Company's consolidated adjusted EBITDA for the prior four-fiscal quarter period ending on the measurement date to adjusted consolidated cash interest expense (as defined in the 2018 Credit Agreement) for the same measurement period. The Company was in compliance with these covenants as of September 25, 2021. The Company evaluated the 2018 Credit Agreement for derivatives pursuant to ASC 815, Derivatives and Hedging , and identified embedded derivatives that required bifurcation as the features were not clearly and closely related to the host instrument. The embedded derivatives were a default provision, which could require additional interest payments, and a provision requiring contingent payments to compensate the lenders for changes in tax deductions. The Company determined that the fair value of these embedded derivatives was nominal as of September 25, 2021. Pursuant to ASC 470, Debt (ASC 470), the accounting related to entering into the 2018 Credit Agreement and using the proceeds to pay off the 2017 Credit Agreement was evaluated on a creditor-by-creditor basis to determine whether each transaction should be accounted for as a modification or extinguishment. Certain creditors under the 2017 Credit Agreement did not participate in this refinancing transaction and ceased being creditors of the Company. As a result, the Company recorded a debt extinguishment loss of $0.8 million in the first quarter of fiscal 2019. For the remainder of the creditors, this transaction was accounted for as a modification because on a creditor-by-creditor basis the present value of the cash flows between the two debt instruments before and after the transaction was less than 10%. Interest expense, non-cash interest expense, the weighted average interest rate, and the interest rate at the end of period under the 2018 Credit Agreement and the 2017 Credit Agreement was as follows: Years Ended September 25, 2021 September 26, 2020 September 28, 2019 Interest expense (1) $ 22.0 $ 46.6 $ 67.0 Non-cash interest expense $ 2.5 $ 2.5 $ 2.6 Weighted average interest rate 1.13 % 2.25 % 3.79 % Interest rate at end of period 1.08 % 1.40 % 3.43 % (1) Interest expense includes non-cash interest expense related to the amortization of the deferred issuance costs and accretion of the debt discount. 2021 Credit Agreement - Subsequent Event On September 27, 2021, the Company and certain of its subsidiaries refinanced its term loan and revolving credit facility under the 2018 Credit Agreement by entering into Refinancing Amendment No. 2 dated as of September 27, 2021, to the Amended and Restated Credit and Guaranty Agreement as of October 3, 2017, as amended (the "2021 Credit Agreement") with Bank of America, N.A. in its capacity as Administrative Agent, Swing Line Lender and L/C Issuer, and certain other lenders. The 2021 Credit Agreement amends the Company's 2018 Credit Agreement. Substantially all of the proceeds under the 2021 Credit Agreement of $1.5 billion were used to repay the amounts outstanding under the 2018 Credit Agreement. Borrowings under the 2021 Credit Agreement are secured by first-priority liens on, and a first-priority security interest in (in each case subject to certain liens permitted under the 2021 Credit Agreement), substantially all of the Company's U.S. assets of the Subsidiary Guarantors. These liens are subject to release during the term of the facilities if the Company is able to achieve certain corporate or corporate family ratings and other conditions are met. The credit facilities under the 2021 Credit Agreement consist of: • A $1.5 billion secured term loan ("2021 Term Loan") with a maturity date of September 25, 2026; and • A secured revolving credit facility ("2021 Revolver") under which the Company may borrow up to $2.0 billion, subject to certain sublimits, with a maturity date of September 25, 2026. Borrowings under the 2021 Credit Agreement, other than Swing Line Loans (as defined in the 2021 Credit Agreement), bear interest, at the Company's option, at the Base Rate (as defined in the 2021 Credit Agreement), at the Eurocurrency Rate (as defined in the 2021 Credit Agreement), at the Alternative Currency Daily Rate (as defined in the 2021 Credit Agreement), or at the LIBOR Daily Floating Rate (as defined in the 2021 Credit Agreement), in each case plus the Applicable Rate (as defined in the 2021 Credit Agreement). The Applicable Rate in regards to the Base Rate, the Eurocurrency Rate, the Alternative Currency Daily Rate, the Alternative Currency Term Rate, and the LIBOR Daily Floating Rate is subject to change depending on the Total Net Leverage Ratio (as defined in the 2021 Credit Agreement). The borrowings of the Term Loan under the 2021 Credit Facilities initially bear interest at an annual rate equal to the Eurocurrency Rate for a one month interest period plus an Applicable Rate equal to 1.00%. The Company is also required to pay a quarterly commitment fee calculated on daily basis equal to the Applicable Rate as of such day multiplied by the undrawn committed amount available under the Revolver (taking into account any outstanding amounts under the LC Sublimit). This commitment fee is initially 0.15% per annum for the Revolver. The Company is required to make scheduled principal payments under the 2021 Term Loan in increasing amounts ranging from $3.75 million per three-month period commencing with the three-month period ending on December 29, 2022 to $18.75 million per three-month period commencing with the three month period ending on December 26, 2025. The remaining balance of $1.335 billion (or such lesser aggregate principal amount of Term Loans then outstanding) on the 2021 Term Loan and any amounts outstanding under the 2021 Revolver are due at maturity. In addition, subject to the terms and conditions set forth in the 2021 Credit Agreement, the Company is required to make certain mandatory prepayments from the net proceeds of specified types of asset sales (subject to certain reinvestment rights), debt issuances and insurance recoveries (subject to certain reinvestment rights). Certain of the mandatory prepayments are subject to reduction or elimination if certain financial covenants are met. These mandatory prepayments are required to be applied by the Company, first to the 2021 Term Loan, second to any outstanding amount under any Swing Line Loans, third to the 2021 Revolver, fourth to prepay any outstanding reimbursement obligations with respect to Letters of Credit and fifth to cash collateralize any Letters of Credit. Subject to certain limitations, the Company may voluntarily prepay any of the 2021 Credit Facilities without premium or penalty. The 2021 Credit Agreement contains affirmative and negative covenants customarily applicable to senior secured credit facilities, including covenants restricting the ability of the Company, subject to negotiated exceptions, to incur additional indebtedness and grant additional liens on its assets, engage in mergers or acquisitions or dispose of assets, enter into sale-leaseback transactions, pay dividends or make other distributions, voluntarily prepay other indebtedness, enter into transactions with affiliated persons, make investments, and change the nature of their businesses. In addition, the 2021 Credit Agreement requires the Borrowers to maintain certain financial ratios. The 2021 Credit Agreement also contains customary representations and warranties and events of default, including payment defaults, breach of representations and warranties, covenant defaults, cross defaults and an event of default upon a change of control of the Company. Senior Notes 2028 Senior Notes On January 19, 2018, the Company completed a private placement of $1.0 billion aggregate principal amount of senior notes and allocated $400 million in aggregate principal amount to its 4.625% Senior Notes due 2028 (the "2028 Senior Notes") at an offering price of 100% of the aggregate principal amount of the 2028 Senior Notes. The 2028 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain domestic subsidiaries. The 2028 Senior Notes mature on February 1, 2028 and bear interest at the rate of 4.625% per year, payable semi-annually on February 1 and August 1 of each year, commencing on August 1, 2018. The Company may redeem the 2028 Senior Notes at any time prior to February 1, 2023 at a price equal to 100% of the aggregate principal amount so redeemed, plus accrued and unpaid interest, if any, to the redemption date and a make-whole premium set forth in the indenture. The Company has the option to redeem the 2028 Senior Notes on or after: February 1, 2023 through February 1, 2024 at 102.312% of par; February 1, 2024 through February 1, 2025 at 101.541% of par; February 1, 2025 through February 1, 2026 at 100.770% of par; and February 1, 2026 and thereafter at 100% of par. In addition, if the Company undergoes a change of control coupled with a decline in ratings, as provided in the indenture, the Company will be required to make an offer to purchase each holder’s 2028 Senior Notes at a price equal to 101% of their principal amount, plus accrued and unpaid interest, if any, to the repurchase date. The Company evaluated the 2028 Senior Notes for derivatives pursuant to ASC 815 and did not identify any embedded derivatives that require bifurcation. All features were deemed to be clearly and closely related to the host instrument. 2029 Senior Notes On September 28, 2020, the Company completed a private placement of $950 million aggregate principal amount of its 3.250% Senior Notes due 2029 (the "2029 Senior Notes") at an offering price of 100% of the aggregate principal amount of the 2029 Senior Notes. The 2029 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain domestic subsidiaries. The 2029 Senior Notes mature on February 15, 2029 and bear interest at the rate of 3.250% per year, payable semi-annually on February 15 and August 15 of each year, commencing on February 15, 2021. The Company may redeem the 2029 Senior Notes at any time prior to September 28, 2023 at a price equal to 100% of the aggregate principal amount so redeemed, plus accrued and unpaid interest, if any, to the redemption date and a make-whole premium set forth in the indenture. The Company may also redeem up to 40% of the aggregate principal amount of the 2029 Senior Notes with the net cash proceeds of certain equity offerings at any time and from time to time before September 28, 2023, at a redemption price equal to 103.250% of the aggregate principal amount so redeemed, plus accrued and unpaid interest, if any, to the redemption date. The Company also has the option to redeem the 2029 Senior Notes on or after: September 28, 2023 through September 27, 2024 at 101.625% of par; September 28, 2024 through September 27, 2025 at 100.813% of par; and September 28, 2025 and thereafter at 100% of par. In addition, if the Company undergoes a change of control coupled with a decline in ratings, as provided in the indenture, the Company will be required to make an offer to purchase each holder’s 2029 Senior Notes at a price equal to 101% of their principal amount, plus accrued and unpaid interest, if any, to the repurchase date. The Company evaluated the 2029 Senior Notes for derivatives pursuant to ASC 815, Derivatives and Hedging , and did not identify any embedded derivatives that require bifurcation. All features were deemed to be clearly and closely related to the host instrument. 2025 Senior Notes The Company had 4.375% Senior Notes due 2025 (the “2025 Senior Notes”) outstanding and bore interest at the rate of 4.375% per year, payable semi-annually on April 15 and October 15 of each year. The Company used the net proceeds of the 2029 Senior Notes offering in the first quarter of fiscal 2021 to redeem in full the 2025 Senior Notes in the aggregate principal amount of $950.0 million on October 15, 2020 at an aggregate redemption price of $970.8 million, which included a premium payment of $20.8 million. Since the Company planned to use the proceeds from the 2029 Senior Notes offering to redeem the 2025 Senior Notes, the Company evaluated the accounting for this transaction under ASC 470 to determine modification versus extinguishment accounting on a creditor-by-creditor basis. Certain 2025 Senior Note holders either did not participate in this refinancing transaction or reduced their holdings and these transactions were accounted for as extinguishments. As a result, the Company recorded a debt extinguishment loss in the first quarter of fiscal 2021 of $21.6 million, which comprised pro-rata amounts of the premium payment, debt discount and debt issuance costs. For the remaining 2025 Senior Notes holders who participated in the refinancing, these transactions were accounted for as modifications because on a creditor-by-creditor basis the present value of the cash flows between the debt instruments before and after the transaction was less than 10%. The Company recorded a portion of the transaction expenses of $5.8 million to interest expense pursuant to ASC 470, subtopic 50-40. The remaining debt issuance costs of $7.9 million and debt discount of $6.4 million related to the modified debt are being amortized over the new term of the 2029 Senior Notes using the effective interest method. Interest expense for the 2029 Senior Notes, 2028 Senior Notes and 2025 Senior Notes was as follows: Years Ended September 25, 2021 September 26, 2020 September 28, 2019 Interest Rate Interest Expense (1) Non-Cash Interest Expense Interest Expense (1) Non-Cash Interest Expense Interest Expense (1) Non-Cash Interest Expense 2029 Senior Notes 3.250 % $ 32.7 $ 2.1 $ — $ — $ — $ — 2028 Senior Notes 4.625 % 19.2 0.7 19.2 0.7 19.2 0.7 2025 Senior Notes 4.375 % 2.3 0.1 43.5 2.1 43.5 2.1 Total $ 54.2 $ 2.9 $ 62.7 $ 2.8 $ 62.7 $ 2.8 (1) Interest expense includes non-cash interest expense related to the amortization of the deferred issuance costs and accretion of the debt discount. Accounts Receivable Securitization Program On April 25, 2016, the Company entered into a one-year $200.0 million accounts receivable securitization program (the "Securitization Program") with several of its wholly owned subsidiaries and certain financial institutions, which provides for annual renewals. Under the terms of the Securitization Program, the Company and certain of its wholly-owned subsidiaries sell their respective customer receivables to a bankruptcy remote special purpose entity, which is also a wholly-owned subsidiary of the Company. In addition, the Company also contributed a portion of its customer receivables to the special purpose entity in connection with its establishment. The Company retains servicing responsibility. The special purpose entity, as borrower, and the Company, as servicer, entered into a Credit and Security Agreement with several lenders pursuant to which the special purpose entity, at that time, could borrow up to $200.0 million from the lenders, with the loans secured by the receivables. The amount that the special purpose entity may borrow at a given point in time is determined based on the amount of qualifying receivables that are present in the special purpose entity at such point in time. Borrowings outstanding under the Securitization Program bear interest at LIBOR plus the applicable margin of 0.8% and are included as a component of current liabilities in the Company's consolidated balance sheet, while the accounts receivable securing these obligations remain as a component of net receivables in the Company's consolidated balance sheet. The Company and the special purpose entity are operated and maintained as separate legal entities. The assets of the special purpose entity secure the amounts borrowed and cannot be used to pay other debts or liabilities of the Company. In subsequent years, the Company amended the agreement to extend it for one-year periods and increased the borrowing capacity up to $250.0 million and lowered the applicable margin to 0.7%. In response to the market uncertainties created by the COVID-19 pandemic, on March 26, 2020, the Company paid off the total amount outstanding of $250.0 million previously borrowed. On April 13, 2020, the Company amended the Credit and Security Agreement with the lenders, temporarily suspending the ability to borrow and the need to comply with covenants for up to a year. On June 11, 2021, the Company amended and restated the Credit and Security Agreement to restart the Securitization Program and increased the maximum borrowing amount to $320.0 million. As of September 25, 2021, there was $248.5 million outstanding under this program. Borrowings under the Securitization Program for fiscal 2021 had a weighted-average interest rate of 0.8%. Interest expense under the Securitization Program was $0.9 million, $3.1 million and $7.1 million for fiscal 2021, 2020 and 2019, respectively. The interest rate on the amounts outstanding at September 25, 2021 was 0.8%. The Credit and Security Agreement contains customary representations and warranties and events of default, including payment defaults, breach of representations and warranties, covenant defaults, and an event of default upon a change of control of the Company. In addition, it contains financial covenants consistent with that of the Credit Agreement. As of September 25, 2021, the Company was not required to be in compliance with the Credit and Security Agreement covenants. Other Other represents debt acquired in the Mobidiag acquisition, which is primarily with the European Investment Bank ("EIB"). Multiple tranches were withdrawn under the agreement and were primarily used to fund research and development projects and expansion efforts. The debt agreement contains change-in-control provisions allowing the EIB to call the debt at any time after a change-in-control, which occurred as a result of Hologic acquiring Mobidiag. Accordingly, the Company has classified the debt as current. The tranches withdrawn under this agreement have interest rates ranging from 6.0% to 7.0%. The debt agreement includes additional payments to the EIB based on revenues generated by products developed under the funding as well as prepayment penalties.

Stockholders' Equity and Stock-

Stockholders' Equity and Stock-Based Compensation	12 Months Ended
	Sep. 25, 2021
Share-based Payment Arrangement [Abstract]
Stockholders' Equity and Stock-Based Compensation	Stockholders' Equity and Stock-Based Compensation Stock Repurchase Program On June 13, 2018, the Board of Directors authorized the repurchase of up to $500.0 million of the Company's outstanding common stock. This share repurchase plan was effective August 1, 2018 and expired March 27, 2020. Under this authorization, during fiscal 2019, the Company repurchased 4.8 million shares of its common stock for total consideration of $200.1 million. During the first and second quarters of fiscal 2020, the Company repurchased 3.9 million shares of its common stock for a total consideration of $210.9 million. As of March 28, 2020, the Company had completed this authorization. On December 11, 2019, the Board of Directors authorized a new share repurchase plan to repurchase up to $500.0 million of the Company's outstanding common stock, effective at the beginning of the third quarter of fiscal 2020. On March 2, 2020 the Board of Directors approved accelerating the effective date of the new share repurchase plan from March 27, 2020 to March 2, 2020. Under this revised authorization during fiscal 2020, the Company repurchased 5.1 million shares of its common stock for a total consideration of $237.7 million. During the first quarter of fiscal 2021, the Company repurchased 1.5 million shares of its common stock under this plan for a total consideration of $101.3 million. On December 9, 2020, the Board of Directors authorized a new five-year share repurchase plan to repurchase up to $1.0 billion of the Company's outstanding common stock. The prior plan was terminated in connection with this new authorization. Under the new authorization, during fiscal 2021, the Company repurchased 4.6 million shares of its common stock for a total consideration of $308.5 million. As of September 25, 2021 $691.6 million remained available under this authorization. Subsequent to September 25, 2021, the Company repurchased 2.3 million shares of its common stock for $167.0 million. On November 19, 2019, the Board of Directors authorized the Company to repurchase up to $205 million of its outstanding shares pursuant to an accelerated share repurchase ("ASR") agreement. On November 22, 2019, the Company executed the ASR agreement with Goldman Sachs & Co. ("Goldman Sachs") pursuant to which the Company repurchased $205 million of the Company's common stock. The initial delivery of approximately 80% of the shares under the ASR was 3.3 million shares for which the Company initially allocated $164.0 million of the $205 million paid to Goldman Sachs during the first quarter of fiscal 2020. The Company evaluated the nature of the forward contract aspect of the ASR under ASC 815 and concluded equity classification was appropriate. Final settlement of the transaction under the ASR occurred in the second quarter of fiscal 2020. At settlement, Goldman Sachs delivered an additional 0.6 million shares of the Company's common stock. Stock-Based Compensation Equity Compensation Plans The Company has one share-based compensation plan pursuant to which awards are currently being issued—the 2008 amended and restated Equity Incentive Plan (“2008 Equity Plan”). The purpose of the 2008 Equity Plan is to provide stock options, restricted stock units and other equity interests in the Company to employees, officers, directors, consultants and advisors of the Company and any other person who is determined by the Board of Directors to have made (or is expected to make) contributions to the Company. The 2008 Equity Plan is administered by the Board of Directors of the Company, and a total of 31.5 million shares were reserved for issuance under this plan. As of September 25, 2021, the Company had 4.6 million shares available for future grant under the 2008 Equity Plan. The following presents stock-based compensation expense in the Company’s Consolidated Statements of Operations in fiscal 2021, 2020 and 2019: 2021 2020 2019 Cost of revenues $ 8.0 $ 6.7 $ 7.1 Research and development 7.7 8.0 9.2 Selling and marketing 9.5 10.2 10.2 General and administrative 38.9 50.9 35.5 Restructuring 0.9 7.5 — $ 65.0 $ 83.3 $ 62.0 Grant-Date Fair Value The Company uses a binomial model to determine the fair value of its stock options. The Company considers a number of factors to determine the fair value of options including the assistance of an outside valuation adviser. Information pertaining to stock options granted during fiscal 2021, 2020 and 2019 and related assumptions are noted in the following table: Years ended September 25, 2021 September 26, 2020 September 28, 2019 Options granted (in millions) 0.6 1.0 1.0 Weighted-average exercise price $ 68.62 $ 45.96 $ 41.36 Weighted-average grant date fair value $ 19.86 $ 13.92 $ 13.54 Assumptions: Risk-free interest rates 0.4 % 1.7 % 3.0 % Expected life (in years) 4.8 4.8 4.8 Expected volatility 35.0 % 33.6 % 34.3 % Dividend yield — — — The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected life of the stock options. In projecting expected stock price volatility, the Company uses a combination of historical stock price volatility and implied volatility from observable market prices of similar equity instruments. The Company estimated the expected life of stock options based on historical experience using employee exercise and option expiration data. Stock-Based Compensation Expense Attribution The Company uses the straight-line attribution method to recognize stock-based compensation expense for stock options and restricted stock units ("RSUs"). The vesting term of stock options is generally four The amount of stock-based compensation recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest. Under ASC 718, the Company's accounting policy is to estimate forfeitures at the time awards are granted and revise, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Based on an analysis of historical forfeitures, the Company has determined a specific forfeiture rate for certain employee groups and has applied forfeiture rates ranging from 0% to 6.0% as of September 25, 2021 depending on the specific employee group. This analysis is re-evaluated annually and the forfeiture rate adjusted as necessary. Ultimately, the actual stock-based compensation expense recognized will only be for those stock options and RSUs that vest. Stock-based compensation expense related to stock options was $13.0 million, $15.5 million, and $14.1 million in fiscal 2021, 2020 and 2019, respectively. Stock compensation expense related to stock units, including RSUs, performance stock units ("PSUs"), free cash flow performance stock units ("FCFs") and market stock units ("MSUs") was $46.1 million, $63.3 million, and $43.7 million in fiscal 2021, 2020 and 2019, respectively. The related tax benefit recorded in the Consolidated Statements of Operations was $7.9 million, $9.5 million and $8.9 million in fiscal 2021, 2020 and 2019, respectively. At September 25, 2021, there was $15.8 million and $50.3 million of unrecognized compensation expense related to stock options and RSUs, respectively, to be recognized over a weighted average period of 2.3 years and 1.8 years, respectively. Share Based Payment Activity The following table summarizes all stock option activity under the Company’s stock option plans for the year ended September 25, 2021: Number Weighted- Weighted- Aggregate Options outstanding at September 26, 2020 4.6 $ 40.37 7.0 $ 109.5 Granted 0.6 68.62 Canceled/ forfeited (0.2) 49.67 Exercised (0.8) 38.46 30.4 Options outstanding at September 25, 2021 4.2 $ 44.66 6.6 $ 132.7 Options exercisable at September 25, 2021 2.3 $ 39.29 5.7 $ 85.4 Options vested and expected to vest at September 25, 2021 (1) 4.1 $ 44.60 6.6 $ 132.2 (1) This represents the number of vested stock options as of September 25, 2021 plus the unvested outstanding options at September 25, 2021 expected to vest in the future, adjusted for estimated forfeitures. During fiscal 2020 and 2019, the total intrinsic value of options exercised (i.e., the difference between the market price on the date of exercise and the price paid by the employee to exercise the options) was $44.8 million and $26.1 million, respectively. A summary of the Company’s RSU, PSU, FCF and MSU activity during the year ended September 25, 2021 is presented below: Non-vested Shares Number of Weighted-Average Non-vested at September 26, 2020 2.4 $ 44.22 Granted 1.1 69.14 Vested (1.7) 43.94 Forfeited (0.1) 52.57 Non-vested at September 25, 2021 1.7 $ 54.21 The number of RSUs vested includes shares withheld on behalf of employees to satisfy minimum statutory tax withholding requirements. The Company pays the minimum statutory tax withholding requirement on behalf of its employees. During fiscal 2021, 2020 and 2019 the total fair value of RSUs vested was $73.1 million, $34.9 million and $34.6 million, respectively. The Company granted 0.5 million, 0.6 million and 0.9 million RSUs during fiscal 2021, 2020 and 2019, respectively. In addition, included in the above chart, the Company also granted 0.1 million, 0.1 million and 0.1 million PSUs during fiscal 2021, 2020, and 2019 respectively, to members of the Company's senior management team, which includes additional shares issued upon achieving metrics within the performance criteria. The PSUs were valued at $68.51, $45.38 and $40.97 per share based on the ending stock price on the date of grant in fiscal 2021, 2020 and 2019, respectively. Each recipient of the PSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of three year performance period provided the Company’s defined Return on Invested Capital metrics are achieved. The Company also granted 0.1 million and 0.1 million of PSUs based on a one-year free cash flow measure (FCF) to its senior management team in fiscal 2021 and 2020, respectively. Each recipient of FCF PSUs is eligible to receive between zero and 200% of the target number of shares of the Company's common stock at the end of the one-year measurement period, but the FCF PSUs vest at the end of the three year service period. The PSUs and FCF PSUs cliff-vest three years from the date of grant, and the Company recognizes compensation expense ratably over the required service period based on its estimate of the number of shares will vest upon achieving the measurement criteria. If there is a change in the estimate of the number of shares that are probable of vesting, the Company will cumulatively adjust compensation expense in the period that the change in estimate is made. The Company also granted 0.1 million, 0.1 million and 0.1 million MSUs during fiscal 2021, 2020 and 2019, respectively, to its senior management team. Each recipient of MSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of three year performance period based upon achieving a certain total shareholder return relative to a defined peer group. The MSUs were valued at $82.31, $43.54 and $55.13 per share using the Monte Carlo simulation model in fiscal 2021, 2020 and 2019, respectively. These awards cliff-vest three years from the date of grant, and the Company recognizes compensation expense for the MSUs ratably over the service period. Employee Stock Purchase Plan The Hologic, Inc. 2012 Employee Stock Purchase Plan (“2012 ESPP”) provides for the granting of up to 2.5 million shares of the Company’s common stock to eligible employees. The 2012 ESPP plan period is semi-annual and allows participants to purchase the Company’s common stock at 85% of the lower of (i) the market value per share of the common stock on the first day of the offering period or (ii) the market value per share of the common stock on the purchase date. Stock-based compensation expense in fiscal 2021, 2020 and 2019 was $5.9 million, $4.5 million and $4.2 million, respectively. The Company uses the Black-Scholes model to estimate the fair value of shares to be issued as of the grant date using the following weighted average assumptions: September 25, 2021 September 26, 2020 September 28, 2019 Assumptions: Risk-free interest rates 0.26 % 1.32 % 2.27 % Expected life (in years) 0.5 0.5 0.5 Expected volatility 34.1 % 26.9 % 27.1 % Dividend yield — — —

401(k) Plan

401(k) Plan	12 Months Ended
	Sep. 25, 2021
Retirement Benefits [Abstract]
Multiemployer Plan	11. 401(k) Plan The Company's U.S. employees have access to a qualified 401(k) defined contribution plan. The Company made contributions of $20.9 million, $19.6 million and $19.2 million for fiscal 2021, 2020 and 2019, respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Sep. 25, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	The Company has certain non-cancelable purchase obligations primarily related to inventory purchases and diagnostics instruments, primarily Panther systems, and to a lesser extent other operating expense commitments. These obligations are not recorded in the Consolidated Balance Sheets. For reasons of quality assurance, sole source availability or cost effectiveness, certain key components and raw materials and instruments are available only from a sole supplier and the Company has certain long-term supply contracts to assure continuity of supply. At September 25, 2021, non-cancelable purchase commitments are as follows: Fiscal 2022 290.3 Fiscal 2023 16.4 Fiscal 2024 9.2 Fiscal 2025 4.1 Fiscal 2026 1.7 Thereafter 0.4 Total $ 322.1

Litigation and Related Matters

Litigation and Related Matters	12 Months Ended
	Sep. 25, 2021
Commitments and Contingencies Disclosure [Abstract]
Litigation and Related Matters	Litigation and Related Matters On November 6, 2015, the Company filed a suit against Minerva Surgical, Inc. (“Minerva”) in the United States District Court for the District of Delaware, alleging that Minerva’s endometrial ablation device infringes U.S. Patent 6,872,183 (the '183 patent), U.S. Patent 8,998,898 and U.S. Patent 9,095,348 (the '348 patent). On January 25, 2016, the Company amended the complaint to include claims against Minerva for unfair competition, deceptive trade practices and tortious interference with business relationships. On February 5, 2016, the Company filed a second amended complaint to additionally allege that Minerva’s endometrial ablation device infringes U.S. Patent 9,247,989 (the '989 patent). On March 4, 2016, Minerva filed an answer and counterclaims against the Company, seeking declaratory judgment on the Company’s claims and asserting claims against the Company for unfair competition, deceptive trade practices, interference with contractual relationships, breach of contract and trade libel. On June 2, 2016, the Court denied the Company’s motion for a preliminary injunction on its patent claims and denied Minerva’s request for preliminary injunction related to the Company’s alleged false and deceptive statements regarding the Minerva product. On June 28, 2018, the Court granted the Company's summary judgment motions on infringement and no invalidity with respect to the ‘183 and ‘348 patents. The Court also granted the Company’s motion for summary judgment on assignor estoppel, which bars Minerva’s invalidity defenses or any reliance on collateral findings regarding invalidity from inter partes review proceedings. The Court also denied all of Minerva’s defenses, including its motions for summary judgment on invalidity, non-infringement, no willfulness, and no unfair competition. On July 27, 2018, after a two-week trial, a jury returned a verdict that: (1) awarded the Company $4.8 million in damages for Minerva’s infringement; (2) found that Minerva’s infringement was not willful; and (3) found for the Company regarding Minerva’s counterclaims. Damages continued to accrue as Minerva continued its infringing conduct. On May 2, 2019, the Court issued rulings that denied the parties' post-trial motions, including the Company's motion for a permanent injunction seeking to prohibit Minerva from selling infringing devices. Both parties appealed the Court's rulings regarding the post-trial motions. On March 4, 2016, Minerva filed two petitions at the USPTO for inter partes review of the '348 patent. On September 12, 2016, the PTAB declined both petitions to review patentability of the ‘348 patent. On April 11, 2016, Minerva filed a petition for inter partes review of the '183 patent. On October 6, 2016, the PTAB granted the petition and instituted a review of the '183 patent. On December 15, 2017, the PTAB issued a final written decision invalidating all claims of the ‘183 patent. On February 9, 2018 the Company appealed this decision to the United States Court of Appeals for the Federal Circuit ("Court of Appeals"). On April 19, 2019, the Court of Appeals affirmed the PTAB's final written decision regarding the '183 patent. On July 16, 2019, the Court of Appeals denied the Company’s petition for rehearing in the appeal regarding the '183 patent. On April 22, 2020, the Court of Appeals affirmed the district court’s summary judgment ruling in favor of the Company of no invalidity and infringement, and summary judgment that assignor estoppel bars Minerva from challenging the validity of the ‘348 patent. The Court of Appeals also denied the Company’s motion for a permanent injunction and ongoing royalties for infringement of the ‘183 patent. The Court of Appeals denied Minerva’s arguments for no damages or, alternatively, a new trial. On May 22, 2020 both parties petitioned for en banc review of the Court of Appeals decision. On July 22, 2020, the Court of Appeals denied both parties' petitions for en banc review. On August 28, 2020, the district court entered final judgment against Minerva but stayed execution pending resolution of Minerva’s petition for Supreme Court review. On September 30, 2020, Minerva filed a petition requesting Supreme Court review on the issue of assignor estoppel. On November 5, 2020, the Company filed a cross- petition requesting Supreme Court review on the issue of assignor estoppel. On January 8, 2021, the Supreme Court granted Minerva's petition to address the issue of assignor estoppel and denied the Company's petition. Oral argument before the Supreme Court was held on April 21, 2021. On June 29, 2021, the Supreme Court ruled 5-4 to uphold the assignor estoppel but limited its application to situations in which an assignor's claim of invalidity contradicts a prior representation the assignor made in assigning the patent. The Court also vacated the ruling of the Court of Appeals and remanded the case for further proceedings consistent with its opinion. On April 11, 2017, Minerva filed suit against the Company and Cytyc Surgical Products, LLC (“Cytyc”) in the United States District Court for the Northern District of California alleging that the Company’s and Cytyc’s NovaSure ADVANCED endometrial ablation device infringes Minerva’s U.S. patent 9,186,208 (the '208 patent). Minerva is seeking a preliminary and permanent injunction against the Company and Cytyc from selling this NovaSure device as well as enhanced damages and interest, including lost profits, price erosion and/or royalty. On January 5, 2018, the Court denied Minerva's motion for a preliminary injunction. On February 2, 2018, at the parties’ joint request, this action was transferred to the District of Delaware. On March 26, 2019, the Magistrate Judge issued a claims construction ruling regarding the disputed terms in the patent, which the District Court Judge adopted in all respects on October 21, 2019. The original trial date of July 20, 2020 was vacated. On October 21, 2020, the trial court scheduled a 10 day trial beginning on August 9, 2021. On July 27. 2021, the Delaware district court granted Hologic's motion for summary judgment on invalidity of the '208 patent and entered judgment in favor of the Company. On August 24, 2021, Minerva appealed this and the other rulings to the Court of Appeals. At this time, based on available information regarding this litigation, the Company is unable to reasonably assess the ultimate outcome of this case or determine an estimate, or a range of estimates, of potential losses. As described in Note 15, the Company has agreed to indemnify CD&R for certain legal matters related to the Medical Aesthetics business that existed at the date of disposition. The Company currently has $8.5 million accrued for such matters as of September 25, 2021. While the Company believes the estimated amounts accrued are reasonable, certain matters are still ongoing and additional accruals could be recorded in the future. The Company is a party to various other legal proceedings and claims arising out of the ordinary course of its business. The Company believes that except for those matters described above there are no other proceedings or claims pending against it the ultimate resolution of which could have a material adverse effect on its financial condition or results of operations. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies . Legal costs are expensed as incurred.

Disposition

Disposition	12 Months Ended
	Sep. 25, 2021
Disposal Groups, Including Discontinued Operations and Collaborative Agreement [Abstract]
Disposition	Disposition Sale of Medical Aesthetics On November 20, 2019, the Company entered into a definitive agreement to sell its Medical Aesthetics business to Clayton Dubilier & Rice ("CD&R") for a sales price of $205.0 million in cash, less certain adjustments. The sale was completed on December 30, 2019, and the Company received cash proceeds of $153.4 million in the second quarter of fiscal 2020. The sale price was subject to adjustment pursuant to the terms of the definitive agreement, and the parties agreed to a final sales price of $150.0 million in the fourth quarter of fiscal 2020. The Company agreed to provide certain transition services for three As a result of this transaction, the Medical Aesthetics asset group was designated as assets held-for-sale in the first quarter of fiscal 2020. Pursuant to ASC 360, Impairment and Disposal of Long-Lived Assets, asset groups under this designation are required to be recorded at fair value less costs to sell. The Company determined that this disposal did not qualify as a discontinued operation as the sale of the Medical Aesthetics business was deemed to not be a strategic shift having or that will have a major effect on the Company's operations and financial results. Based on the terms in the agreement of the sales price and formula for net working capital and related adjustments, its estimate of the fair value for transition services and the amount that must be carved out of the sale proceeds, and liabilities the Company will retain or for which it has agreed to indemnify CD&R, the Company recorded an impairment charge of $30.2 million in the first quarter of fiscal 2020. The impairment charge was allocated to Medical Aesthetics long-lived assets, of which $25.8 million was allocated to cost of product revenues and $4.4 million to operating expenses. Loss from operations of the disposed business presented below represents the operating loss of the business as it was operated prior to the date of disposition. The operating expenses include only those that were incurred directly by and were retained by the disposed business. As noted above, the Company had performed a number of transition services and the financial impact from these services are not included in the amounts presented below. In addition, the Company will continue to incur expenses related to this business under the indemnification provisions primarily related to legal and tax matters that existed as of the date of disposition. Subsequent to the disposition, the Company recorded additional expenses of $6.2 million in fiscal 2020 primarily for accelerated stock compensation, inventory reserves under the manufacturing supply agreement, and legal expenses and settlements, which are not included in the below amounts. Loss from operations of the disposed business for fiscal 2020 and 2019 was as follows: Years Ended September 26, 2020 September 28, 2019 Loss from operations $ (46.5) $ (781.2)

Business Segments and Geographi

Business Segments and Geographic Information	12 Months Ended
	Sep. 25, 2021
Segment Reporting [Abstract]
Business Segments and Geographic Information	Business Segments and Geographic Information The Company reports segment information in accordance with ASC 280, Segment Reporting. Operating segments are identified as components of an enterprise about which separate, discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions about how to allocate resources and assess performance. The Company’s chief operating decision maker is its chief executive officer, and the Company’s reportable segments have been identified based on the types of products manufactured and the end markets to which the products are sold. Each reportable segment generates revenue from either the sale of medical equipment and related services and/or sale of disposable supplies, primarily used for diagnostic testing and surgical procedures. During fiscal 2021, the Company had four reportable segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. During the first quarter of fiscal 2020 and Identifiable assets for the reportable segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no intersegment revenues. Segment information for fiscal 2021, 2020, and 2019 was as follows: Years ended September 25, September 26, September 28, Total revenues: Diagnostics $ 3,695.0 $ 2,102.1 $ 1,205.5 Breast Health 1,352.3 1,151.9 1,314.2 GYN Surgical 488.1 376.1 437.2 Skeletal Health 96.9 81.0 94.8 Medical Aesthetics — 65.3 315.6 $ 5,632.3 $ 3,776.4 $ 3,367.3 Operating income (loss): Diagnostics $ 2,140.1 $ 929.7 $ 163.1 Breast Health 284.2 192.8 399.3 GYN Surgical 58.9 42.0 99.2 Skeletal Health (2.9) (2.4) (4.2) Medical Aesthetics — (57.1) (781.2) $ 2,480.3 $ 1,105.0 $ (123.8) Depreciation and amortization: Diagnostics $ 260.4 $ 237.3 $ 246.6 Breast Health 52.7 48.8 36.8 GYN Surgical 93.1 85.1 87.7 Skeletal Health 0.7 0.7 0.6 Medical Aesthetics — 4.1 91.4 $ 406.9 $ 376.0 $ 463.1 Capital expenditures: Diagnostics $ 126.2 $ 110.7 $ 59.2 Breast Health 14.2 22.4 18.3 GYN Surgical 14.5 17.9 15.7 Skeletal Health 0.3 0.2 1.2 Medical Aesthetics — 1.4 7.0 Corporate 1.0 3.8 7.7 $ 156.2 $ 156.4 $ 109.1 Identifiable assets: Diagnostics $ 3,348.8 $ 2,161.4 $ 2,276.6 Breast Health 1,233.9 1,200.9 1,127.8 GYN Surgical 1,369.7 1,438.7 1,328.6 Skeletal Health 31.9 38.9 27.3 Medical Aesthetics — — 159.3 Corporate 2,935.6 2,355.9 1,522.5 $ 8,919.9 $ 7,195.8 $ 6,442.1 The Company operates in the following major geographic areas as noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from France, the United Kingdom and Germany. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “Rest of world” designation includes Canada, Latin America and the Middle East. Revenues by geography as a percentage of total revenues were as follows: Years ended September 25, September 26, September 28, United States 69.3 % 75.8 % 75.3 % Europe 21.3 % 15.1 % 11.8 % Asia-Pacific 6.5 % 6.0 % 8.5 % Rest of world 2.9 % 3.1 % 4.4 % 100.0 % 100.0 % 100.0 % The Company’s property, plant and equipment, net were geographically located as follows: September 25, 2021 September 26, 2020 September 28, 2019 United States $ 403.2 $ 383.0 $ 355.5 Europe 122.9 77.5 64.4 Costa Rica 26.9 20.8 33.0 Rest of world 11.7 10.2 18.0 $ 564.7 $ 491.5 $ 470.9

Accrued Expenses and Other Long

Accrued Expenses and Other Long-Term Liabilities	12 Months Ended
	Sep. 25, 2021
Payables and Accruals [Abstract]
Accrued Expenses and Other Long-Term Liabilities	Accrued Expenses and Other Long-Term Liabilities Accrued expenses and other long-term liabilities consisted of the following: September 25, 2021 September 26, 2020 Accrued Expenses Compensation and employee benefits $ 297.2 $ 262.7 Income and other taxes 70.9 125.3 Contingent consideration 16.3 — Operating leases 26.8 23.5 Accrued interest 16.9 22.1 Other 168.1 114.0 $ 596.2 $ 547.6 September 25, 2021 September 26, 2020 Other Long-Term Liabilities Reserve for income tax uncertainties $ 210.0 $ 103.7 Contingent consideration 58.8 81.8 Operating leases 66.1 65.6 Interest rate swap 7.6 23.0 Pension liabilities 10.0 11.1 Other 16.2 18.0 $ 368.7 $ 303.2

Pension and Other Employee Bene

Pension and Other Employee Benefits	12 Months Ended
	Sep. 25, 2021
Retirement Benefits [Abstract]
Pension and Other Employee Benefits	Pension and Other Employee Benefits The Company has certain defined benefit pension plans covering the employees of its Hitec Imaging German subsidiary (the “Pension Benefits”). As of September 25, 2021 and September 26, 2020, the Company’s pension liability was $10.3 million and $10.9 million, respectively, which is primarily recorded as a component of long-term liabilities in the Consolidated Balance Sheets. Under German law, there are no rules governing investment or statutory supervision of the pension plan. As such, there is no minimum funding requirement imposed on employers. Pension benefits are safeguarded by the Pension Guaranty Fund, a form of compulsory reinsurance that guarantees an employee will receive vested pension benefits in the event of insolvency. The pension plans were closed on December 31, 1997 and only eligible employees at that date could participate in the plans prior to closing to new participants. The tables below provide a reconciliation of benefit obligations, plan assets, funded status, and related actuarial assumptions of the Company’s German Pension Benefits. Change in Benefit Obligation Years ended September 25, 2021 September 26, 2020 September 28, 2019 Benefit obligation at beginning of year $ (10.9) $ (10.0) $ (9.7) Service cost — — — Interest cost (0.1) (0.1) (0.2) Plan participants’ contributions — — — Actuarial gain (loss) 0.5 (0.5) (1.0) Foreign exchange gain (0.1) (0.7) 0.6 Benefits paid 0.3 0.4 0.3 Benefit obligation at end of year (10.3) (10.9) (10.0) Plan assets — — — Benefit obligation at end of year $ (10.3) $ (10.9) $ (10.0) The tables below outline the components of the net periodic benefit cost and related actuarial assumptions of the Company’s German Pension Benefits. Components of Net Periodic Benefit Cost Years ended September 25, 2021 September 26, 2020 September 28, 2019 Service cost $ — $ — $ — Interest cost 0.1 0.1 0.2 Expected return on plan assets — — — Amortization of prior service cost — — — Recognized net actuarial gain 0.3 0.2 0.1 Net periodic benefit cost $ 0.4 $ 0.3 $ 0.3 Weighted-Average Net Periodic Benefit Cost Assumptions 2021 2020 2019 Discount rate 1.00 % 0.80 % 1.10 % Expected return on plan assets — % — % — % Rate of compensation increase — % — % — % The projected benefit obligation for the German Pension Benefits with projected benefit obligations in excess of plan assets was $10.3 million and $10.9 million at September 25, 2021 and September 26, 2020, respectively, and the accumulated benefit obligation for the German Pension Benefits was $10.3 million and $10.9 million at September 25, 2021 and September 26, 2020, respectively. The Company is also obligated to pay long-term service award benefits under the German Pension Benefits. The projected benefit obligation for long-term service awards was $0.1 million at both September 25, 2021 and September 26, 2020, respectively. The table below reflects the total Pension Benefits expected to be paid for the German Pension Benefits each fiscal year as of September 25, 2021: 2022 $ 0.4 2023 $ 0.4 2024 $ 0.4 2025 $ 0.4 2026 $ 0.4 2027 to 2031 $ 2.2

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 25, 2021
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The Company’s fiscal year ends on the last Saturday in September. Fiscal 2021, 2020 and 2019 ended on September 25, 2021, September 26, 2020 and September 28, 2019, respectively. Fiscal 2021, 2020 and 2019 were 52-week years.
Management's Estimates	Management’s Estimates and Uncertainties The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions by management affect the Company’s revenue recognition for multiple performance obligation arrangements, valuations, purchase price allocations and contingent consideration related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets and goodwill, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, restructuring and other related charges, contingent liabilities, tax reserves, deferred tax rates and recoverability of the Company’s net deferred tax assets and related valuation allowances, and stock-based compensation. Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. The Company is subject to a number of risks similar to those of other companies of similar size in its industry, including dependence on third-party reimbursements to support the markets of the Company’s products, early stage of development of certain products, rapid technological changes, recoverability of long-lived assets (including intangible assets and goodwill), competition, stability of world financial markets, ability to obtain regulatory approvals, changes in the regulatory environment, limited number of suppliers, customer concentration, integration of acquisitions, substantial indebtedness, government regulations, management of international activities, protection of proprietary rights, patent and other litigation, dependence on contract manufacturers and dependence on key individuals.
Cash Equivalents	Cash Equivalents Cash equivalents are highly liquid investments with insignificant interest rate risk and maturities of three months or less at the time of acquisition.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents, cost-method investments and trade accounts receivable. The Company invests its cash and cash equivalents with high credit quality financial institutions. The Company’s customers are principally located in the U.S., Europe and Asia. The Company performs ongoing credit evaluations of the financial condition of its customers and generally does not require collateral. Although the Company is
Inventories	Inventories Inventories are valued at the lower of cost or market on a first in, first out basis. Work-in-process and finished goods inventories consist of materials, labor and manufacturing overhead. The valuation of inventory requires management to estimate excess and obsolete inventory. The Company employs a variety of methodologies to determine the net realizable value of its inventory. Provisions for excess and obsolete inventory are primarily based on management’s estimates of forecasted sales, usage levels and expiration dates, as applicable for certain disposable products. A significant change in the timing or level of demand for the Company’s products compared to forecasted amounts may result in recording additional charges for excess and obsolete inventory in the future. The Company records charges for excess and obsolete inventory within cost of product revenues. Inventories consisted of the following: September 25, 2021 September 26, 2020 Raw materials $ 163.3 $ 152.3 Work-in-process 53.0 46.5 Finished goods 284.9 196.3 $ 501.2 $ 395.1
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment is recorded at cost less allowances for depreciation and impairments. The straight-line method of depreciation is used for all property and equipment. Property, plant and equipment consisted of the following: Estimated Useful Life September 25, 2021 September 26, 2020 Equipment 3–10 years $ 467.1 $ 460.7 Equipment under customer usage agreements 3–8 years 484.6 456.8 Buildings and improvements 20–35 years 191.2 167.3 Leasehold improvements Shorter of the Original Term of Lease or Estimated Useful Life 49.7 44.3 Land 41.3 40.7 Furniture and fixtures 5–7 years 16.8 16.1 Finance lease right-of-use asset 9.9 — 1,260.6 1,185.9 Less - accumulated depreciation and amortization (695.9) (694.4) $ 564.7 $ 491.5 Equipment under customer usage agreements primarily consists of diagnostic instrumentation and imaging equipment located at customer sites but owned by the Company. Generally, the customer has the right to use the equipment for a period of time provided they meet certain agreed to conditions. The Company recovers the cost of providing the equipment from the sale of disposables, primarily assays, tests and handpieces. The depreciation costs associated with equipment under customer usage agreements are charged to cost of product revenues over the estimated useful life of the equipment. The costs to maintain the equipment in the field are charged to cost of product revenue as incurred.
Long-Lived Assets	Long-Lived Assets The Company reviews its long-lived assets, which includes property, plant and equipment and identifiable intangible assets (see below for discussion of intangible assets), for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable in accordance with ASC 360-10-35-15, Property, Plant and Equipment—Impairment or Disposal of Long-Lived Assets
Business Combinations and Acquisition of Intangible Assets	Business Combinations and Acquisition of Intangible Assets The Company accounts for the acquisition of a business in accordance with ASC 805, Business Combinations (ASC 805). Amounts paid to acquire a business are allocated to the assets acquired and liabilities assumed based on their fair values at the date of acquisition. Contingent consideration not deemed to be linked to continuing employment is recorded at fair value as measured on the date of acquisition. The value recorded is based on estimates of future financial projections under various potential scenarios using a Monte Carlo simulation. These cash flow projections are discounted with an appropriate risk adjusted rate. Each quarter until such contingent amounts are earned, the fair value of the liability is remeasured at each reporting period and adjusted as a component of operating expenses based on changes to the underlying assumptions. The estimates used to determine the fair value of the contingent consideration liability are subject to significant judgment and actual results are likely to differ from the amounts originally recorded. The Company determines the fair value of acquired intangible assets based on detailed valuations that use certain information and assumptions provided by management. The Company allocates any excess purchase price over the fair value of the net tangible and intangible assets acquired to goodwill. The Company uses the income approach to determine the fair value of developed technology and in-process research and development ("IPR&D") acquired in a business combination. This approach determines fair value by estimating the after-tax cash flows attributable to the respective asset over its useful life and then discounting these after-tax cash flows back to a present value. The Company bases its revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected product introductions by competitors. Developed technology represents patented and unpatented technology and know-how. The value of the in-process projects is based on the project's stage of completion, the complexity of the work completed as of the acquisition date, the projected costs to complete, the contribution of core technologies and other acquired assets, the expected introduction date, the estimated cash flows to be generated upon commercial release and the estimated useful life of the technology. The Company believes that the estimated developed technology and IPR&D amounts represent the fair value at the date of acquisition and do not exceed the amount a third-party would pay for the assets. The significant assumptions used to estimate the fair value of intangible assets include discount rates and certain assumptions that form the basis of the forecasted results specifically revenue growth rates. These significant assumptions are forward looking and could be affected by future economic and market conditions.
Other Assets	Other Assets Other assets consisted of the following: September 25, 2021 September 26, 2020 Other Assets Tax receivable $ 24.7 $ 325.7 Right of use assets 83.6 80.7 Life insurance contracts 64.3 49.3 Deferred tax assets 21.9 15.5 Cost-method equity investments 9.5 11.4 Other 41.7 34.0 $ 245.7 $ 516.6 The tax receivable in fiscal 2020 primarily related to a discrete tax benefit from the sale of Cynosure in the second quarter of fiscal 2020. This receivable was reclassified to a current asset in fiscal 2021 as the Company filed the carryback claim and expects to receive the refund within the next twelve months, subject to Internal Revenue Service processing times. The right of use assets were recorded in connection with the adoption of ASC 842, Leases
Research and Software Development Costs	Research and Software Development Costs Costs incurred for the research and development of the Company’s products are expensed as incurred. Nonrefundable advance payments for goods or services to be received in the future by the Company for use in research and development activities are deferred. The deferred costs are expensed as the related goods are delivered or the services are performed. The Company accounts for the development costs of software embedded in the Company’s products in accordance with ASC 985, Software. Costs incurred in the research, design and development of software embedded in products to be sold to customers are charged to expense until technological feasibility of the ultimate product to be sold is established. The Company’s policy is that technological feasibility is achieved when a working model, with the key features and functions of the product, is available for customer testing. Software development costs incurred after the establishment of technological feasibility and until the product is available for general release are capitalized, provided recoverability is reasonably assured. Capitalized software development costs are amortized over their estimated useful life and recorded within cost of revenues - product.
Foreign Currency Translation	Foreign Currency Translation The financial statements of the Company’s foreign subsidiaries are translated in accordance with ASC 830, Foreign Currency Matters. The reporting currency for the Company is the U.S. dollar. The functional currency of the Company’s foreign subsidiaries is determined based on the guidance in ASC 830. The majority of the Company's foreign subsidiaries' functional currency is the applicable local currency, although certain of the Company's foreign subsidiaries' functional currency
Accumulated Other Comprehensive Income	Accumulated Other Comprehensive Income (Loss) Other comprehensive income (loss) includes certain transactions that have generally been reported in the statement of stockholders’ equity. The following tables summarize the components and changes in accumulated balances of other comprehensive loss for the periods presented: Year Ended September 25, 2021 Year Ended September 26, 2020 Foreign Currency Translation Pension Plans Hedged Interest Rate Caps Hedged Interest Rate Swaps Total Foreign Currency Translation Pension Plans Hedged Interest Rate Caps Hedged Interest Rate Swaps Total Beginning Balance $ (22.9) $ (1.8) $ (0.9) $ (24.1) $ (49.7) $ (41.4) $ (1.7) $ (2.7) $ 3.5 $ (42.3) Other comprehensive income (loss) before reclassifications (20.2) 0.5 0.4 9.4 (9.9) 18.5 (0.1) (0.5) (27.6) (9.7) Charges (gains) reclassified to statement of operations — — 0.5 — 0.5 — — 2.3 — 2.3 Ending Balance $ (43.1) $ (1.3) $ — $ (14.7) $ (59.1) $ (22.9) $ (1.8) $ (0.9) $ (24.1) $ (49.7)
Derivatives	Derivatives Interest Rate Cap - Cash Flow Hedge The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company manages its exposure to some of its interest rate risk through the use of interest rate caps, which are derivative financial instruments. The Company does not use derivatives for speculative purposes. For a derivative that is designated as a cash flow hedge, changes in the fair value of the derivative are recognized in accumulated other comprehensive income ("AOCI") to the extent the derivative is effective at offsetting the changes in the cash flows being hedged until the hedged item affects earnings. To the extent there is any hedge ineffectiveness, changes in fair value relating to the ineffective portion are immediately recognized in earnings in other income (expense), net in the Consolidated Statements of Operations. During fiscal 2018, the Company entered into separate interest rate cap agreements with multiple counter-parties to mitigate the interest rate volatility associated with the variable interest rate on its amounts borrowed under the term loan feature of its credit facilities (see Note 7). Interest rate cap agreements provide the right to receive cash if the reference interest rate rises above a contractual rate. The aggregate premium paid for these interest rate cap agreements was $3.7 million, which was the initial fair value of the instruments recorded in the Company's financial statements. During fiscal 2019, the Company entered into additional separate interest rate cap agreements with multiple counter-parties to extend the expiration date of its hedges by an additional year. The aggregate premium paid for these interest cap agreements was $1.5 million, which was the initial fair value of the instruments recorded in the Company’s financial statements. The critical terms of the interest rate caps were designed to mirror the terms of the Company’s LIBOR-based borrowings under its Credit Agreement, that has been amended multiple times, and therefore are highly effective at offsetting the cash flows being hedged. The Company designated these derivatives as cash flow hedges of the variability of the LIBOR-based interest payments on $1.0 billion of principal, which ended on December 27, 2019 (the first quarter of fiscal 2020) for the contracts entered into in fiscal 2018, and on December 23, 2020 (the first quarter of fiscal 2021) for the interest rate cap agreements entered into in fiscal 2019. During fiscal 2021, 2020 and 2019, interest expense of $0.5 million, $2.3 million and $3.1 million, respectively, was reclassified from AOCI to the Company's Consolidated Statements of Operations related to the interest rate cap agreements. The last interest rate cap agreement matured as of December 26, 2020. Interest Rate Swap - Cash Flow Hedge In fiscal 2019, in order to hedge a portion of its variable rate debt beyond the contracted period under interest cap agreements, the Company entered into an interest rate swap contract with an effective date of December 23, 2020 and a termination date of December 17, 2023. The notional amount of this swap is $1.0 billion. The interest rate swap effectively fixes the LIBOR component of the variable interest rate on $1.0 billion of the notional amount under the 2018 Credit Agreement at 1.23%. The critical terms of the interest rate swap are designed to mirror the terms of the Company’s LIBOR-based borrowings under its credit agreement and therefore are highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the LIBOR-based interest payments on $1.0 billion of principal. Therefore, changes in the fair value of the swap are recorded in AOCI and net of taxes were a gain of $9.4 million, a loss of $27.6 million and a gain of $3.5 million for fiscal years 2021, 2020, and 2019, respectively. The fair value of this derivative was in a liability position of $18.7 million as of September 25, 2021. Forward Foreign Currency Contracts and Foreign Currency Option Contracts The Company enters into forward foreign currency exchange contracts and foreign currency option contracts to mitigate certain operational exposures from the impact of changes in foreign currency exchange rates. Such exposures result from the portion of the Company's cash and operations that are denominated in currencies other than the U.S. dollar, primarily the Euro, the UK Pound, the Australian dollar, the Canadian dollar, the Chinese Yuan and the Japanese Yen. These foreign currency exchange contracts are entered into to support transactions made in the ordinary course of business and are not speculative in nature. The contracts are generally for periods of one year or less. The Company did not elect hedge accounting for these contracts; however, the Company may seek to apply hedge accounting in future scenarios. The change in the fair value of these contracts is recognized directly in earnings as a component of other income, net. Years Ended September 25, 2021 September 26, 2020 September 28, 2019 Amount of realized (loss) gain recognized in income Forward foreign currency contracts $ (3.6) $ 0.7 $ 11.0 Foreign currency option contracts (6.1) (1.9) — $ (9.7) $ (1.2) $ 11.0 Amount of unrealized (loss) gain recognized in income Forward foreign currency contracts $ 0.5 $ (0.2) $ (2.2) Foreign currency option contracts (4.0) 4.0 0.1 $ (3.5) $ 3.8 $ (2.1) Amount of gain (loss) recognized in income Total $ (13.2) $ 2.6 $ 8.9 As of September 25, 2021, the Company had outstanding forward foreign currency contracts that were not designated for hedge accounting and are used to hedge fluctuations in the U.S dollar of certain of the Company's cash balances denominated in the Euro and UK pound, as well as forecasted transactions denominated in the Euro, UK pound, Australian Dollar, Canadian Dollar, Chinese Yuan and Japanese Yen with an aggregate notional amount of $861.5 million. Financial Instrument Presentation The table below presents the fair value of the Company's derivative financial instruments as well as their classification on the balance sheet as of September 25, 2021: Balance Sheet Location September 25, 2021 September 26, 2020 Assets: Derivatives not designated as hedging instruments: Forward foreign currency contracts Prepaid expenses and other current assets $ 1.7 $ 1.1 Foreign currency option contracts Prepaid expenses and other current assets — 10.1 $ 1.7 $ 11.2 Liabilities: Derivative instruments designated as a cash flow hedge: Interest rate swap contract Accrued expenses $ 11.1 $ 8.2 Interest rate swap contract Other long-term liabilities 7.6 23.0 Total $ 18.7 $ 31.2 Derivatives not designated as hedging instruments: Forward foreign currency contracts Accrued expenses $ 0.6 $ — The following table presents the unrealized gain (loss) recognized in AOCI related to the interest rate caps and interest rate swap for the following reporting periods: Years Ended September 25, 2021 September 26, 2020 September 28, 2019 Amount of gain (loss) recognized in other comprehensive income (loss), net of taxes: Interest rate swap $ 9.4 $ (27.6) $ 3.5 Interest rate cap agreements 0.4 (0.5) (8.0) Total $ 9.8 $ (28.1) $ (4.5)
Accounts Receivable and Reserves	Effective September 27, 2020, the Company adopted ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) , which requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The expected credit losses are developed using an estimated loss rate method that considers historical collection experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The estimated loss rates are applied to trade receivables with similar risk characteristics such as the length of time the balance has been outstanding and the location of the customer. In certain instances, the Company may identify individual trade receivable assets that do not share risk characteristics with other trade receivables, in which case the Company records its expected credit losses on an individual asset basis. For example, potential adverse changes to customer liquidity from new macroeconomic events, such as the COVID-19 pandemic, must be taken into consideration. To date, the Company has not experienced significant customer payment defaults, or identified other significant collectability concerns as a result of the COVID-19 pandemic. In connection with assessing credit losses for individual trade receivable assets, the Company considers significant factors relevant to collectability including those specific to the customer such as bankruptcy, length of time an account is outstanding, and the liquidity and financial position of the customer. If a trade receivable asset is evaluated on an individual basis, the Company excludes those assets from the portfolios of trade receivables evaluated on a collective basis. The following is a rollforward of the allowance for credit losses for fiscal 2021, 2020 and 2019: Balance at Charged to Divested Write- Balance at Period Ended: September 25, 2021 $ 31.6 $ 15.0 $ — $ (6.1) $ 40.5 September 26, 2020 $ 17.8 $ 26.8 $ (5.8) $ (7.2) $ 31.6 September 28, 2019 $ 16.2 $ 4.4 $ — $ (2.8) $ 17.8
Cost of Service and Other Revenues	Cost of Service and Other Revenues Cost of service and other revenues primarily represents payroll and related costs associated with the Company’s professional services, employees, consultants, infrastructure costs and overhead allocations, including depreciation, rent and materials consumed in providing the service.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for share-based payments in accordance with ASC 718, Stock Compensation (ASC 718) .
Net Income Per Share	Net Income (Loss) Per Share Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding. Diluted net income per share is computed by dividing net income by the weighted average number of common shares and the dilutive effect of potential future issuances of common stock from outstanding stock options and restricted stock units for the period outstanding determined by applying the treasury stock method. In accordance with ASC 718, the assumed proceeds under the treasury stock method include the average unrecognized compensation expense of in-the-money stock options and restricted stock units. This results in the assumed buyback of additional shares, thereby reducing the dilutive impact of equity awards.
Product Warranties	Product Warranties The Company generally offers a one number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. Product warranty activity for fiscal 2021 and 2020 was as follows: Balance at Provisions Acquired Divested Settlements/ Balance at End Period ended: September 25, 2021 $ 9.9 $ 7.7 $ 0.3 $ — $ (9.1) $ 8.8 September 26, 2020 $ 13.9 $ 11.7 $ 0.5 $ (6.1) $ (10.1) $ 9.9
Advertising Costs	Advertising Costs Advertising costs are charged to operations as incurred. The Company does not have any direct-response advertising. Advertising costs, which include trade shows and conventions, were approximately $9.8 million, $15.6 million and $29.5 million for fiscal 2021, 2020 and 2019, respectively, and were included in selling and marketing expense in the Consolidated Statements of Operations.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Sep. 25, 2021
Accounting Policies [Abstract]
Supplemental Cash Flow Statement Information	Supplemental Cash Flow Statement Information Years ended September 25, 2021 September 26, 2020 September 28, 2019 Cash paid during the period for income taxes $ 615.1 $ 265.9 $ 180.6 Cash paid during the period for interest $ 93.2 $ 109.5 $ 132.5 Non-Cash Financing Activities: Fair value of contingent consideration at acquisition $ — $ 82.7 $ —
Schedule of Inventories	Inventories consisted of the following: September 25, 2021 September 26, 2020 Raw materials $ 163.3 $ 152.3 Work-in-process 53.0 46.5 Finished goods 284.9 196.3 $ 501.2 $ 395.1
Schedule of Property, Plant and Equipment	Property, plant and equipment consisted of the following: Estimated Useful Life September 25, 2021 September 26, 2020 Equipment 3–10 years $ 467.1 $ 460.7 Equipment under customer usage agreements 3–8 years 484.6 456.8 Buildings and improvements 20–35 years 191.2 167.3 Leasehold improvements Shorter of the Original Term of Lease or Estimated Useful Life 49.7 44.3 Land 41.3 40.7 Furniture and fixtures 5–7 years 16.8 16.1 Finance lease right-of-use asset 9.9 — 1,260.6 1,185.9 Less - accumulated depreciation and amortization (695.9) (694.4) $ 564.7 $ 491.5
Schedule of Intangible Assets	Intangible assets consisted of the following: September 25, 2021 September 26, 2020 Description Gross Accumulated Gross Accumulated Acquired intangible assets: Developed technology $ 4,597.7 $ 3,184.2 $ 4,054.0 $ 2,907.2 In-process research and development 71.6 — — — Customer relationships 591.7 510.1 549.1 477.8 Trade names 268.1 191.8 245.5 181.2 Non-competition agreements 1.5 1.5 1.5 1.3 Business licenses 2.5 2.5 2.4 2.3 Total acquired intangible assets $ 5,533.1 $ 3,890.1 $ 4,852.5 $ 3,569.8 Internal-use software 23.5 17.2 51.8 43.2 Capitalized software embedded in products 25.5 15.6 26.8 10.6 Total intangible assets $ 5,582.1 $ 3,922.9 $ 4,931.1 $ 3,623.6
Schedule of Estimated Amortization Expense	The estimated amortization expense at September 25, 2021 for each of the five succeeding fiscal years was as follows: Fiscal 2022 $ 326.5 Fiscal 2023 $ 231.3 Fiscal 2024 $ 222.3 Fiscal 2025 $ 208.9 Fiscal 2026 $ 178.1
Rollforward of Goodwill Activity by Reportable Segment	A rollforward of goodwill activity by reportable segment from September 26, 2020 to September 25, 2021 is as follows: Diagnostics Breast Health GYN Surgical Skeletal Health Total Balance at September 26, 2020 $ 821.6 $ 764.8 $ 1,063.4 $ 8.1 $ 2,657.9 Mobidiag acquisition 432.6 — — — 432.6 Diagenode acquisition 83.5 — — — 83.5 Biotheranostics acquisition 80.9 — — — 80.9 Somatex acquisition — 32.4 — — 32.4 Foreign currency and other adjustments (7.8) (0.1) 2.2 — (5.7) Balance at September 25, 2021 $ 1,410.8 $ 797.1 $ 1,065.6 $ 8.1 $ 3,281.6
Schedule of Other Assets	Other assets consisted of the following: September 25, 2021 September 26, 2020 Other Assets Tax receivable $ 24.7 $ 325.7 Right of use assets 83.6 80.7 Life insurance contracts 64.3 49.3 Deferred tax assets 21.9 15.5 Cost-method equity investments 9.5 11.4 Other 41.7 34.0 $ 245.7 $ 516.6
Changes in accumulated balances of other comprehensive income	The following tables summarize the components and changes in accumulated balances of other comprehensive loss for the periods presented: Year Ended September 25, 2021 Year Ended September 26, 2020 Foreign Currency Translation Pension Plans Hedged Interest Rate Caps Hedged Interest Rate Swaps Total Foreign Currency Translation Pension Plans Hedged Interest Rate Caps Hedged Interest Rate Swaps Total Beginning Balance $ (22.9) $ (1.8) $ (0.9) $ (24.1) $ (49.7) $ (41.4) $ (1.7) $ (2.7) $ 3.5 $ (42.3) Other comprehensive income (loss) before reclassifications (20.2) 0.5 0.4 9.4 (9.9) 18.5 (0.1) (0.5) (27.6) (9.7) Charges (gains) reclassified to statement of operations — — 0.5 — 0.5 — — 2.3 — 2.3 Ending Balance $ (43.1) $ (1.3) $ — $ (14.7) $ (59.1) $ (22.9) $ (1.8) $ (0.9) $ (24.1) $ (49.7)
Schedule of Accumulated Other Comprehensive Income (Loss) Related to Derivatives	Years Ended September 25, 2021 September 26, 2020 September 28, 2019 Amount of realized (loss) gain recognized in income Forward foreign currency contracts $ (3.6) $ 0.7 $ 11.0 Foreign currency option contracts (6.1) (1.9) — $ (9.7) $ (1.2) $ 11.0 Amount of unrealized (loss) gain recognized in income Forward foreign currency contracts $ 0.5 $ (0.2) $ (2.2) Foreign currency option contracts (4.0) 4.0 0.1 $ (3.5) $ 3.8 $ (2.1) Amount of gain (loss) recognized in income Total $ (13.2) $ 2.6 $ 8.9
Schedule of Derivative Instruments on the Consolidated Balance Sheets	The table below presents the fair value of the Company's derivative financial instruments as well as their classification on the balance sheet as of September 25, 2021: Balance Sheet Location September 25, 2021 September 26, 2020 Assets: Derivatives not designated as hedging instruments: Forward foreign currency contracts Prepaid expenses and other current assets $ 1.7 $ 1.1 Foreign currency option contracts Prepaid expenses and other current assets — 10.1 $ 1.7 $ 11.2 Liabilities: Derivative instruments designated as a cash flow hedge: Interest rate swap contract Accrued expenses $ 11.1 $ 8.2 Interest rate swap contract Other long-term liabilities 7.6 23.0 Total $ 18.7 $ 31.2 Derivatives not designated as hedging instruments: Forward foreign currency contracts Accrued expenses $ 0.6 $ —
Schedule of Unrealized Loss Recognized in AOCI	The following table presents the unrealized gain (loss) recognized in AOCI related to the interest rate caps and interest rate swap for the following reporting periods: Years Ended September 25, 2021 September 26, 2020 September 28, 2019 Amount of gain (loss) recognized in other comprehensive income (loss), net of taxes: Interest rate swap $ 9.4 $ (27.6) $ 3.5 Interest rate cap agreements 0.4 (0.5) (8.0) Total $ 9.8 $ (28.1) $ (4.5)
Accounts Receivable Reserve Activity	2021, 2020 and 2019: Balance at Charged to Divested Write- Balance at Period Ended: September 25, 2021 $ 31.6 $ 15.0 $ — $ (6.1) $ 40.5 September 26, 2020 $ 17.8 $ 26.8 $ (5.8) $ (7.2) $ 31.6 September 28, 2019 $ 16.2 $ 4.4 $ — $ (2.8) $ 17.8
Schedule of Reconciliation of Basic and Diluted Share Amounts	A reconciliation of basic and diluted share amounts for fiscal 2021, 2020, and 2019 was as follows: September 25, 2021 September 26, 2020 September 28, 2019 Basic weighted average common shares outstanding 257,046 262,727 269,413 Weighted average common stock equivalents from assumed exercise of stock options and restricted stock units 2,660 1,886 — Diluted weighted average common shares outstanding 259,706 264,613 269,413 Weighted-average anti-dilutive shares related to: Outstanding stock options and restricted stock units 528 1,158 4,098
Schedule of Product Warranty Activity	Product warranty activity for fiscal 2021 and 2020 was as follows: Balance at Provisions Acquired Divested Settlements/ Balance at End Period ended: September 25, 2021 $ 9.9 $ 7.7 $ 0.3 $ — $ (9.1) $ 8.8 September 26, 2020 $ 13.9 $ 11.7 $ 0.5 $ (6.1) $ (10.1) $ 9.9

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Sep. 25, 2021
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table provides revenue from contracts with customers by business and geographic region on a disaggregated basis: Years Ended September 25, 2021 September 26, 2020 September 28, 2019 Business (in millions) United States Intl. Total United States Intl. Total United States Intl. Total Diagnostics: Cytology & Perinatal $ 304.6 $ 169.3 $ 473.9 $ 266.3 $ 143.8 $ 410.1 $ 312.9 $ 159.1 $ 472.0 Molecular Diagnostics 2,038.9 1,132.6 3,171.5 1,272.5 375.9 1,648.4 549.9 125.1 675.0 Blood Screening 49.6 — 49.6 43.6 — 43.6 58.5 — 58.5 Total 2,393.1 1,301.9 3,695.0 1,582.4 519.7 2,102.1 921.3 284.2 1,205.5 Breast Health: Breast Imaging 830.4 253.0 1,083.4 722.0 231.6 953.6 853.1 241.5 1,094.6 Interventional Breast Solutions 221.4 47.5 268.9 166.6 31.7 198.3 184.8 34.8 219.6 Total 1,051.8 300.5 1,352.3 888.6 263.3 1,151.9 1,037.9 276.3 1,314.2 GYN Surgical 396.4 91.7 488.1 310.1 66.0 376.1 362.8 74.4 437.2 Skeletal Health 61.0 35.9 96.9 51.2 29.8 81.0 58.6 36.2 94.8 Medical Aesthetics — — — 30.9 34.4 65.3 155.4 160.2 315.6 Total $ 3,902.3 $ 1,730.0 $ 5,632.3 $ 2,863.2 $ 913.2 $ 3,776.4 $ 2,536.0 $ 831.3 $ 3,367.3 Years Ended Geographic Regions ( in millions ) September 25, 2021 September 26, 2020 September 28, 2019 United States $ 3,902.3 $ 2,863.2 $ 2,536.0 Europe 1,201.8 569.8 396.0 Asia-Pacific 365.0 226.8 286.0 Rest of World 163.2 116.6 149.3 $ 5,632.3 $ 3,776.4 $ 3,367.3 The following table provides revenue recognized by source: Years Ended Revenue by type ( in millions ) September 25, 2021 September 26, 2020 September 28, 2019 Disposables $ 4,198.2 $ 2,561.1 $ 1,786.4 Capital equipment, components and software 769.1 665.9 984.9 Service 598.1 516.6 568.3 Other 66.9 32.8 27.7 $ 5,632.3 $ 3,776.4 $ 3,367.3

Leases (Tables)

Leases (Tables)	12 Months Ended
	Sep. 25, 2021
Leases [Abstract]
Assets And Liabilities, Lessee	The following table presents supplemental balance sheet information related to the Company's operating and finance leases: September 25, 2021 September 26, 2020 Balance Sheet Location Operating Leases Finance Leases Operating Leases Finance Leases Assets Lease right-of-use assets Other assets $ 83.6 $ — $ 80.7 $ — Finance lease right-of-use assets (non-current) Property, plant and equipment, net $ — $ 9.3 $ — $ — Liabilities Operating lease liabilities (current) Accrued expenses $ 26.8 $ — $ 23.5 $ — Finance lease liabilities (current) Finance lease obligations - short term $ — $ 3.7 $ — $ 1.9 Operating lease liabilities (non-current) Other long-term liabilities $ 66.1 $ — $ 65.6 $ — Finance lease liabilities (non-current) Finance lease obligations - long term $ — $ 22.8 $ — $ 17.4 The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases: As of September 25, 2021 As of September 26, 2020 Operating Leases Finance Lease Operating Leases Finance Lease Weighted average remaining lease term 4.95 7.52 5.58 7.64 Weighted average discount rate 1.6 % 4.3 % 2.0 % 5.1 %
Lease, Cost	The following table provides information related to the Company’s operating and finance leases: Year Ended September 25, 2021 Year Ended September 26, 2020 Operating lease cost (a) $ 30.1 $ 27.5 Finance lease cost - amortization of right-of-use assets $ 0.6 $ 0.3 Finance lease cost - interest cost $ 1.0 $ 1.0 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 1.0 $ 1.0 Operating cash flows from operating leases $ 28.2 $ 23.9 Financing cash flows from finance leases $ 2.4 $ 1.7 Total cash paid for amounts included in the measurement of lease liabilities $ 31.6 $ 26.6 ROU assets arising from entering into new operating lease obligations $ 28.6 $ 13.3 ROU assets arising from entering into new finance lease obligations $ 9.1 $ — (a) Includes short-term lease expense and variable lease costs, which were immaterial for the year ended September 25, 2021. Rent expense under FASB ASC Topic 840 was $23.1 million for fiscal 2019.
Finance Lease, Liability, Maturity	The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of September 25, 2021: Fiscal Year Operating Leases Finance Lease 2022 $ 28.2 $ 4.4 2023 22.0 4.2 2024 16.4 3.9 2025 11.8 3.9 2026 7.4 3.9 Thereafter 11.7 10.2 Total future minimum lease payments 97.5 30.5 Less: imputed interest (4.6) (4.0) Present value of lease liabilities $ 92.9 $ 26.5
Lessee, Operating Lease, Liability, Maturity	The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of September 25, 2021: Fiscal Year Operating Leases Finance Lease 2022 $ 28.2 $ 4.4 2023 22.0 4.2 2024 16.4 3.9 2025 11.8 3.9 2026 7.4 3.9 Thereafter 11.7 10.2 Total future minimum lease payments 97.5 30.5 Less: imputed interest (4.6) (4.0) Present value of lease liabilities $ 92.9 $ 26.5
Operating Lease, Lease Income	The future minimum annual rental income payments under these lease and sublease agreements at September 25, 2021 are as follows: Fiscal 2022 $ 3.1 Fiscal 2023 3.0 Fiscal 2024 3.0 Fiscal 2025 2.0 Fiscal 2026 0.9 Thereafter 2.3 Total $ 14.3

Business Combinations (Tables)

Business Combinations (Tables)	12 Months Ended
	Sep. 25, 2021
Business Combinations [Abstract]
Schedule of Purchase Price Allocation	The total purchase price was allocated to Mobidiag's preliminary tangible and identifiable intangible assets and liabilities based on the estimated fair values as of June 17, 2021, as set forth below. Cash $ 7.0 Accounts receivable 4.2 Inventory 13.7 Other assets 29.6 Accounts payable and accrued expenses (19.1) Other liabilities (11.7) Identifiable intangible assets: Developed technology 285.0 In-process research and development 74.0 Customer relationships 20.9 Trade names 20.0 Current debt (66.1) Deferred income taxes, net (60.5) Goodwill 432.6 Purchase Price $ 729.6 The total purchase price was allocated to Biotheranostics' preliminary tangible and identifiable intangible assets and liabilities based on the estimated fair values as of February 22, 2021, as set forth below. Cash $ 9.6 Accounts receivable 6.6 Other assets 6.5 Accounts payable and accrued expenses (8.2) Other liabilities (8.1) Identifiable intangible assets: Developed technology 160.3 Trade names 2.1 Deferred income taxes, net (18.4) Goodwill 80.9 Purchase Price $ 231.3 Cash $ 5.6 Accounts receivable 9.3 Inventory 9.0 Other assets 13.9 Accounts payable and accrued expenses (16.7) Other liabilities (9.2) Identifiable intangible assets: Developed technology 69.8 Customer relationships 9.2 Deferred income taxes, net (19.3) Goodwill 83.5 Purchase Price $ 155.1 The total purchase price was allocated to Acessa's tangible and identifiable intangible assets and liabilities based on the estimated fair values of those assets as of August 23, 2020, as set forth below. Cash $ 1.2 Inventory 4.0 Other assets 4.4 Accounts payable and accrued expenses (4.7) Identifiable intangible assets: Developed Technology 127.0 Trade names 1.2 Deferred income taxes, net (20.2) Goodwill 49.1 Purchase Price $ 162.0 The total purchase price was allocated to SSI's tangible and identifiable intangible assets and liabilities based on the estimated fair values of those assets as of November 21, 2019, as set forth below. Cash $ 2.6 Accounts receivable 7.1 Inventory 10.0 Property, plant and equipment 6.5 Other assets 4.3 Accounts payable and accrued expenses (24.5) Deferred revenue (1.8) Short and long-term debt (8.8) Other liabilities (3.8) Identifiable intangible assets: Developed technology 38.3 Customer relationships 4.0 Trade names 3.0 Deferred income taxes, net (1.9) Goodwill 34.3 Purchase Price $ 69.3 The total purchase price was allocated to Focal's tangible and identifiable intangible assets and liabilities based on the estimated fair values of those assets as of October 1, 2018, as set forth below: Cash $ 2.2 Accounts receivable 2.0 Inventory 7.9 Other assets 0.5 Accounts payable and accrued expenses (5.6) Long-term debt (2.5) Identifiable intangible assets: Developed technology 83.1 In-process research and development 11.4 Trade names 2.7 Deferred income taxes, net (12.7) Goodwill 31.1 Purchase Price $ 120.1

Restructuring Charges (Tables)

Restructuring Charges (Tables)	12 Months Ended
	Sep. 25, 2021
Restructuring and Related Activities [Abstract]
Charges Taken Related to Restructuring Actions	The following table displays charges taken related to restructuring actions in fiscal 2021, 2020 and 2019 and a rollforward of the charges to the accrued balances as of September 25, 2021: Fiscal 2021 Actions Fiscal 2020 Actions Fiscal 2019 Actions Other Total Restructuring Charges Fiscal 2019 charges: Workforce reductions $ — $ — $ 4.0 $ 1.4 $ 5.4 Facility closure costs — — — 1.2 1.2 Fiscal 2019 restructuring charges $ — $ — $ 4.0 $ 2.6 $ 6.6 Fiscal 2020 charges: Workforce reductions $ — $ 13.2 $ 0.3 $ (0.1) $ 13.4 Facility closure costs — 1.9 — — 1.9 Fiscal 2020 restructuring charges $ — $ 15.1 $ 0.3 $ (0.1) $ 15.3 Fiscal 2021 charges: Workforce reductions $ 8.7 $ 0.6 $ — $ — $ 9.3 Fiscal 2021 restructuring charges $ 8.7 $ 0.6 $ — $ — $ 9.3
Charges Taken Related to Accrued Restructuring Actions	Fiscal 2021 Actions Fiscal 2020 Actions Fiscal 2019 Actions Fiscal 2018 Actions Previous Other Charges Total Rollforward of Accrued Restructuring Balance as of September 29, 2018 $ — $ — $ — $ 4.3 $ 4.8 $ 9.1 Fiscal 2019 restructuring charges $ — $ — $ 4.0 $ 1.2 $ 1.4 $ 6.6 Severance payments and adjustments — — (3.0) (3.9) (0.8) (7.7) Other payments — — — (0.5) (1.6) (2.1) Balance as of September 28, 2019 $ — $ — $ 1.0 $ 1.1 $ 3.8 $ 5.9 Fiscal 2020 restructuring charges $ — $ 15.1 $ 0.3 $ (0.1) $ — $ 15.3 Stock-based compensation — (7.5) — — — (7.5) Severance payments and adjustments — (4.4) (1.3) (0.2) — (5.9) Other payments and adjustments (1) — 0.5 — — (3.8) (3.3) Balance as of September 26, 2020 $ — $ 3.7 $ — $ 0.8 $ — $ 4.5 Fiscal 2021 restructuring charges $ 8.7 $ 0.6 $ — $ — $ — $ 9.3 Stock-based compensation (0.9) — — — — (0.9) Severance payments and adjustments (4.6) (3.4) — (0.8) — (8.8) Balance as of September 25, 2021 $ 3.2 $ 0.9 $ — $ — $ — $ 4.1

Borrowings and Credit Arrange_2

Borrowings and Credit Arrangements (Tables)	12 Months Ended
	Sep. 25, 2021
Debt Disclosure [Abstract]
Company's Borrowings and Interest Expense	The Company’s borrowings consisted of the following: September 25, September 26, Current debt obligations, net of debt discount and deferred issuance costs: Term Loan $ — $ 74.9 Revolver — 250.0 Securitization Program 248.5 — Other 64.5 — Total current debt obligations $ 313.0 $ 324.9 Long-term debt obligations, net of debt discount and issuance costs: Term Loan 1,382.3 1,379.9 2025 Senior Notes — 939.4 2028 Senior Notes 395.4 394.6 2029 Senior Notes 934.5 — Total long-term debt obligations 2,712.2 2,713.9 Total debt obligations $ 3,025.2 $ 3,038.8 Interest expense for the 2029 Senior Notes, 2028 Senior Notes and 2025 Senior Notes was as follows: Years Ended September 25, 2021 September 26, 2020 September 28, 2019 Interest Rate Interest Expense (1) Non-Cash Interest Expense Interest Expense (1) Non-Cash Interest Expense Interest Expense (1) Non-Cash Interest Expense 2029 Senior Notes 3.250 % $ 32.7 $ 2.1 $ — $ — $ — $ — 2028 Senior Notes 4.625 % 19.2 0.7 19.2 0.7 19.2 0.7 2025 Senior Notes 4.375 % 2.3 0.1 43.5 2.1 43.5 2.1 Total $ 54.2 $ 2.9 $ 62.7 $ 2.8 $ 62.7 $ 2.8 (1) Interest expense includes non-cash interest expense related to the amortization of the deferred issuance costs and accretion of the debt discount.
Schedule Of Long Term Debt By Maturity Table	The debt maturity schedule for the Company’s obligations as of September 25, 2021 was as follows: 2022 2023 2024 2025 2026 2027 and Thereafter Total Term Loan* $ 75.0 $ 112.5 $ 1,200.0 $ — $ — $ — $ 1,387.5 Securitization Program 248.5 — — — — — 248.5 2028 Senior Notes — — — — — 400.0 400.0 2029 Senior Notes — — — — — 950.0 950.0 Other 64.5 — — — — — 64.5 $ 388.0 $ 112.5 $ 1,200.0 $ — $ — $ 1,350.0 $ 3,050.5 *The Term Loan debt maturity schedule herein represents the 2018 Credit Agreement as of September 25, 2021. The Company amended the credit agreement on September 27, 2021, which resulted in a change in the principal maturity schedule.
Schedule of Credit Agreements	Interest expense, non-cash interest expense, the weighted average interest rate, and the interest rate at the end of period under the 2018 Credit Agreement and the 2017 Credit Agreement was as follows: Years Ended September 25, 2021 September 26, 2020 September 28, 2019 Interest expense (1) $ 22.0 $ 46.6 $ 67.0 Non-cash interest expense $ 2.5 $ 2.5 $ 2.6 Weighted average interest rate 1.13 % 2.25 % 3.79 % Interest rate at end of period 1.08 % 1.40 % 3.43 % (1) Interest expense includes non-cash interest expense related to the amortization of the deferred issuance costs and accretion of the debt discount.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Sep. 25, 2021
Fair Value Disclosures [Abstract]
Fair Value Assets and Liabilities Measured on Recurring Basis	Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following: Fair Value Measurements at September 25, 2021 Carrying Value Quoted Prices in Significant Significant Assets: Forward foreign currency contracts $ 1.7 $ — $ 1.7 — Total $ 1.7 $ — $ 1.7 $ — Liabilities: Contingent consideration $ 75.1 $ — $ — $ 75.1 Interest rate swaps - derivative 18.7 — 18.7 — Forward foreign currency contracts 0.6 — 0.6 — Total $ 94.4 $ — $ 19.3 $ 75.1 Fair Value Measurements at September 26, 2020 Carrying Value Quoted Prices in Significant Significant Assets: Forward currency option contracts $ 10.1 $ — $ 10.1 $ — Forward foreign currency contracts 1.1 — $ 1.1 — Total $ 11.2 $ — $ 11.2 $ — Liabilities: Contingent consideration $ 81.8 $ — $ — $ 81.8 Interest rate swaps - derivative 31.2 — 31.2 — Total $ 113.0 $ — $ 31.2 $ 81.8 Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of contingent consideration liabilities, during the years ended September 25, 2021, September 26, 2020, and September 28, 2019 were as follows: Years Ended 2021 2020 2019 Balance at beginning of period $ 81.8 $ 9.1 $ 7.8 Contingent consideration recorded at acquisition — 82.7 — Fair value adjustments (6.7) 0.3 1.7 Payments/Accruals — (10.3) (0.4) Balance at end of period $ 75.1 $ 81.8 $ 9.1

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Sep. 25, 2021
Income Tax Disclosure [Abstract]
Income (Loss) Before Income Taxes	The Company’s income (loss) before income taxes consisted of the following: Years ended September 25, 2021 September 26, 2020 September 28, 2019 Domestic $ 2,267.8 $ 921.1 $ (174.3) Foreign 93.3 80.8 (83.4) $ 2,361.1 $ 1,001.9 $ (257.7)
Provision for Income Taxes	The provision (benefit) for income taxes contained the following components: Years ended September 25, 2021 September 26, 2020 September 28, 2019 Federal: Current $ 453.6 $ (62.1) $ 142.9 Deferred (45.6) (76.6) (189.9) 408.0 (138.7) (47.0) State: Current 84.7 33.9 22.1 Deferred (11.9) (12.5) (41.0) 72.8 21.4 (18.9) Foreign: Current 23.2 14.0 16.5 Deferred (12.6) (5.3) (4.7) 10.6 8.7 11.8 $ 491.4 $ (108.6) $ (54.1)
Reconciliation of Income Tax (Benefit) at U.S. Federal Statutory Rate to Company's Effective Tax Rate	The income tax provision (benefit) differed from the tax provision (benefit) computed at the U.S. federal statutory rate due to the following: Years ended September 25, 2021 September 26, 2020 September 28, 2019 Income tax (benefit) provision at federal statutory rate 21.0 % 21.0 % (21.0) % Increase (decrease) in tax resulting from: Loss on sale of Cynosure — (31.3) — State income taxes, net of federal benefit 2.7 2.9 (0.7) U.S. tax on foreign earnings (2.7) (2.6) (2.1) Internal restructuring — — (3.8) Tax credits (0.3) (0.6) (3.3) Tax reform — — 2.0 Unrecognized tax benefits 0.3 — (0.1) Compensation 0.1 0.4 0.8 Foreign rate differential (0.7) (1.2) (5.4) Change in deferred tax rate (0.3) (0.6) — Change in valuation allowance — 1.3 9.5 Other 0.7 (0.1) 3.1 20.8 % (10.8) % (21.0) %
Significant Components of the Company's Deferred Tax Assets and Liabilities	The Company’s significant deferred tax assets and liabilities were as follows: September 25, 2021 September 26, 2020 Deferred tax assets Net operating loss carryforwards $ 91.5 $ 81.1 Capital losses 52.0 57.0 Non-deductible accruals 34.9 24.9 Non-deductible reserves 41.8 33.2 Stock-based compensation 17.6 18.6 Tax credits 10.0 10.2 Nonqualified deferred compensation plan 16.8 14.4 Lease liability 16.2 17.3 Other temporary differences 17.4 25.2 298.2 281.9 Less: valuation allowance (121.3) (118.5) $ 176.9 $ 163.4 Deferred tax liabilities Depreciation and amortization $ (389.7) $ (333.9) Right of use asset (15.8) (15.8) $ (405.5) $ (349.7) $ (228.6) $ (186.3)
Activity of the Company's Unrecognized Income Tax Benefits	The Company’s unrecognized income tax benefits activity for fiscal 2021 and 2020 was as follows: 2021 2020 Balance at beginning of fiscal year $ 197.1 $ 101.6 Tax positions related to current year: Additions 8.0 109.6 Reductions — — Tax positions related to prior years: Additions related to change in estimate 7.9 1.5 Reductions (0.3) (0.7) Payments — — Lapses in statutes of limitations (1.7) (15.6) Acquired tax positions: Additions related to reserves acquired from acquisitions 1.8 0.7 Balance as of the end of the fiscal year $ 212.8 $ 197.1

Stockholders' Equity and Stoc_2

Stockholders' Equity and Stock-Based Compensation (Tables)	12 Months Ended
	Sep. 25, 2021
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation Expense in Consolidated Statement of Operations	The following presents stock-based compensation expense in the Company’s Consolidated Statements of Operations in fiscal 2021, 2020 and 2019: 2021 2020 2019 Cost of revenues $ 8.0 $ 6.7 $ 7.1 Research and development 7.7 8.0 9.2 Selling and marketing 9.5 10.2 10.2 General and administrative 38.9 50.9 35.5 Restructuring 0.9 7.5 — $ 65.0 $ 83.3 $ 62.0
Information Pertaining to Stock Options Granted and Related Assumptions	Information pertaining to stock options granted during fiscal 2021, 2020 and 2019 and related assumptions are noted in the following table: Years ended September 25, 2021 September 26, 2020 September 28, 2019 Options granted (in millions) 0.6 1.0 1.0 Weighted-average exercise price $ 68.62 $ 45.96 $ 41.36 Weighted-average grant date fair value $ 19.86 $ 13.92 $ 13.54 Assumptions: Risk-free interest rates 0.4 % 1.7 % 3.0 % Expected life (in years) 4.8 4.8 4.8 Expected volatility 35.0 % 33.6 % 34.3 % Dividend yield — — —
Stock Option Activity	The following table summarizes all stock option activity under the Company’s stock option plans for the year ended September 25, 2021: Number Weighted- Weighted- Aggregate Options outstanding at September 26, 2020 4.6 $ 40.37 7.0 $ 109.5 Granted 0.6 68.62 Canceled/ forfeited (0.2) 49.67 Exercised (0.8) 38.46 30.4 Options outstanding at September 25, 2021 4.2 $ 44.66 6.6 $ 132.7 Options exercisable at September 25, 2021 2.3 $ 39.29 5.7 $ 85.4 Options vested and expected to vest at September 25, 2021 (1) 4.1 $ 44.60 6.6 $ 132.2 (1) This represents the number of vested stock options as of September 25, 2021 plus the unvested outstanding options at September 25, 2021 expected to vest in the future, adjusted for estimated forfeitures.
Restricted Stock Unit Activity	A summary of the Company’s RSU, PSU, FCF and MSU activity during the year ended September 25, 2021 is presented below: Non-vested Shares Number of Weighted-Average Non-vested at September 26, 2020 2.4 $ 44.22 Granted 1.1 69.14 Vested (1.7) 43.94 Forfeited (0.1) 52.57 Non-vested at September 25, 2021 1.7 $ 54.21
Black-Scholes Model Weighted Average Assumptions Used to Estimate Fair Value of Shares to Be Issued as of Grant Date	The Company uses the Black-Scholes model to estimate the fair value of shares to be issued as of the grant date using the following weighted average assumptions: September 25, 2021 September 26, 2020 September 28, 2019 Assumptions: Risk-free interest rates 0.26 % 1.32 % 2.27 % Expected life (in years) 0.5 0.5 0.5 Expected volatility 34.1 % 26.9 % 27.1 % Dividend yield — — —

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Sep. 25, 2021
Commitments and Contingencies Disclosure [Abstract]
Unrecorded Unconditional Purchase Obligations Disclosure	At September 25, 2021, non-cancelable purchase commitments are as follows: Fiscal 2022 290.3 Fiscal 2023 16.4 Fiscal 2024 9.2 Fiscal 2025 4.1 Fiscal 2026 1.7 Thereafter 0.4 Total $ 322.1

Disposition (Tables)

Disposition (Tables)	12 Months Ended
	Sep. 25, 2021
Disposal Groups, Including Discontinued Operations and Collaborative Agreement [Abstract]
Schedule of Disposed Business, Income from Operations and Assets held-for-sale	Loss from operations of the disposed business for fiscal 2020 and 2019 was as follows: Years Ended September 26, 2020 September 28, 2019 Loss from operations $ (46.5) $ (781.2)

Business Segments and Geograp_2

Business Segments and Geographic Information (Tables)	12 Months Ended
	Sep. 25, 2021
Segment Reporting [Abstract]
Segment Information	Segment information for fiscal 2021, 2020, and 2019 was as follows: Years ended September 25, September 26, September 28, Total revenues: Diagnostics $ 3,695.0 $ 2,102.1 $ 1,205.5 Breast Health 1,352.3 1,151.9 1,314.2 GYN Surgical 488.1 376.1 437.2 Skeletal Health 96.9 81.0 94.8 Medical Aesthetics — 65.3 315.6 $ 5,632.3 $ 3,776.4 $ 3,367.3 Operating income (loss): Diagnostics $ 2,140.1 $ 929.7 $ 163.1 Breast Health 284.2 192.8 399.3 GYN Surgical 58.9 42.0 99.2 Skeletal Health (2.9) (2.4) (4.2) Medical Aesthetics — (57.1) (781.2) $ 2,480.3 $ 1,105.0 $ (123.8) Depreciation and amortization: Diagnostics $ 260.4 $ 237.3 $ 246.6 Breast Health 52.7 48.8 36.8 GYN Surgical 93.1 85.1 87.7 Skeletal Health 0.7 0.7 0.6 Medical Aesthetics — 4.1 91.4 $ 406.9 $ 376.0 $ 463.1 Capital expenditures: Diagnostics $ 126.2 $ 110.7 $ 59.2 Breast Health 14.2 22.4 18.3 GYN Surgical 14.5 17.9 15.7 Skeletal Health 0.3 0.2 1.2 Medical Aesthetics — 1.4 7.0 Corporate 1.0 3.8 7.7 $ 156.2 $ 156.4 $ 109.1 Identifiable assets: Diagnostics $ 3,348.8 $ 2,161.4 $ 2,276.6 Breast Health 1,233.9 1,200.9 1,127.8 GYN Surgical 1,369.7 1,438.7 1,328.6 Skeletal Health 31.9 38.9 27.3 Medical Aesthetics — — 159.3 Corporate 2,935.6 2,355.9 1,522.5 $ 8,919.9 $ 7,195.8 $ 6,442.1
Revenues by Geography	Revenues by geography as a percentage of total revenues were as follows: Years ended September 25, September 26, September 28, United States 69.3 % 75.8 % 75.3 % Europe 21.3 % 15.1 % 11.8 % Asia-Pacific 6.5 % 6.0 % 8.5 % Rest of world 2.9 % 3.1 % 4.4 % 100.0 % 100.0 % 100.0 %
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	The Company’s property, plant and equipment, net were geographically located as follows: September 25, 2021 September 26, 2020 September 28, 2019 United States $ 403.2 $ 383.0 $ 355.5 Europe 122.9 77.5 64.4 Costa Rica 26.9 20.8 33.0 Rest of world 11.7 10.2 18.0 $ 564.7 $ 491.5 $ 470.9

Accrued Expenses and Other Lo_2

Accrued Expenses and Other Long-Term Liabilities (Tables)	12 Months Ended
	Sep. 25, 2021
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses and other long-term liabilities consisted of the following: September 25, 2021 September 26, 2020 Accrued Expenses Compensation and employee benefits $ 297.2 $ 262.7 Income and other taxes 70.9 125.3 Contingent consideration 16.3 — Operating leases 26.8 23.5 Accrued interest 16.9 22.1 Other 168.1 114.0 $ 596.2 $ 547.6
Schedule of Other Long-Term Liabilities	September 25, 2021 September 26, 2020 Other Long-Term Liabilities Reserve for income tax uncertainties $ 210.0 $ 103.7 Contingent consideration 58.8 81.8 Operating leases 66.1 65.6 Interest rate swap 7.6 23.0 Pension liabilities 10.0 11.1 Other 16.2 18.0 $ 368.7 $ 303.2

Pension and Other Employee Be_2

Pension and Other Employee Benefits (Tables)	12 Months Ended
	Sep. 25, 2021
Retirement Benefits [Abstract]
Schedule of Reconciliation of Benefit Obligations, Plan Assets, Funded Status and Related Actuarial Assumptions	The tables below provide a reconciliation of benefit obligations, plan assets, funded status, and related actuarial assumptions of the Company’s German Pension Benefits. Change in Benefit Obligation Years ended September 25, 2021 September 26, 2020 September 28, 2019 Benefit obligation at beginning of year $ (10.9) $ (10.0) $ (9.7) Service cost — — — Interest cost (0.1) (0.1) (0.2) Plan participants’ contributions — — — Actuarial gain (loss) 0.5 (0.5) (1.0) Foreign exchange gain (0.1) (0.7) 0.6 Benefits paid 0.3 0.4 0.3 Benefit obligation at end of year (10.3) (10.9) (10.0) Plan assets — — — Benefit obligation at end of year $ (10.3) $ (10.9) $ (10.0)
Components of Net Periodic Benefit Cost and Related Actuarial Assumptions	The tables below outline the components of the net periodic benefit cost and related actuarial assumptions of the Company’s German Pension Benefits. Components of Net Periodic Benefit Cost Years ended September 25, 2021 September 26, 2020 September 28, 2019 Service cost $ — $ — $ — Interest cost 0.1 0.1 0.2 Expected return on plan assets — — — Amortization of prior service cost — — — Recognized net actuarial gain 0.3 0.2 0.1 Net periodic benefit cost $ 0.4 $ 0.3 $ 0.3
Schedule of Weighted-Average Net Periodic Benefit Cost Assumptions	Weighted-Average Net Periodic Benefit Cost Assumptions 2021 2020 2019 Discount rate 1.00 % 0.80 % 1.10 % Expected return on plan assets — % — % — % Rate of compensation increase — % — % — %
Schedule of Expected Pension Benefit	The table below reflects the total Pension Benefits expected to be paid for the German Pension Benefits each fiscal year as of September 25, 2021: 2022 $ 0.4 2023 $ 0.4 2024 $ 0.4 2025 $ 0.4 2026 $ 0.4 2027 to 2031 $ 2.2

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail)	Oct. 14, 2021USD ($)	Sep. 25, 2021USD ($)Customer	Dec. 26, 2020USD ($)	Dec. 28, 2019USD ($)	Sep. 28, 2019	Mar. 30, 2019USD ($)	Dec. 29, 2018USD ($)	Dec. 30, 2017USD ($)	Sep. 25, 2021USD ($)Customer	Sep. 26, 2020USD ($)Customer	Sep. 28, 2019USD ($)	Aug. 23, 2020USD ($)
Significant Accounting Policies [Line Items]
Impairment charge		$ 1,800,000	$ 30,200,000	$ 30,200,000		$ 685,400,000
Cash Equivalents Maturity Period									three months or less
Gross Carrying Value		5,582,100,000							$ 5,582,100,000	$ 4,931,100,000
Accumulated Amortization		3,922,900,000							3,922,900,000	3,623,600,000
Goodwill		3,281,600,000							3,281,600,000	2,657,900,000
Purchase of interest rate caps							$ 1,500,000	$ 3,700,000	0	0	$ 1,500,000
Principal amount of borrowings		1,000,000,000							1,000,000,000
Notional Amount		861,500,000							$ 861,500,000
Product Warranty Term									1 year
Advertising cost									$ 9,800,000	15,600,000	29,500,000
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax									500,000	$ 2,300,000
Goodwill and Intangible Asset Impairment											685,400,000
Notional amount		$ 1,000,000,000							$ 1,000,000,000
Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers with balance greater than specified percentage | Customer		0							0	1
Trade names
Significant Accounting Policies [Line Items]
Gross Carrying Value		$ 268,100,000							$ 268,100,000	$ 245,500,000
Accumulated Amortization		191,800,000							191,800,000	181,200,000
Developed technology
Significant Accounting Policies [Line Items]
Gross Carrying Value		4,597,700,000							4,597,700,000	4,054,000,000
Accumulated Amortization		3,184,200,000							3,184,200,000	2,907,200,000
In-process research and development
Significant Accounting Policies [Line Items]
Gross Carrying Value		71,600,000							71,600,000	0
Accumulated Amortization		0							$ 0	$ 0
Accounts receivable [Member] | Customer Concentration Risk | One Customer
Significant Accounting Policies [Line Items]
Concentration risk, percentage										11.90%
Minimum
Significant Accounting Policies [Line Items]
Intangible assets useful life									2 years
Minimum | Accounts receivable [Member] | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Concentration risk, percentage									10.00%	10.00%
Minimum | Total revenues [Member] | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Concentration risk, percentage					10.00%				10.00%	10.00%
Maximum
Significant Accounting Policies [Line Items]
Intangible assets useful life									30 years
Interest rate caps - derivative
Significant Accounting Policies [Line Items]
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax									$ 500,000	$ 2,300,000
Interest Rate Swap [Member]
Significant Accounting Policies [Line Items]
Interest rate caps - derivative		$ 18,700,000							18,700,000
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax									0	0
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax									$ 9,400,000	(27,600,000)	3,500,000
Acessa Health
Significant Accounting Policies [Line Items]
Goodwill												$ 49,100,000
Acessa Health | Trade names
Significant Accounting Policies [Line Items]
Identifiable intangible assets:										1,200,000
Bolder Surgical | Subsequent Event
Significant Accounting Policies [Line Items]
Payments to Acquire Businesses, Gross	$ 160,000,000
Medical Aesthetics
Significant Accounting Policies [Line Items]
Impairment charge				$ 30,200,000
Medical Aesthetics | Distribution agreement [Member]
Significant Accounting Policies [Line Items]
Impairment charge											27,700,000
Medical Aesthetics | Customer Relationships
Significant Accounting Policies [Line Items]
Impairment charge											22,400,000
Medical Aesthetics | Trade names
Significant Accounting Policies [Line Items]
Impairment charge											48,600,000
Medical Aesthetics | Developed Technology
Significant Accounting Policies [Line Items]
Impairment charge											576,900,000
Medical Aesthetics | Property, Plant and Equipment [Member]
Significant Accounting Policies [Line Items]
Impairment charge											9,800,000
Forward foreign currency contracts
Significant Accounting Policies [Line Items]
Derivative contract period, or less									1 year
Interest rate caps - derivative
Significant Accounting Policies [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax									$ 500,000	2,300,000	3,100,000
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax									$ 400,000	$ (500,000)	$ (8,000,000)

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Supplemental Cash Flow Statement Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Accounting Policies [Abstract]
Cash paid during the period for income taxes	$ 615.1	$ 265.9	$ 180.6
Cash paid during the period for interest	93.2	109.5	132.5
Contingent consideration recorded at acquisition	$ 0	$ 82.7	$ 0

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Inventories (Detail) - USD ($) $ in Millions	Sep. 25, 2021	Sep. 26, 2020
Accounting Policies [Abstract]
Raw materials	$ 163.3	$ 152.3
Work-in-process	53	46.5
Finished goods	284.9	196.3
Inventories	$ 501.2	$ 395.1

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipments (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Dec. 26, 2020	Sep. 26, 2020	Sep. 25, 2021	Sep. 28, 2019
Property, Plant and Equipment [Line Items]
Manufacturing Equipment And Software		$ 460.7	$ 467.1
Equipment Under Customer Usage Agreements		456.8	484.6
Buildings and Improvements, Gross		167.3	191.2
Leasehold Improvements, Gross		44.3	49.7
Land		40.7	41.3
Furniture and Fixtures, Gross		16.1	16.8
Finance Lease, Right-of-Use Asset		0
Property, Plant and Equipment, Gross		1,185.9	1,260.6
Less - accumulated depreciation and amortization		(694.4)	(695.9)
Property, plant and equipment, net		491.5	564.7	$ 470.9
Grants received from Department of defense	$ 119.3	$ 7.6
Department of defense funds received			21.2
Property, Plant and Equipment [Member]
Property, Plant and Equipment [Line Items]
Finance Lease, Right-of-Use Asset			$ 9.9
Equipment and Software [Member] | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful life			3 years
Equipment and Software [Member] | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful life			10 years
Equipment Under Customer Usage Agreements [Member] | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful life			3 years
Equipment Under Customer Usage Agreements [Member] | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful life			8 years
Building and Improvements [Member] | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful life			20 years
Building and Improvements [Member] | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful life			35 years
Furniture and Fixtures [Member] | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful life			5 years
Furniture and Fixtures [Member] | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful life			7 years

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Schedule of Intangible Assets (Detail) - USD ($)	3 Months Ended				12 Months Ended
	Sep. 25, 2021	Dec. 26, 2020	Dec. 28, 2019	Mar. 30, 2019	Sep. 28, 2019	Jun. 26, 2021	Mar. 27, 2021	Sep. 26, 2020
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 5,582,100,000							$ 4,931,100,000
Accumulated Amortization	3,922,900,000							3,623,600,000
Impairment charge	1,800,000	$ 30,200,000	$ 30,200,000	$ 685,400,000
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	4,597,700,000							4,054,000,000
Accumulated Amortization	3,184,200,000							2,907,200,000
In-process research and development
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	71,600,000							0
Accumulated Amortization	0							0
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	591,700,000							549,100,000
Accumulated Amortization	510,100,000							477,800,000
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	268,100,000							245,500,000
Accumulated Amortization	191,800,000							181,200,000
Non-competition agreements
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	1,500,000							1,500,000
Accumulated Amortization	1,500,000							1,300,000
Business licenses
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	2,500,000							2,400,000
Accumulated Amortization	2,500,000							2,300,000
Acquired intangible assets [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	5,533,100,000							4,852,500,000
Accumulated Amortization	3,890,100,000							3,569,800,000
Internal-use software [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	23,500,000							51,800,000
Accumulated Amortization	17,200,000							43,200,000
Capitalized software [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	25,500,000							26,800,000
Accumulated Amortization	$ 15,600,000							10,600,000
Medical Aesthetics
Finite-Lived Intangible Assets [Line Items]
Impairment charge			$ 30,200,000
Medical Aesthetics | Developed Technology
Finite-Lived Intangible Assets [Line Items]
Impairment charge					$ 576,900,000
Medical Aesthetics | Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Impairment charge					22,400,000
Medical Aesthetics | Trade names
Finite-Lived Intangible Assets [Line Items]
Impairment charge					48,600,000
Medical Aesthetics | Property, Plant and Equipment [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment charge					$ 9,800,000
Mobidiag Oy | In-process research and development
Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets:						$ 74,000,000
Mobidiag Oy | Trade names
Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets:						20,000,000
Mobidiag Oy | Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets:						20,900,000
Mobidiag Oy | Developed Technology
Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets:						$ 285,000,000
Biotheranostics | Trade names
Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets:							$ 2,100,000
Biotheranostics | Developed Technology
Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets:							160,300,000
Diagenode | Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets:							9,200,000
Diagenode | Developed Technology
Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets:							69,800,000
Somatex | Customer relationships
Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets:							1,200,000
Somatex | Trade names
Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets:							900,000
Somatex | Developed Technology
Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets:							$ 38,000,000
Acessa Health | Trade names
Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets:								1,200,000
Acessa Health | Developed Technology
Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets:								$ 127,000,000

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Medical Aesthetics Impairment and Other Activity (Details) - USD ($)	3 Months Ended				12 Months Ended
	Sep. 25, 2021	Dec. 26, 2020	Dec. 28, 2019	Mar. 30, 2019	Sep. 28, 2019	Sep. 26, 2020
Business Acquisition [Line Items]
Impairment charge	$ 1,800,000	$ 30,200,000	$ 30,200,000	$ 685,400,000
Goodwill and Intangible Asset Impairment					$ 685,400,000
Acessa Health | Trade names
Business Acquisition [Line Items]
Identifiable intangible assets:						$ 1,200,000
Medical Aesthetics
Business Acquisition [Line Items]
Impairment charge			$ 30,200,000
Distribution agreement [Member] | Medical Aesthetics
Business Acquisition [Line Items]
Impairment charge					27,700,000
Customer Relationships | Medical Aesthetics
Business Acquisition [Line Items]
Impairment charge					22,400,000
Trade names | Medical Aesthetics
Business Acquisition [Line Items]
Impairment charge					48,600,000
Developed Technology | Medical Aesthetics
Business Acquisition [Line Items]
Impairment charge					576,900,000
Property, Plant and Equipment [Member] | Medical Aesthetics
Business Acquisition [Line Items]
Impairment charge					$ 9,800,000

Summary of Significant Accou_10

Summary of Significant Accounting Policies - Schedule of Estimated Amortization Expense (Detail) $ in Millions	Sep. 25, 2021USD ($)
Accounting Policies [Abstract]
Fiscal 2022	$ 326.5
Fiscal 2023	231.3
Fiscal 2024	222.3
Fiscal 2025	208.9
Fiscal 2026	$ 178.1

Summary of Significant Accou_11

Summary of Significant Accounting Policies - Rollforward of Goodwill Activity by Reportable Segments (Detail) $ in Millions	12 Months Ended
	Sep. 25, 2021USD ($)
Goodwill [Roll Forward]
Balance at September 26, 2020	$ 2,657.9
Foreign currency and other adjustments	(5.7)
Balance at September 25, 2021	3,281.6
Diagnostics
Goodwill [Roll Forward]
Balance at September 26, 2020	821.6
Foreign currency and other adjustments	(7.8)
Balance at September 25, 2021	1,410.8
Breast Health
Goodwill [Roll Forward]
Balance at September 26, 2020	764.8
Foreign currency and other adjustments	(0.1)
Balance at September 25, 2021	797.1
Gyn Surgical [Member]
Goodwill [Roll Forward]
Balance at September 26, 2020	1,063.4
Foreign currency and other adjustments	2.2
Balance at September 25, 2021	1,065.6
Skeletal Health
Goodwill [Roll Forward]
Balance at September 26, 2020	8.1
Foreign currency and other adjustments	0
Balance at September 25, 2021	8.1
Mobidiag Oy
Goodwill [Roll Forward]
Tax adjustment	432.6
Mobidiag Oy | Diagnostics
Goodwill [Roll Forward]
Tax adjustment	432.6
Diagenode
Goodwill [Roll Forward]
Tax adjustment	83.5
Diagenode | Diagnostics
Goodwill [Roll Forward]
Tax adjustment	83.5
Biotheranostics
Goodwill [Roll Forward]
Tax adjustment	80.9
Biotheranostics | Diagnostics
Goodwill [Roll Forward]
Tax adjustment	80.9
Somatex
Goodwill [Roll Forward]
Tax adjustment	32.4
Somatex | Breast Health
Goodwill [Roll Forward]
Tax adjustment	$ 32.4

Summary of Significant Accou_12

Summary of Significant Accounting Policies - Intangible Assets and Goodwill (Details) - USD ($) $ in Millions	Sep. 25, 2021	Sep. 26, 2020	Aug. 23, 2020
Finite-Lived Intangible Assets [Line Items]
Goodwill	$ 3,281.6	$ 2,657.9
Goodwill not at risk of failing impairment	$ 3,300
Acessa Health
Finite-Lived Intangible Assets [Line Items]
Goodwill			$ 49.1

Summary of Significant Accou_13

Summary of Significant Accounting Policies - Schedule of Other Assets (Detail) - USD ($) $ in Millions	Sep. 25, 2021	Sep. 26, 2020
Accounting Policies [Abstract]
Income Taxes Receivable	$ 24.7	$ 325.7
Operating lease, right-of-use assets	83.6	80.7
Life insurance contracts	64.3	49.3
Manufacturing access fees	21.9	15.5
Cost-method equity investments	9.5	11.4
Other	41.7	34
Other assets	$ 245.7	$ 516.6

Summary of Significant Accou_14

Summary of Significant Accounting Policies - Changes in accumulated balances of other comprehensive income (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	$ (43.1)	$ (22.9)	$ (41.4)
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax	(1.3)	(1.8)	(1.7)
Accumulated other comprehensive Income loss Hedge	0	(0.9)	(2.7)
Accumulated Other Comprehensive Income (Loss), Net of Tax	(59.1)	(49.7)	(42.3)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent	(20.2)	18.5	(14.8)
Changes in pension plans, net of taxes of $0.2 in 2021, $0.1 in 2020, and $0.3 in 2019	0.5	(0.1)	(0.6)
Other Comprehensive Income (Loss), before Reclassifications, before Tax	(9.9)	(9.7)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0.5	2.3
Notional Amount	861.5
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0	0
Pension in Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0	0
Interest Rate Swap [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive Income loss Hedge	(14.7)	(24.1)	$ 3.5
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0	0
Interest rate caps - derivative
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	$ 0.5	$ 2.3

Summary of Significant Accou_15

Summary of Significant Accounting Policies - Schedule of Derivative Instruments in Other Comprehensive Income (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Gain (loss) on derivative	$ (9.7)	$ (1.2)	$ 11
Unrealized gain (loss) on derivative	(3.5)	3.8	(2.1)
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net	(13.2)	2.6	8.9
Forward foreign currency contracts
Accumulated Other Comprehensive Income (Loss) [Line Items]
Gain (loss) on derivative	(3.6)	0.7	11
Unrealized gain (loss) on derivative	0.5	(0.2)	(2.2)
Foreign Exchange Option
Accumulated Other Comprehensive Income (Loss) [Line Items]
Gain (loss) on derivative	(6.1)	(1.9)	0
Unrealized gain (loss) on derivative	$ (4)	$ 4	$ 0.1

Summary of Significant Accou_16

Summary of Significant Accounting Policies - Schedule of Derivative Instruments on the Consolidated Balance Sheets (Details) - USD ($) $ in Millions	Sep. 25, 2021	Sep. 26, 2020
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Liability	$ 18.7	$ 31.2
Prepaid Expenses and Other Current Assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value	1.7	11.2
Forward foreign currency contracts | Prepaid Expenses and Other Current Assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value	1.7	1.1
Forward foreign currency contracts | Accrued expenses
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value	0.6	0
Foreign Exchange Option | Prepaid Expenses and Other Current Assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value	0	10.1
Interest Rate Swap [Member] | Accrued expenses | Not Designated as Hedging Instrument [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value	11.1	8.2
Interest Rate Swap [Member] | Other long-term liabilities | Not Designated as Hedging Instrument [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value	$ 7.6	$ 23

Summary of Significant Accou_17

Summary of Significant Accounting Policies - Amount of loss recognized in other comprehensive income, net of taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Notional amount	$ 1,000
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0.5	$ 2.3
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax	0.4	(0.5)
Accumulated other comprehensive Income loss Hedge	0	(0.9)	$ (2.7)
Interest Rate Swap [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0	0
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax	9.4	(27.6)
Accumulated other comprehensive Income loss Hedge	(14.7)	(24.1)	$ 3.5
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	$ 0	$ 0

Summary of Significant Accou_18

Summary of Significant Accounting Policies - Schedule of Unrealized Loss Recognized in AOCI (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Derivative [Line Items]
Loss recognized in other comprehensive income (loss), net	$ 9.8	$ (28.1)	$ (4.5)
Interest rate caps - derivative
Derivative [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax	0.4	(0.5)	(8)
Interest Rate Swap [Member]
Derivative [Line Items]
Loss recognized in other comprehensive income (loss), net	$ 9.4	$ (27.6)	$ 3.5

Summary of Significant Accou_19

Summary of Significant Accounting Policies - Accounts Receivable Reserve Activity (Detail) - USD ($)	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Allowance for Doubtful Accounts Receivable [Roll Forward]
Balance at Beginning of Period	$ 31,600,000	$ 17,800,000	$ 16,200,000
Charged to Costs and Expenses	15,000,000	26,800,000	4,400,000
Accounts receivable reserve divested	0	(5,800,000)	0
Write- offs and Payments	(6,100,000)	(7,200,000)	(2,800,000)
Balance at End of Period	$ 40,500,000	$ 31,600,000	$ 17,800,000

Summary of Significant Accou_20

Summary of Significant Accounting Policies - Reconciliation of Basic and Diluted Share Amounts (Detail) - shares shares in Thousands	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Earnings Per Share [Line Items]
Basic weighted average common shares outstanding (in shares)	257,046	262,727	269,413
Weighted average common stock equivalents from assumed exercise of stock options and restricted stock units (in shares)	2,660	1,886	0
Diluted weighted average common shares outstanding (in shares)	259,706	264,613	269,413
Outstanding Stock Options and stock units [Member]
Weighted-average anti-dilutive shares related to:
Weighted-average anti-dilutive shares (in shares)	528	1,158	4,098

Summary of Significant Accou_21

Summary of Significant Accounting Policies - Product Warranty (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020
Movement in Standard Product Warranty Accrual [Roll Forward]
Balance at Beginning of Period	$ 9.9	$ 13.9
Provisions	7.7	11.7
Standard and Extended Product Warranty Accrual, Additions from Business Acquisition	0.3	0.5
Standard Product Warranty Accrual, Period Increase (Decrease)	0	(6.1)
Settlements/ Adjustments	(9.1)	(10.1)
Balance at End of Period	$ 8.8	$ 9.9

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020
Revenue from Contract with Customer [Abstract]
Estimated remaining performance obligation	$ 830.6
Revenue recognized that was included in contract liability at prior year end	$ 112.1	$ 106.2

Revenue - Business Revenue (Det

Revenue - Business Revenue (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Disaggregation of Revenue [Line Items]
Revenues	$ 5,632.3	$ 3,776.4	$ 3,367.3
United States
Disaggregation of Revenue [Line Items]
Revenues	3,902.3	2,863.2	2,536
International
Disaggregation of Revenue [Line Items]
Revenues	1,730	913.2	831.3
Diagnostics
Disaggregation of Revenue [Line Items]
Revenues	3,695	2,102.1	1,205.5
Diagnostics | United States
Disaggregation of Revenue [Line Items]
Revenues	2,393.1	1,582.4	921.3
Diagnostics | International
Disaggregation of Revenue [Line Items]
Revenues	1,301.9	519.7	284.2
Diagnostics | Cytology & Perinatal
Disaggregation of Revenue [Line Items]
Revenues	473.9	410.1	472
Diagnostics | Cytology & Perinatal | United States
Disaggregation of Revenue [Line Items]
Revenues	304.6	266.3	312.9
Diagnostics | Cytology & Perinatal | International
Disaggregation of Revenue [Line Items]
Revenues	169.3	143.8	159.1
Diagnostics | Molecular Diagnostics
Disaggregation of Revenue [Line Items]
Revenues	3,171.5	1,648.4	675
Diagnostics | Molecular Diagnostics | United States
Disaggregation of Revenue [Line Items]
Revenues	2,038.9	1,272.5	549.9
Diagnostics | Molecular Diagnostics | International
Disaggregation of Revenue [Line Items]
Revenues	1,132.6	375.9	125.1
Diagnostics | Blood Screening
Disaggregation of Revenue [Line Items]
Revenues	49.6	43.6	58.5
Diagnostics | Blood Screening | United States
Disaggregation of Revenue [Line Items]
Revenues	49.6	43.6	58.5
Diagnostics | Blood Screening | International
Disaggregation of Revenue [Line Items]
Revenues	0	0	0
Breast Health
Disaggregation of Revenue [Line Items]
Revenues	1,352.3	1,151.9	1,314.2
Breast Health | United States
Disaggregation of Revenue [Line Items]
Revenues	1,051.8	888.6	1,037.9
Breast Health | International
Disaggregation of Revenue [Line Items]
Revenues	300.5	263.3	276.3
Breast Health | Breast Imaging
Disaggregation of Revenue [Line Items]
Revenues	1,083.4	953.6	1,094.6
Breast Health | Breast Imaging | United States
Disaggregation of Revenue [Line Items]
Revenues	830.4	722	853.1
Breast Health | Breast Imaging | International
Disaggregation of Revenue [Line Items]
Revenues	253	231.6	241.5
Breast Health | Interventional Breast Solutions
Disaggregation of Revenue [Line Items]
Revenues	268.9	198.3	219.6
Breast Health | Interventional Breast Solutions | United States
Disaggregation of Revenue [Line Items]
Revenues	221.4	166.6	184.8
Breast Health | Interventional Breast Solutions | International
Disaggregation of Revenue [Line Items]
Revenues	47.5	31.7	34.8
Gyn Surgical [Member]
Disaggregation of Revenue [Line Items]
Revenues	488.1	376.1	437.2
Gyn Surgical [Member] | United States
Disaggregation of Revenue [Line Items]
Revenues	396.4	310.1	362.8
Gyn Surgical [Member] | International
Disaggregation of Revenue [Line Items]
Revenues	91.7	66	74.4
Skeletal Health
Disaggregation of Revenue [Line Items]
Revenues	96.9	81	94.8
Skeletal Health | United States
Disaggregation of Revenue [Line Items]
Revenues	61	51.2	58.6
Skeletal Health | International
Disaggregation of Revenue [Line Items]
Revenues	35.9	29.8	36.2
Medical Aesthetics
Disaggregation of Revenue [Line Items]
Revenues	0	65.3	315.6
Medical Aesthetics | United States
Disaggregation of Revenue [Line Items]
Revenues	0	30.9	155.4
Medical Aesthetics | International
Disaggregation of Revenue [Line Items]
Revenues	$ 0	$ 34.4	$ 160.2

Revenue - Geographical Revenue

Revenue - Geographical Revenue (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Disaggregation of Revenue [Line Items]
Revenues	$ 5,632.3	$ 3,776.4	$ 3,367.3
United States
Disaggregation of Revenue [Line Items]
Revenues	3,902.3	2,863.2	2,536
Europe
Disaggregation of Revenue [Line Items]
Revenues	1,201.8	569.8	396
Asia-Pacific
Disaggregation of Revenue [Line Items]
Revenues	365	226.8	286
Rest of World
Disaggregation of Revenue [Line Items]
Revenues	$ 163.2	$ 116.6	$ 149.3

Revenue - Revenue by Type (Deta

Revenue - Revenue by Type (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Disaggregation of Revenue [Line Items]
Revenues	$ 5,632.3	$ 3,776.4	$ 3,367.3
United States
Disaggregation of Revenue [Line Items]
Revenues	3,902.3	2,863.2	2,536
International
Disaggregation of Revenue [Line Items]
Revenues	1,730	913.2	831.3
Capital equipment, components and software
Disaggregation of Revenue [Line Items]
Revenues	769.1	665.9	984.9
Consumables
Disaggregation of Revenue [Line Items]
Revenues	4,198.2	2,561.1	1,786.4
Service
Disaggregation of Revenue [Line Items]
Revenues	598.1	516.6	568.3
Other
Disaggregation of Revenue [Line Items]
Revenues	$ 66.9	$ 32.8	$ 27.7

Revenue - Remaining Performance

Revenue - Remaining Performance Obligations (Details)	Sep. 25, 2021
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-09-29
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation over time (percent)	40.00%
Remaining performance obligation over time	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-09-29
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation over time (percent)	27.00%
Remaining performance obligation over time	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-09-29
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation over time (percent)	18.00%
Remaining performance obligation over time	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-09-29
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation over time (percent)	10.00%
Remaining performance obligation over time	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-09-29
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation over time (percent)	5.00%
Remaining performance obligation over time

Leases - Narrative (Details)

Leases - Narrative (Details)	3 Months Ended	12 Months Ended
	Sep. 25, 2021USD ($)	Sep. 25, 2021USD ($)	Sep. 26, 2020USD ($)	Sep. 28, 2019USD ($)	Sep. 29, 2019USD ($)
Lessee, Lease, Description [Line Items]
Period with option to terminate lease		1 year
Extension period		10 years
Weighted average discount rate		0.0225
Finance lease liabilities (current)	$ 3,700,000	$ 3,700,000	$ 1,900,000
Finance lease liabilities (non-current)	$ 22,800,000	22,800,000	17,400,000
Rent expense				$ 23,100,000
Lease revenue as a percentage of total	0.05
Right-of-use asset obtained in exchange for finance lease liability		9,100	0
Lease receivable	$ 17,400,000	17,400,000
Operating lease, right-of-use assets	83,600,000	83,600,000	80,700,000
Finance Lease, Right-of-Use Asset			0
Present value of lease liabilities	92,900	92,900			$ 96,600,000
Present value of lease liabilities	26,500	26,500			$ 21,000,000
Property, plant and equipment, net	(564,700,000)	(564,700,000)	(491,500,000)	(470,900,000)
Other long-term liabilities	(368,700,000)	(368,700,000)	(303,200,000)
Operating Lease, Liability, Statement of Financial Position [Extensible List]					us-gaap:LiabilitiesAbstract
Finance Lease, Liability, Statement of Financial Position [Extensible List]					us-gaap:LiabilitiesAbstract
ROU assets arising from entering into new operating lease obligations		28,600	13,300
Sublease Income		2,600,000	2,000,000	$ 2,700,000
Operating lease, right of use asset at adoption of 842					$ 91,700,000
Finance lease, right of use asset at adoption of 842					10,200,000
Cynosure
Lessee, Lease, Description [Line Items]
Right-of-use asset obtained in exchange for finance lease liability			10,200,000
Property, Plant and Equipment [Member]
Lessee, Lease, Description [Line Items]
Finance Lease, Right-of-Use Asset	9,900,000	9,900,000
Finance lease obligations - short term
Lessee, Lease, Description [Line Items]
Finance lease liabilities (current)	3,700	3,700	1,900
Finance lease obligations - long term
Lessee, Lease, Description [Line Items]
Finance lease liabilities (current)	9,300	9,300
Finance lease liabilities (non-current)	$ 22,800	$ 22,800	$ 17,400
Accounting Standards Update 2016-02 [Member]
Lessee, Lease, Description [Line Items]
Property, plant and equipment, net					32,600,000
Other long-term liabilities					$ 35,200,000
Minimum
Lessee, Lease, Description [Line Items]
Lessee, operating and finance lease, remaining lease term		1 year
Maximum
Lessee, Lease, Description [Line Items]
Lessee, operating and finance lease, remaining lease term		14 years

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information (Details) - USD ($)	Sep. 25, 2021	Sep. 26, 2020
Lessee, Lease, Description [Line Items]
Operating lease, right-of-use assets	$ 83,600,000	$ 80,700,000
Operating lease liabilities (current)	26,800,000	23,500,000
Finance lease liabilities (current)	$ 3,700,000	1,900,000
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other long-term liabilities
Operating lease liabilities (non-current)	$ 66,100,000	65,600,000
Finance lease liabilities (non-current)	$ 22,800,000	$ 17,400,000
Operating leases, weighted average remaining lease term	4 years 11 months 12 days	5 years 6 months 29 days
Finance leases, weighted average remaining lease term	7 years 6 months 7 days	7 years 7 months 20 days
Operating leases, weighted average discount rate	1.60%	2.00%
Finance leases, weighted average discount rate	4.30%	5.10%
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Other assets
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Accrued expenses
Other assets
Lessee, Lease, Description [Line Items]
Operating lease, right-of-use assets	$ 83,600	$ 80,700
Accrued expenses
Lessee, Lease, Description [Line Items]
Operating lease liabilities (current)	26,800	23,500
Other long-term liabilities
Lessee, Lease, Description [Line Items]
Operating lease liabilities (non-current)	66,100	65,600
Finance lease obligations - short term
Lessee, Lease, Description [Line Items]
Finance lease liabilities (current)	3,700	1,900
Finance lease obligations - long term
Lessee, Lease, Description [Line Items]
Finance lease liabilities (current)	9,300
Finance lease liabilities (non-current)	$ 22,800	$ 17,400

Leases - Additional Lease Infor

Leases - Additional Lease Information (Details)	Mar. 01, 2021Segment	Sep. 25, 2021USD ($)	Sep. 26, 2020USD ($)
Leases [Abstract]
Operating lease cost		$ 30,100	$ 27,500
Finance lease cost - amortization of right-of-use assets		600	300
Finance lease cost - interest cost		1,000	1,000
Operating cash flows from finance leases		1,000	1,000
Operating cash flows from operating leases		28,200	23,900
Financing cash flows from finance leases		2,400	1,700
Total cash paid for amounts included in the measurement of lease liabilities		31,600	26,600
ROU assets arising from entering into new operating lease obligations		28,600	13,300
Right-of-use asset obtained in exchange for finance lease liability		$ 9,100	$ 0
Lessee, Lease, Description [Line Items]
Number of finance leases | Segment	2
Lessee, Finance Lease, Bargain Purchase Option, Percentage	3.00%
Minimum
Lessee, Lease, Description [Line Items]
Lessee, Finance Lease, Remaining Lease Term	7 years
Maximum
Lessee, Lease, Description [Line Items]
Lessee, Finance Lease, Remaining Lease Term	11 years

Leases - Lease Liability Maturi

Leases - Lease Liability Maturity Schedule 2020 (Details) - USD ($)	Sep. 25, 2021	Sep. 29, 2019
Operating Leases
2021	$ 28,200
2022	22,000
2023	16,400
2024	11,800
2025	7,400
Thereafter	11,700
Total future minimum lease payments	97,500
Less: imputed interest	(4,600)
Present value of lease liabilities	92,900	$ 96,600,000
Finance Lease
2021	4,400
2022	4,200
2023	3,900
2024	3,900
2025	3,900
Thereafter	10,200
Total future minimum lease payments	30,500
Less: imputed interest	(4,000)
Present value of lease liabilities	$ 26,500	$ 21,000,000

Leases - Future Minimum Annual

Leases - Future Minimum Annual Rental Income Payments (Details) $ in Millions	Sep. 25, 2021USD ($)
Leases [Abstract]
Sub lease Rental income current	$ 3.1
Sub lease rental income due in 2 years	3
Sub lease rental income due in 3 years	3
Sub lease rental income due in 4 years	2
Sub lease rental income due in 5years	0.9
Sub lease rental income due thereafter	2.3
Sub lease rental income	$ 14.3

Business Combination - Narrativ

Business Combination - Narrative (Details) - USD ($) $ / shares in Units, shares in Millions

Jun. 17, 2021

Mar. 01, 2021

Feb. 22, 2021

Jan. 04, 2021

Sep. 28, 2020

Aug. 23, 2020

Dec. 30, 2019

Nov. 21, 2019

Oct. 01, 2019

Aug. 01, 2019

Oct. 01, 2018

Nov. 30, 2019

Sep. 30, 2019

Sep. 28, 2019

Sep. 25, 2021

Jun. 26, 2021

Sep. 25, 2021

Sep. 26, 2020

Mar. 28, 2020

Nov. 20, 2019

Business Acquisition [Line Items]

Goodwill

$ 3,281,600,000

$ 3,281,600,000

$ 2,657,900,000

Contingent consideration

16,300,000

16,300,000

0

Intangible assets, net

1,659,200,000

1,659,200,000

1,307,500,000

Portion allocable to fair value of noncontrolling interest

$ 8,600,000

Mobidiag Oy

Business Acquisition [Line Items]

Total purchase price

$ 729,600,000

Developed technology

285,000,000

Customer relationships

20,900,000

Trade names

20,000,000

Goodwill

$ 432,600,000

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Decrease In Research And Development In Process

29,000,000

Mobidiag Oy | Minimum

Business Acquisition [Line Items]

Fair value, discount rate

15.00%

Mobidiag Oy | Maximum

Business Acquisition [Line Items]

Fair value, discount rate

19.00%

Mobidiag Oy | Developed Technology | Minimum

Business Acquisition [Line Items]

Weighted average amortization period

8 years

Mobidiag Oy | Developed Technology | Maximum

Business Acquisition [Line Items]

Weighted average amortization period

12 years

Mobidiag Oy | Customer Relationships | Minimum

Business Acquisition [Line Items]

Weighted average amortization period

5 years

Mobidiag Oy | Customer Relationships | Maximum

Business Acquisition [Line Items]

Weighted average amortization period

10 years

Mobidiag Oy | Trade names | Minimum

Business Acquisition [Line Items]

Weighted average amortization period

8 years

Mobidiag Oy | Trade names | Maximum

Business Acquisition [Line Items]

Weighted average amortization period

12 years

Biotheranostics

Business Acquisition [Line Items]

Total purchase price

$ 231,300,000

Fair value, discount rate

18.00%

Weighted average amortization period

10 years

Developed technology

$ 160,300,000

Trade names

2,100,000

Goodwill

$ 80,900,000

Diagenode

Business Acquisition [Line Items]

Total purchase price

$ 155,100,000

Weighted average amortization period

10 years

Developed technology

$ 69,800,000

Customer relationships

9,200,000

Goodwill

$ 83,500,000

Diagenode | Developed Technology

Business Acquisition [Line Items]

Fair value, discount rate

14.50%

Diagenode | Customer Relationships

Business Acquisition [Line Items]

Fair value, discount rate

13.50%

Somatex Medical Technologies

Business Acquisition [Line Items]

Total purchase price

$ 62,900,000

Developed technology

38,000,000

Customer relationships

1,200,000

Trade names

900,000

Goodwill

32,400,000

Net acquired tangible assets and liabilities

$ 9,600,000

NXC Imaging

Business Acquisition [Line Items]

Total purchase price

$ 5,600,000

NXC Imaging | Customer Relationships

Business Acquisition [Line Items]

Weighted average amortization period

5 years

Acessa Health

Business Acquisition [Line Items]

Total purchase price

$ 162,000,000

Fair value, discount rate

18.00%

Weighted average amortization period

10 years

Developed technology

$ 127,000,000

Trade names

1,200,000

Goodwill

49,100,000

Contingent consideration

81,800,000

Increase in contingent consideration liability

(6,700,000)

Acessa Health | Holdback

Business Acquisition [Line Items]

Contingent consideration

$ 3,000,000

Health Beacons

Business Acquisition [Line Items]

Total purchase price

$ 19,700,000

Goodwill

6,200,000

6,200,000

Holdback

2,300,000

2,300,000

Intangible assets, net

10,700,000

10,700,000

Acquired tangible assets and liabilities

2,800,000

2,800,000

Alpha Imaging

Business Acquisition [Line Items]

Total purchase price

$ 18,000,000

Contingent consideration

$ 900,000

$ 900,000

Holdback

$ 1,000,000

SuperSonic Imagine

Business Acquisition [Line Items]

Total purchase price

69,300,000

$ 18,200,000

Fair value, discount rate

12.00%

Developed technology

38,300,000

Customer relationships

4,000,000

Trade names

3,000,000

Goodwill

$ 34,300,000

Percentage of voting interests acquired

46.00%

50.00%

Cash tender offer price per share

$ 1.50

Acquired shares

7.6

Additional purchase consideration

$ 12,600,000

Ownership of outstanding shares (as a percent)

78.00%

Equity interest in acquiree (as a percent)

46.00%

100.00%

100.00%

Remeasurement gain

$ 3,200,000

Portion allocable to equity method investment

17,900,000

Portion allocable to newly acquired shares

$ 12,600,000

Portion allocable to loan repaymnet

$ 30,200,000

Additional outstanding shares purchased (in shares)

4.8

1.1

Additional outstanding shares purchased, amount

$ 8,500,000

$ 1,800,000

SuperSonic Imagine | Other Income

Business Acquisition [Line Items]

Income (loss) from equity method investments

$ 3,300,000

SuperSonic Imagine | Customer Relationships

Business Acquisition [Line Items]

Weighted average amortization period

9 years

SuperSonic Imagine | Trade names

Business Acquisition [Line Items]

Weighted average amortization period

8 years 7 months 6 days

SuperSonic Imagine | Developed technology

Business Acquisition [Line Items]

Weighted average amortization period

9 years

Focal Therapeutics

Business Acquisition [Line Items]

Total purchase price

$ 12,500,000

$ 120,100,000

Developed technology

83,100,000

Trade names

2,700,000

Goodwill

31,100,000

Contingent consideration

$ 14,000,000

$ 1,500,000

Payment period for contingent consideration

1 year

Focal Therapeutics | Trade names

Business Acquisition [Line Items]

Weighted average amortization period

13 years

Focal Therapeutics | Developed technology

Business Acquisition [Line Items]

Weighted average amortization period

11 years

Focal Therapeutics | In-process research and development | Minimum | Measurement Input, Discount Rate

Business Acquisition [Line Items]

Fair value, discount rate

15.50%

Focal Therapeutics | In-process research and development | Maximum | Measurement Input, Discount Rate

Business Acquisition [Line Items]

Fair value, discount rate

16.50%

Business Combinations Business

Business Combinations Business Combinations - Purchase Price Allocation (Details) - USD ($) $ in Millions	Sep. 25, 2021	Jun. 17, 2021	Mar. 01, 2021	Feb. 22, 2021	Sep. 26, 2020	Aug. 23, 2020	Nov. 21, 2019	Oct. 01, 2018
Business Acquisition [Line Items]
Goodwill	$ 3,281.6				$ 2,657.9
Mobidiag Oy
Business Acquisition [Line Items]
Cash		$ 7
Accounts receivable		4.2
Inventory		13.7
Other assets		29.6
Accounts payable and accrued expenses		(19.1)
Other liabilities		(11.7)
Developed technology		285
In-process research and development		74
Customer relationships		20.9
Trade names		20
Long-term debt		(66.1)
Deferred income taxes, net		(60.5)
Goodwill		432.6
Purchase Price		$ 729.6
Biotheranostics
Business Acquisition [Line Items]
Cash				$ 9.6
Accounts receivable				6.6
Other assets				6.5
Accounts payable and accrued expenses				(8.2)
Other liabilities				(8.1)
Developed technology				160.3
Trade names				2.1
Deferred income taxes, net				(18.4)
Goodwill				80.9
Purchase Price				$ 231.3
Diagenode
Business Acquisition [Line Items]
Cash			$ 5.6
Accounts receivable			9.3
Inventory			9
Other assets			13.9
Accounts payable and accrued expenses			(16.7)
Other liabilities			(9.2)
Developed technology			69.8
Customer relationships			9.2
Deferred income taxes, net			(19.3)
Goodwill			83.5
Purchase Price			$ 155.1
Acessa Health
Business Acquisition [Line Items]
Cash						$ 1.2
Inventory						4
Other assets						4.4
Accounts payable and accrued expenses						(4.7)
Developed technology						127
Trade names						1.2
Deferred income taxes, net						(20.2)
Goodwill						49.1
Purchase Price						$ 162
SuperSonic Imagine
Business Acquisition [Line Items]
Cash							$ 2.6
Accounts receivable							7.1
Inventory							10
Property, plant and equipment							6.5
Other assets							4.3
Accounts payable and accrued expenses							(24.5)
Deferred revenue							1.8
Short and long-term debt							(8.8)
Other liabilities							(3.8)
Developed technology							38.3
Customer relationships							4
Trade names							3
Deferred income taxes, net							(1.9)
Goodwill							34.3
Purchase Price							$ 69.3
Focal Therapeutics
Business Acquisition [Line Items]
Cash								$ 2.2
Accounts receivable								2
Inventory								7.9
Other assets								0.5
Accounts payable and accrued expenses								(5.6)
Developed technology								83.1
In-process research and development								11.4
Trade names								2.7
Long-term debt								(2.5)
Deferred income taxes, net								(12.7)
Goodwill								31.1
Purchase Price								$ 120.1

Equity Method Investment (Detai

Equity Method Investment (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Schedule of Equity Method Investments [Line Items]
Purchase of equity method investment	$ 0	$ 0	$ 18.2

Restructuring Charges - Charges

Restructuring Charges - Charges Taken Related to Restructuring Actions (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 27, 2021	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Restructuring Cost and Reserve [Line Items]
Divestiture charges	$ 1,900,000
Fiscal 2019 restructuring charges | Restructuring Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions				$ 5,400,000
Facility closure costs				1,200,000
Fiscal restructuring charges				6,600,000
Fiscal 2020 restructuring charges | Restructuring Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions			$ 13,400,000
Facility closure costs			1,900,000
Fiscal restructuring charges		$ 8,700,000	15,300,000
Fiscal 2021 restructuring charges | Restructuring Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions		9,300,000
Fiscal restructuring charges		9,300,000
Fiscal 2021 Actions | Fiscal 2019 restructuring charges | Restructuring Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions				0
Facility closure costs				0
Fiscal restructuring charges				0
Fiscal 2021 Actions | Fiscal 2020 restructuring charges | Restructuring Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions			0
Facility closure costs			0
Fiscal restructuring charges			0
Fiscal 2021 Actions | Fiscal 2021 restructuring charges | Restructuring Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions		8,700,000
Fiscal restructuring charges		8,700,000
Fiscal 2020 Actions | Fiscal 2019 restructuring charges | Restructuring Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions				0
Facility closure costs				0
Fiscal restructuring charges				0
Fiscal 2020 Actions | Fiscal 2020 restructuring charges | Restructuring Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions			13,200,000
Facility closure costs			1,900,000
Fiscal restructuring charges			15,100,000
Fiscal 2020 Actions | Fiscal 2021 restructuring charges | Restructuring Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions		600,000
Fiscal restructuring charges		600,000
Fiscal 2019 Actions | Fiscal 2019 restructuring charges | Restructuring Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions				4,000,000
Facility closure costs				0
Fiscal restructuring charges				4,000,000
Fiscal 2019 Actions | Fiscal 2020 restructuring charges | Restructuring Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions			300,000
Facility closure costs			0
Fiscal restructuring charges			300,000
Fiscal 2019 Actions | Fiscal 2021 restructuring charges | Restructuring Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions		0
Fiscal restructuring charges		0
Other | Fiscal 2019 restructuring charges | Restructuring Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions				1,400,000
Facility closure costs				1,200,000
Fiscal restructuring charges				$ 2,600,000
Other | Fiscal 2020 restructuring charges | Restructuring Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions			(100,000)
Facility closure costs			0
Fiscal restructuring charges			$ (100,000)
Other | Fiscal 2021 restructuring charges | Restructuring Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions		0
Fiscal restructuring charges		$ 0

Restructuring Charges - Charg_2

Restructuring Charges - Charges Taken Related to Accrued Restructuring Actions (Detail) - Restructuring Charges - USD ($) $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Fiscal 2018 restructuring charges
Restructuring Reserve [Roll Forward]
Balance			$ 9.1
Fiscal 2018 restructuring charges | Fiscal 2021 Actions
Restructuring Reserve [Roll Forward]
Balance			0
Fiscal 2018 restructuring charges | Fiscal 2020 Actions
Restructuring Reserve [Roll Forward]
Balance			0
Fiscal 2018 restructuring charges | Fiscal 2019 Actions
Restructuring Reserve [Roll Forward]
Balance			0
Fiscal 2018 restructuring charges | Fiscal 2018 Actions
Restructuring Reserve [Roll Forward]
Balance			4.3
Fiscal 2018 restructuring charges | Previous Other Charges
Restructuring Reserve [Roll Forward]
Balance			4.8
Fiscal 2019 restructuring charges
Restructuring Reserve [Roll Forward]
Balance		$ 5.9
Fiscal restructuring charges			6.6
Severance payments and adjustments			(7.7)
Other payments			(2.1)
Balance			5.9
Fiscal 2019 restructuring charges | Fiscal 2021 Actions
Restructuring Reserve [Roll Forward]
Balance		0
Fiscal restructuring charges			0
Severance payments and adjustments			0
Other payments			0
Balance			0
Fiscal 2019 restructuring charges | Fiscal 2020 Actions
Restructuring Reserve [Roll Forward]
Balance		0
Fiscal restructuring charges			0
Severance payments and adjustments			0
Other payments			0
Balance			0
Fiscal 2019 restructuring charges | Fiscal 2019 Actions
Restructuring Reserve [Roll Forward]
Balance		1
Fiscal restructuring charges			4
Severance payments and adjustments			(3)
Other payments			0
Balance			1
Fiscal 2019 restructuring charges | Fiscal 2018 Actions
Restructuring Reserve [Roll Forward]
Balance		1.1
Fiscal restructuring charges			1.2
Severance payments and adjustments			(3.9)
Other payments			(0.5)
Balance			1.1
Fiscal 2019 restructuring charges | Previous Other Charges
Restructuring Reserve [Roll Forward]
Balance		3.8
Fiscal restructuring charges			1.4
Severance payments and adjustments			(0.8)
Other payments			(1.6)
Balance			$ 3.8
Fiscal 2020 restructuring charges
Restructuring Reserve [Roll Forward]
Balance	$ 4.5
Fiscal restructuring charges	8.7	15.3
Stock-based compensation		(7.5)
Severance payments and adjustments		(5.9)
Other payments		(3.3)
Balance		4.5
Fiscal 2020 restructuring charges | Fiscal 2021 Actions
Restructuring Reserve [Roll Forward]
Balance	0
Fiscal restructuring charges		0
Stock-based compensation		0
Severance payments and adjustments		0
Other payments		0
Balance		0
Fiscal 2020 restructuring charges | Fiscal 2020 Actions
Restructuring Reserve [Roll Forward]
Balance	3.7
Fiscal restructuring charges		15.1
Stock-based compensation		(7.5)
Severance payments and adjustments		(4.4)
Other payments		0.5
Balance		3.7
Fiscal 2020 restructuring charges | Fiscal 2019 Actions
Restructuring Reserve [Roll Forward]
Balance	0
Fiscal restructuring charges		0.3
Stock-based compensation		0
Severance payments and adjustments		(1.3)
Other payments		0
Balance		0
Fiscal 2020 restructuring charges | Fiscal 2018 Actions
Restructuring Reserve [Roll Forward]
Balance	0.8
Fiscal restructuring charges		(0.1)
Stock-based compensation		0
Severance payments and adjustments		(0.2)
Other payments		0
Balance		0.8
Fiscal 2020 restructuring charges | Previous Other Charges
Restructuring Reserve [Roll Forward]
Balance	0
Fiscal restructuring charges		0
Stock-based compensation		0
Severance payments and adjustments		0
Other payments		(3.8)
Balance		$ 0
Fiscal 2021 restructuring charges
Restructuring Reserve [Roll Forward]
Fiscal restructuring charges	9.3
Stock-based compensation	(0.9)
Severance payments and adjustments	(8.8)
Balance	4.1
Fiscal 2021 restructuring charges | Fiscal 2021 Actions
Restructuring Reserve [Roll Forward]
Fiscal restructuring charges	8.7
Stock-based compensation	(0.9)
Severance payments and adjustments	(4.6)
Balance	3.2
Fiscal 2021 restructuring charges | Fiscal 2020 Actions
Restructuring Reserve [Roll Forward]
Fiscal restructuring charges	0.6
Stock-based compensation	0
Severance payments and adjustments	(3.4)
Balance	0.9
Fiscal 2021 restructuring charges | Fiscal 2019 Actions
Restructuring Reserve [Roll Forward]
Fiscal restructuring charges	0
Stock-based compensation	0
Severance payments and adjustments	0
Balance	0
Fiscal 2021 restructuring charges | Fiscal 2018 Actions
Restructuring Reserve [Roll Forward]
Fiscal restructuring charges	0
Stock-based compensation	0
Severance payments and adjustments	(0.8)
Balance	0
Fiscal 2021 restructuring charges | Previous Other Charges
Restructuring Reserve [Roll Forward]
Fiscal restructuring charges	0
Stock-based compensation	0
Severance payments and adjustments	0
Balance	$ 0

Restructuring Charges - Additio

Restructuring Charges - Additional Information (Detail) - USD ($)	3 Months Ended					12 Months Ended
	Mar. 27, 2021	Jun. 27, 2020	Jun. 29, 2019	Dec. 29, 2018	Jun. 30, 2018	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Restructuring Cost and Reserve [Line Items]
Severance charges						$ 13,400,000	$ 4,000,000
Incremental cost						5,000,000
Divestiture charges	$ 1,900,000
Tepnel [Member]
Restructuring Cost and Reserve [Line Items]
Divestiture charges	1,300,000
Cynosure
Restructuring Cost and Reserve [Line Items]
Incremental cost	2,600,000
Divestiture charges	$ 2,000,000
Bedford
Restructuring Cost and Reserve [Line Items]
Facility closure costs		$ 1,400,000	$ 1,600,000	$ 3,500,000	$ 1,300,000
Remaining lease balance						$ 3,800,000
Fiscal 2019 restructuring charges | Fiscal 2018 Actions
Restructuring Cost and Reserve [Line Items]
Severance charges							$ 1,000,000
Restructuring Charges | Fiscal 2019 restructuring charges
Restructuring Cost and Reserve [Line Items]
Facility closure costs								$ 1,200,000
Workforce reductions								$ 5,400,000

Borrowings and Credit Arrange_3

Borrowings and Credit Arrangements - Company's Borrowings (Detail) - USD ($) $ in Millions	Sep. 25, 2021	Sep. 26, 2020
Debt Instrument [Line Items]
Current debt obligations, net of debt discount	$ 313	$ 324.9
Total long-term debt obligations	2,712.2	2,713.9
Total debt obligations	3,025.2	3,038.8
Term Loan
Debt Instrument [Line Items]
Current debt obligations, net of debt discount	0	74.9
Long term debt obligations. excluding convertible notes	1,382.3	1,379.9
Revolver
Debt Instrument [Line Items]
Current debt obligations, net of debt discount	0	250
Securitization Program
Debt Instrument [Line Items]
Current debt obligations, net of debt discount	248.5	0
2025 Senior Notes
Debt Instrument [Line Items]
Long term debt obligations. excluding convertible notes	0	939.4
2028 Senior Notes
Debt Instrument [Line Items]
Long term debt obligations. excluding convertible notes	395.4	394.6
Other Debt Obligations
Debt Instrument [Line Items]
Current debt obligations, net of debt discount	64.5	0
2029 Senior Notes
Debt Instrument [Line Items]
Long term debt obligations. excluding convertible notes	$ 934.5	$ 0

Borrowings and Credit Arrange_4

Borrowings and Credit Arrangements - Debt Maturity Schedule for Components of Company's Obligations (Details) $ in Millions	Sep. 25, 2021USD ($)
Debt Instrument [Line Items]
2020	$ 388
2021	112.5
2022	1,200
2023	0
2024	0
2027 and Thereafter	1,350
Total	3,050.5
Term Loan
Debt Instrument [Line Items]
2020	75
2021	112.5
2022	1,200
2023	0
2024	0
2027 and Thereafter	0
Total	1,387.5
Securitization Program
Debt Instrument [Line Items]
2020	248.5
2021	0
2022	0
2023	0
2024	0
2027 and Thereafter	0
Total	248.5
2028 Senior Notes
Debt Instrument [Line Items]
2020	0
2021	0
2022	0
2023	0
2024	0
2027 and Thereafter	400
Total	400
2029 Senior Notes
Debt Instrument [Line Items]
2020	0
2021	0
2022	0
2023	0
2024	0
2027 and Thereafter	950
Total	950
Other Debt Obligations
Debt Instrument [Line Items]
2020	64.5
2021	0
2022	0
2023	0
2024	0
2027 and Thereafter	0
Total	$ 64.5

Borrowings and Credit Arrange_5

Borrowings and Credit Arrangements - Interest Expense Credit Agreement (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019	Sep. 29, 2018
2018 Credit Agreement
Line of Credit Facility [Line Items]
Interest expense	$ 22
Non-cash interest expense	$ 2.5
Weighted average interest rate	1.13%
Interest rate at end of period	1.08%
2017 Credit Agreement
Line of Credit Facility [Line Items]
Interest expense		$ 46.6
Non-cash interest expense		$ 2.5
Weighted average interest rate		2.25%
Interest rate at end of period		1.40%
Prior Credit Agreement
Line of Credit Facility [Line Items]
Interest expense			$ 67
Non-cash interest expense			$ 2.6
Weighted average interest rate			3.79%
Interest rate at end of period				3.43%

Borrowings and Credit Arrange_6

Borrowings and Credit Arrangements - Additional Information (Detail)	Jun. 25, 2022	Sep. 27, 2021USD ($)	Oct. 15, 2020USD ($)	Sep. 28, 2020	Dec. 17, 2018USD ($)	Jan. 19, 2018USD ($)	Apr. 25, 2016USD ($)	Sep. 25, 2021USD ($)	Mar. 27, 2021USD ($)	Dec. 26, 2020USD ($)debt_instrument	Sep. 25, 2021USD ($)	Sep. 26, 2020USD ($)	Sep. 28, 2019USD ($)	Jun. 17, 2021	Jun. 11, 2021USD ($)	Sep. 29, 2018
Debt Instrument [Line Items]
Debt extinguishment loss											$ 21,600,000	$ 0	$ 800,000
Redemption price, percentage				40.00%
Current debt obligations, net of debt discount								$ 313,000,000			313,000,000	324,900,000
Proceeds from revolving credit line											$ 0	$ 750,000,000	$ 480,000,000
Minimum | Mobidiag Oy
Debt Instrument [Line Items]
Interest rate (percent)														6.00%
Maximum | Mobidiag Oy
Debt Instrument [Line Items]
Interest rate (percent)														7.00%
2018 Amended Credit Facility
Debt Instrument [Line Items]
Leverage ratio maximum											5
Interest coverage ratio											3.75
2018 Amended Credit Facility | Forecast
Debt Instrument [Line Items]
Leverage ratio maximum	4.50
2017 Credit Agreement
Debt Instrument [Line Items]
Debt extinguishment loss										$ (800,000)
Number of debt instruments | debt_instrument										2
Maximum range of present value of cash flow (percent)										10.00%
Weighted-average interest rate (percent)												2.25%
Interest rate at end of period												1.40%
Prior Credit Agreement
Debt Instrument [Line Items]
Weighted-average interest rate (percent)													3.79%
Interest rate at end of period																3.43%
Securitization Program
Debt Instrument [Line Items]
Basis spread on variable rate							0.80%				0.70%
Interest expense											$ 900,000	$ 3,100,000	$ 7,100,000
Term of accounts receivable securitization program							1 year
Accounts receivable from securitization							$ 200,000,000
Maximum borrowing under securitization program							$ 200,000,000	250,000,000			250,000,000				$ 320,000,000
2021 Credit Agreement | Subsequent Event
Debt Instrument [Line Items]
Proceeds from revolving credit line		$ 1,500,000,000
Secured Term Loan | 2018 Amended Term Loan
Debt Instrument [Line Items]
Debt instrument face amount					$ 1,500,000,000
Secured Term Loan | 2018 Amended Term Loan | Minimum
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Principal Per Quarter					9,375,000
Debt Instrument, Estimated Due At Maturity After Scheduled Principal Payments								$ 1,200,000,000			$ 1,200,000,000
Secured Term Loan | 2018 Amended Term Loan | Maximum
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Principal Per Quarter					$ 28,125,000
Secured Term Loan | 2018 Amended Term Loan | LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate					1.00%
Secured Term Loan | 2021 Term Loan | Subsequent Event
Debt Instrument [Line Items]
Debt instrument face amount		$ 1,500,000,000
Secured Term Loan | 2021 Term Loan | Eurocurrency Rate | Subsequent Event
Debt Instrument [Line Items]
Basis spread on variable rate		1.00%
Debt Instrument, Periodic Payment, Principal Per Quarter		$ 1,335,000,000
Debt Instrument, Commitment Fee, Percentage		0.15%
Secured Term Loan | 2021 Term Loan | Eurocurrency Rate | Minimum | Subsequent Event
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Principal Per Quarter		$ 3,750,000
Secured Term Loan | 2021 Term Loan | Eurocurrency Rate | Maximum | Subsequent Event
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Principal Per Quarter		18,750,000
Revolver
Debt Instrument [Line Items]
Interest rate (percent)								1.08%			1.08%
Current debt obligations, net of debt discount								$ 0			$ 0	250,000,000
Revolver | 2021 Revolver | Subsequent Event
Debt Instrument [Line Items]
Line of credit borrowing capacity		$ 2,000,000,000
Line of Credit | 2018 Amended Revolver
Debt Instrument [Line Items]
Line of credit borrowing capacity					$ 1,500,000,000
Line of Credit | 2018 Amended Revolver | LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate					1.00%
Senior Notes | 2025 Senior Notes
Debt Instrument [Line Items]
Debt instrument face amount								$ 950,000,000			$ 950,000,000
Debt extinguishment loss									$ (21,600,000)
Interest rate (percent)								4.375%			4.375%
Interest expense									5,800,000
Extinguishment of Debt, Amount			$ 970,800,000
Debt Redemption, Premium Paid			$ 20,800,000
Debt Issuance Costs, Net									7,900,000
Debt Instrument, Unamortized Discount									$ 6,400,000
Senior Notes | 2028 Senior Notes
Debt Instrument [Line Items]
Debt instrument face amount								$ 400,000,000			$ 400,000,000
Interest rate (percent)								4.625%			4.625%
Proceeds from issuance of senior long-term debt						$ 1,000,000,000
Offering price, percent of face value								100.00%			100.00%
Percentage of redemption price, third period								102.312%			102.312%
Percentage of redemption price, fourth period								101.541%			101.541%
Percentage of redemption price, fifth period								100.77%			100.77%
Percentage redemption price, sixth period								100.00%			100.00%
Percentage price of principal amount for repurchase of senior notes											101.00%
Senior Notes | 2029 Senior Notes
Debt Instrument [Line Items]
Interest rate (percent)								3.25%			3.25%
Redemption price, percentage				100.00%
Senior notes principal amount								$ 950,000,000			$ 950,000,000
Senior Notes | 2029 Senior Notes | Period One
Debt Instrument [Line Items]
Redemption price, percentage				103.25%
Senior Notes | 2029 Senior Notes | Period Two
Debt Instrument [Line Items]
Redemption price, percentage				101.625%
Senior Notes | 2029 Senior Notes | Period Three
Debt Instrument [Line Items]
Redemption price, percentage				100.813%
Senior Notes | 2029 Senior Notes | Period Four
Debt Instrument [Line Items]
Redemption price, percentage				100.00%
Senior Notes | 2029 Senior Notes | Period Five
Debt Instrument [Line Items]
Redemption price, percentage				101.00%
Securitization Program
Debt Instrument [Line Items]
Repayments of Debt								250,000,000
Current debt obligations, net of debt discount								$ 248,500,000			$ 248,500,000	$ 0
Debt, Weighted Average Interest Rate								0.80%			0.80%
Debt Instrument, Interest Rate, Effective Percentage								0.80%			0.80%

Borrowings and Credit Arrange_7

Borrowings and Credit Arrangements - Interest Expense Senior Notes (Details) - Senior Notes - USD ($) $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Debt Instrument [Line Items]
Interest expense	$ 54.2	$ 62.7	$ 62.7
Non-cash interest expense	2.9	2.8	2.8
2028 Senior Notes
Debt Instrument [Line Items]
Interest expense	19.2	19.2	19.2
Non-cash interest expense	$ 0.7	0.7	0.7
Interest rate (percent)	4.625%
2025 Senior Notes
Debt Instrument [Line Items]
Interest expense	$ 2.3	43.5	43.5
Non-cash interest expense	$ 0.1	2.1	2.1
Interest rate (percent)	4.375%
2029 Senior Notes
Debt Instrument [Line Items]
Interest expense	$ 32.7	0	0
Non-cash interest expense	$ 2.1	$ 0	$ 0
Interest rate (percent)	3.25%

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Assets:
Assets measured at fair value on a recurring basis	$ 1.7	$ 11.2
Liabilities:
Liabilities measured at fair value on a recurring basis	94.4	113
Fair value adjustments	(6.7)	0.3	$ 1.7
Contingent consideration recorded at acquisition	0	82.7	$ 0
Quoted Prices in Active Market for Identical Assets (Level 1)
Assets:
Assets measured at fair value on a recurring basis	0	0
Liabilities:
Liabilities measured at fair value on a recurring basis	0	0
Significant Other Observable Inputs (Level 2)
Assets:
Assets measured at fair value on a recurring basis	1.7	11.2
Liabilities:
Liabilities measured at fair value on a recurring basis	19.3	31.2
Significant Unobservable Inputs (Level 3)
Assets:
Assets measured at fair value on a recurring basis	0	0
Liabilities:
Liabilities measured at fair value on a recurring basis	75.1	81.8
Interest Rate Swap [Member]
Assets:
Assets measured at fair value on a recurring basis	18.7	31.2
Interest Rate Swap [Member] | Quoted Prices in Active Market for Identical Assets (Level 1)
Assets:
Assets measured at fair value on a recurring basis	0
Interest Rate Swap [Member] | Significant Other Observable Inputs (Level 2)
Assets:
Assets measured at fair value on a recurring basis	18.7
Interest Rate Swap [Member] | Significant Unobservable Inputs (Level 3)
Assets:
Assets measured at fair value on a recurring basis	0
Stock Options
Assets:
Forward foreign currency contracts		10.1
Stock Options | Assets | Quoted Prices in Active Market for Identical Assets (Level 1)
Assets:
Forward foreign currency contracts		0
Stock Options | Assets | Significant Other Observable Inputs (Level 2)
Assets:
Forward foreign currency contracts		10.1
Stock Options | Assets | Significant Unobservable Inputs (Level 3)
Assets:
Forward foreign currency contracts		0
Forward foreign currency contracts | Assets
Assets:
Forward foreign currency contracts	1.7	1.1
Forward foreign currency contracts | Assets | Quoted Prices in Active Market for Identical Assets (Level 1)
Assets:
Forward foreign currency contracts	0	0
Forward foreign currency contracts | Assets | Significant Other Observable Inputs (Level 2)
Assets:
Forward foreign currency contracts	1.7	1.1
Forward foreign currency contracts | Assets | Significant Unobservable Inputs (Level 3)
Assets:
Forward foreign currency contracts	0	0
Forward foreign currency contracts | Liability
Liabilities:
Liabilities measured at fair value on a recurring basis	0.6
Forward foreign currency contracts | Liability | Quoted Prices in Active Market for Identical Assets (Level 1)
Liabilities:
Liabilities measured at fair value on a recurring basis	0
Forward foreign currency contracts | Liability | Significant Other Observable Inputs (Level 2)
Liabilities:
Liabilities measured at fair value on a recurring basis	0.6
Forward foreign currency contracts | Liability | Significant Unobservable Inputs (Level 3)
Liabilities:
Liabilities measured at fair value on a recurring basis	0
contingent consideration
Liabilities:
Liabilities measured at fair value on a recurring basis	75.1
contingent consideration | Quoted Prices in Active Market for Identical Assets (Level 1)
Liabilities:
Liabilities measured at fair value on a recurring basis	0	0
contingent consideration | Significant Other Observable Inputs (Level 2)
Liabilities:
Liabilities measured at fair value on a recurring basis	0	0
contingent consideration | Significant Unobservable Inputs (Level 3)
Liabilities:
Liabilities measured at fair value on a recurring basis	$ 75.1	$ 81.8

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	3 Months Ended
	Sep. 25, 2021	Dec. 26, 2020	Dec. 28, 2019	Mar. 30, 2019	Sep. 26, 2020
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Investments, fair value	$ 1,700,000				$ 11,200,000
Borrowed principal under credit agreement	1,000,000,000
Impairment charge	1,800,000	$ 30,200,000	$ 30,200,000	$ 685,400,000
Medical Aesthetics Business | Acquired intangible assets [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Impairment charge				675,600,000
Medical Aesthetics Business | Equipment [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Impairment charge				$ 9,800,000
Credit Agreement
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Borrowed principal under credit agreement	1,390,000,000
Significant Unobservable Inputs (Level 3)
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Investments, fair value	0				$ 0
2028 Senior Notes
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Fair value of debt instrument	424,500,000
2029 Senior Notes
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Fair value of debt instrument	$ 964,700,000

Fair Value Measurements - Fai_2

Fair Value Measurements - Fair Value Assets and Liabilities Measured Using Unobservable Inputs (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Fair Value Disclosures [Abstract]
Beginning balance	$ 81.8	$ 9.1	$ 7.8
Contingent consideration recorded at acquisition	0	82.7	0
Fair value adjustments	(6.7)	0.3	1.7
Payments/Accruals	0	(10.3)	(0.4)
Ending balance	$ 75.1	$ 81.8	$ 9.1

Income Taxes - Income (Loss) Be

Income Taxes - Income (Loss) Before Income Taxes (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Income Tax Disclosure [Abstract]
Domestic	$ 2,267.8	$ 921.1	$ (174.3)
Foreign	93.3	80.8	(83.4)
Income (loss) before income taxes	$ 2,361.1	$ 1,001.9	$ (257.7)

Income Taxes - Provision for In

Income Taxes - Provision for Income Taxes (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Federal:
Current	$ 453.6	$ (62.1)	$ 142.9
Deferred	(45.6)	(76.6)	(189.9)
Federal, Total	408	(138.7)	(47)
State:
Current	84.7	33.9	22.1
Deferred	(11.9)	(12.5)	(41)
State, Total	72.8	21.4	(18.9)
Foreign:
Current	23.2	14	16.5
Deferred	(12.6)	(5.3)	(4.7)
Foreign, Total	10.6	8.7	11.8
Provision (benefit) for income taxes	$ 491.4	$ (108.6)	$ (54.1)

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Income Tax (Benefit) at U.S. Federal Statutory Rate to Company's Effective Tax Rate (Detail)	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Increase (decrease) in tax resulting from:
Income tax (benefit) provision at federal statutory rate	21.00%	21.00%	21.00%
Loss on sale of Cynosure	0.00%	(31.30%)	0.00%
State income taxes, net of federal benefit	2.70%	2.90%	(0.70%)
U.S. tax on foreign earnings	(2.70%)	(2.60%)	(2.10%)
Internal restructuring	0.00%	0.00%	(3.80%)
Tax credits	(0.30%)	(0.60%)	(3.30%)
Tax reform	0	0	0.020
Unrecognized tax benefits	0.30%	0.00%	(0.10%)
Compensation	0.10%	0.40%	0.80%
Foreign rate differential	(0.70%)	(1.20%)	(5.40%)
Change in deferred tax rate	(0.30%)	(0.60%)	0.00%
Change in valuation allowance	0.00%	1.30%	9.50%
Other	0.70%	(0.10%)	3.10%
Effective income tax rate	20.80%	(10.80%)	21.00%

Income Taxes - Significant Comp

Income Taxes - Significant Components of Company's Deferred Tax Assets and Liabilities (Detail) - USD ($)	Sep. 25, 2021	Sep. 26, 2020
Deferred tax assets
Net operating loss carryforwards	$ 91,500,000	$ 81,100,000
Capital losses	52,000,000	57,000,000
Non-deductible accruals	34,900,000	24,900,000
Non-deductible reserves	41,800,000	33,200,000
Stock-based compensation	17,600,000	18,600,000
Tax credits	10,000,000	10,200,000
Nonqualified deferred compensation plan	16,800,000	14,400,000
Lease liability	16,200,000	17,300,000
Other temporary differences	17,400,000	25,200,000
Deferred tax assets, gross	298,200,000	281,900,000
Less: valuation allowance	(121,300,000)	(118,500,000)
Deferred tax assets, net	176,900,000	163,400,000
Deferred tax liabilities
Depreciation and amortization	(389,700,000)	(333,900,000)
Right of use asset	(15,800,000)	(15,800,000)
Deferred tax liabilities, net	(405,500,000)	(349,700,000)
Net deferred tax liabilities	$ (228,600,000)	$ (186,300,000)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Sep. 25, 2021	Mar. 30, 2019	Sep. 25, 2021	Sep. 26, 2020
Income Taxes [Line Items]
Decrease in valuation allowance			$ (2,800,000)
Net operating losses	$ 33,000,000		33,000,000
Federal net operating loss expected to be expired unutilized	1,700,000		1,700,000
State net operating loss expected to be expired unutilized	48,000,000		48,000,000
Foreign net operating loss expected to be expired unutilized	900,000		900,000
Gross unrecognized tax benefits, excluding interest	212,800,000		212,800,000	$ 197,100,000
Unrecognized tax benefit that would impact effective tax rate	197,000,000		197,000,000	184,900,000
Change in gross unrecognized tax benefits				15,700,000
Interest accrued on unrecognized tax benefits	13,700,000		13,700,000	11,900,000
Increase to income tax expense adoption of ASU 2016-16			27,800,000
Decrease in deferred tax liabilities due to ASU 2016-16			37,700,000
Increase to Net Income resulted from adoption of ASU 2016-16			$ 9,900,000
Increase to Earnings per Share resulted from adoption of ASU 2016-16			$ 0.04
state loss carryforward expected to unutilize	26,200,000		$ 26,200,000
Capital losses	52,000,000		52,000,000	$ 57,000,000
Gross state loss carryforwards	26,200,000		26,200,000
Gross foreign loss carryforwards	33,000,000		33,000,000
Medical Aesthetics
Income Taxes [Line Items]
Other Tax Expense (Benefit)			313,400,000
General and Administrative Expense
Income Taxes [Line Items]
Non-income tax loss		$ (11,200,000)
Other Noncurrent Assets
Income Taxes [Line Items]
Income Tax Receivable Reclassification	310,000,000
Prepaid Expenses and Other Current Assets
Income Taxes [Line Items]
Income Tax Receivable Reclassification	(404,900,000)
Net Operating Losses Carryforwards
Income Taxes [Line Items]
Amount with unlimited carry forward periods			235,400,000
Tax Credit Carryforward
Income Taxes [Line Items]
Amount with unlimited carry forward periods			2,300,000
Maximum
Income Taxes [Line Items]
Decrease in unrecognized tax benefits is reasonably possible	13,000,000		13,000,000
Domestic Tax Authority
Income Taxes [Line Items]
Net operating losses	89,100,000		89,100,000
Credit carry forwards	4,300,000		4,300,000
State and Local Jurisdiction
Income Taxes [Line Items]
Net operating losses	135,000,000		135,000,000
Credit carry forwards	6,000,000		6,000,000
Foreign Tax Authority
Income Taxes [Line Items]
Net operating losses	263,200,000		263,200,000
Credit carry forwards	$ 500,000		$ 500,000

Income Taxes - Activity of Comp

Income Taxes - Activity of Company's Unrecognized Income Tax Benefits (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020
Income Tax Disclosure [Abstract]
Balance at beginning of fiscal year	$ 197.1	$ 101.6
Tax positions related to current year:
Additions	8	109.6
Reductions	0	0
Tax positions related to prior years:
Additions related to change in estimate	7.9	1.5
Reductions	(0.3)	(0.7)
Payments	0	0
Lapses in statutes of limitations	(1.7)	(15.6)
Acquired tax positions:
Additions related to reserves acquired from acquisitions	1.8	0.7
Balance as of the end of the fiscal year	$ 212.8	$ 197.1

Stockholders' Equity and Stoc_3

Stockholders' Equity and Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Millions	1 Months Ended		2 Months Ended	3 Months Ended				12 Months Ended
	Dec. 31, 2013	Mar. 31, 2012	Nov. 16, 2021	Sep. 25, 2021	Jun. 26, 2021	Mar. 27, 2021	Dec. 26, 2020	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019	Dec. 09, 2020	Dec. 11, 2019	Jun. 13, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized value of common shares to be repurchased													$ 500,000,000
Stock-based compensation, period of vest term granted to employees, years								3 years
Cliff vesting period from grant date								3 years
Tax benefit related to stock based compensation								$ 7,900,000	$ 9,500,000	$ 8,900,000
Intrinsic value of option exercised								$ 30,400,000	44,800,000	26,100,000
Granted								1.1
Minimum eligible percentage to receive target number of shares of company's common stock								0.00%
Maximum eligible percentage to receive target number of shares of company's common stock								200.00%
Stock-based compensation expense								$ 65,000,000	$ 83,300,000	62,000,000
Shares repurchased (in shares)									4.8
Common stock repurchases									$ 200,100,000
ASR Shares Repurchased during the period					$ 600,000
ASR Authorized				$ 205		$ 205,000,000
Amount paid during the period under ASR Agreement						$ 164,000,000
Percentage of award vested upon meeting defined market based criteria	33.33%
Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares repurchased (in shares)			2.3
Common stock repurchases			$ 167,000,000
June 13, 2019 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares repurchased (in shares)						3.9
Common stock repurchases						$ 210,900,000
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of forfeiture rates								0.00%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of forfeiture rates								6.00%
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense								$ 13,000,000	15,500,000	14,100,000
Unrecognized compensation expense				15,800,000				$ 15,800,000
Weighted average period of unrecognized stock-based compensation, years								2 years 3 months 18 days
Stock Options | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation, period of vest term granted to employees, years								4 years
Percentage of vesting for stock options granted to employees								25.00%
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation, period of vest term granted to employees, years								3 years
Stock-based compensation expense								$ 46,100,000	63,300,000	43,700,000
Unrecognized compensation expense				$ 50,300,000				$ 50,300,000
Weighted average period of unrecognized stock-based compensation, years								1 year 9 months 18 days
Fair value of RSUs vested								$ 73,100,000	$ 34,900,000	$ 34,600,000
RSUs | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vesting for RSUs granted to employees								33.00%
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted								0.1	0.1	0.1
Vested, weighted average grant date fair value (in usd per share)								$ 68.51	$ 45.38	$ 40.97
Market Based Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cliff vesting period from grant date								3 years
Granted								0.1	0.1	0.1
Vested, weighted average grant date fair value (in usd per share)								$ 82.31	$ 43.54	$ 55.13
Minimum eligible percentage to receive target number of shares of company's common stock								0.00%
Maximum eligible percentage to receive target number of shares of company's common stock								200.00%
PSU Free Cash Flow [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted								0.1	0.1
Minimum eligible percentage to receive target number of shares of company's common stock								0.00%
Maximum eligible percentage to receive target number of shares of company's common stock								200.00%
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted								0.5	0.6	0.9
2008 Equity Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized				31.5				31.5
Shares available for grant				4.6				4.6
2012 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares that may be issued under Employee Stock Purchase Plan		2.5
Percentage of common stock price for ESPP		85.00%
Stock-based compensation expense								$ 5,900,000	$ 4,500,000	$ 4,200,000
Dec 11, 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining authorized repurchase amount				$ 691,600,000				$ 691,600,000
Authorized value of common shares to be repurchased												$ 500,000,000
Shares repurchased (in shares)							1.5	5.1
Common stock repurchases							$ 101,300,000	$ 237,700,000
Dec 9, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized value of common shares to be repurchased											$ 1,000,000,000
Shares repurchased (in shares)								4.6
Common stock repurchases								$ 308,500,000

Stockholders' Equity and Stoc_4

Stockholders' Equity and Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statement of Operations (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 65	$ 83.3	$ 62
Cost of revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	8	6.7	7.1
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	7.7	8	9.2
Selling and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	9.5	10.2	10.2
General and Administrative Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	38.9	50.9	35.5
Restructuring Charges
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 0.9	$ 7.5	$ 0

Stockholders' Equity and Stoc_5

Stockholders' Equity and Stock-Based Compensation - Information Pertaining to Stock Options Granted and Related Assumptions (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Share-based Payment Arrangement [Abstract]
Options granted (in shares)	0.6	1	1
Weighted-average exercise price	$ 68.62	$ 45.96	$ 41.36
Weighted average grant date fair value (in usd per share)	$ 19.86	$ 13.92	$ 13.54
Assumptions:
Risk-free interest rates	0.40%	1.70%	3.00%
Expected life (in years)	4 years 9 months 18 days	4 years 9 months 18 days	4 years 9 months 18 days
Expected volatility	35.00%	33.60%	34.30%
Dividend yield	$ 0	$ 0	$ 0

Stockholders' Equity and Stoc_6

Stockholders' Equity and Stock-Based Compensation - Stock Option Activity (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	1.1
Number of Shares (in millions)
Options outstanding at September 26, 2020	4.6
Granted	0.6	1	1
Canceled/ forfeited	(0.2)
Exercised	(0.8)
Options outstanding at September 25, 2021	4.2	4.6
Options exercisable at September 25, 2021	2.3
Options vested and expected to vest at September 25, 2021 (1)	4.1
Weighted- Average Exercise Price
Options outstanding at September 26, 2020	$ 40.37
Granted	68.62	$ 45.96	$ 41.36
Canceled/ forfeited	49.67
Exercised	38.46
Options outstanding at September 29, 2018	44.66	$ 40.37
Options exercisable at September 25, 2021	39.29
Options vested and expected to vest at September 25, 2021 (1)	$ 44.60
Weighted- Average Remaining Contractual Life (in Years)
Options outstanding at September 26, 2020	6 years 7 months 6 days	7 years
Options exercisable at September 25, 2021	5 years 8 months 12 days
Options vested and expected to vest at September 25, 2021 (1)	6 years 7 months 6 days
Options outstanding at September 25, 2021	6 years 7 months 6 days	7 years
Aggregate Intrinsic Value (in millions)
Options outstanding at September 26, 2020	$ 109.5
Exercised	30.4	$ 44.8	$ 26.1
Options outstanding at September 25, 2021	132.7	$ 109.5
Options exercisable at September 25, 2021	85.4
Options vested and expected to vest at September 25, 2021 (1)	$ 132.2
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	0.1	0.1	0.1
Market Based Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	0.1	0.1	0.1

Stockholders' Equity and Stoc_7

Stockholders' Equity and Stock-Based Compensation - Restricted Stock Unit Activity (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Share-based Payment Arrangement [Abstract]
Tax benefit related to stock based compensation	$ 7.9	$ 9.5	$ 8.9
Number of Shares (in millions)
Non-vested at September 26, 2020	2.4
Granted	1.1
Vested	(1.7)
Forfeited	(0.1)
Non-vested at September 25, 2021	1.7	2.4
Weighted-Average Grant-Date Fair Value
Non-vested at September 26, 2020	$ 44.22
Granted	69.14
Vested	43.94
Forfeited	52.57
Non-vested at September 25, 2021	$ 54.21	$ 44.22

Stockholders' Equity and Stoc_8

Stockholders' Equity and Stock-Based Compensation - Assumptions to Value Stock Options (Detail) - USD ($)	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Assumptions:
Risk-free interest rates	0.40%	1.70%	3.00%
Expected life (in years)	4 years 9 months 18 days	4 years 9 months 18 days	4 years 9 months 18 days
Expected volatility	35.00%	33.60%	34.30%
Dividend yield	$ 0	$ 0	$ 0
ESPP
Assumptions:
Risk-free interest rates	0.26%	1.32%	2.27%
Expected life (in years)	6 months	6 months	6 months
Expected volatility	34.10%	26.90%	27.10%
Dividend yield	$ 0	$ 0	$ 0

401(k) Plan - Additional Inform

401(k) Plan - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Multiemployer Plan, Employer Contribution, Cost [Abstract]
Contributions made by company	$ 20.9	$ 19.6	$ 19.2

Deferred Compensation Plan - Ad

Deferred Compensation Plan - Additional Information (Detail) - USD ($)	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Deferred Compensation Liability, Current and Noncurrent	$ 76,100,000	$ 57,700,000
Nonqualified Deferred Compensation Plan [Member]
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Maximum employee contributions from base salary, percentage	75.00%
Maximum employee contributions from annual bonus, percentage	100.00%
Employee contributions vested, percentage	100.00%
Percent vested annually	33.33%
Compensation expense for the DCP discretionary contributions	$ 3,200,000	3,100,000	$ 2,700,000
Investment in group life insurance contracts	$ 64,300,000	$ 49,300,000
Nonqualified Deferred Compensation Plan [Member] | One Third Annually [Member]
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Contributions, vesting period, years	3 years

Commitments and Contingencies -

Commitments and Contingencies - Summary of Purchase Commitments (Details) $ in Millions	Sep. 25, 2021USD ($)
Commitments and Contingencies Disclosure [Abstract]
Fiscal 2022	$ 290.3
Fiscal 2023	16.4
Fiscal 2024	9.2
Fiscal 2025	4.1
Fiscal 2026	1.7
Thereafter	0.4
Total	$ 322.1

Litigation and Other Matters -

Litigation and Other Matters - Additional Information (Detail) - USD ($)	Jul. 27, 2018	Sep. 25, 2021
Company Vs. Minerva Surgical, Inc. | Judicial Ruling
Loss Contingencies [Line Items]
Awarded damages	$ 4,800,000
Medical Aesthetics Business
Loss Contingencies [Line Items]
Legal Accrual		$ 8,500,000

Disposition - Additional Inform

Disposition - Additional Information (Details) - USD ($)	Nov. 20, 2019	Sep. 25, 2021	Dec. 26, 2020	Dec. 28, 2019	Mar. 30, 2019	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture of businesses						$ 0	$ 139,300,000	$ 0
Impairment charge		$ 1,800,000	$ 30,200,000	$ 30,200,000	$ 685,400,000
Cost of revenues
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment charge			25,800,000
Operating Expense
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment charge			$ 4,400,000
Medical Aesthetics Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Expenses from disposition		6,200,000
Medical Aesthetics Business | Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sales price	$ 205,000,000
Proceeds from divestiture of businesses	$ 153,400,000
Final sales price		150,000,000				150,000,000
Indemnification liabily		$ 10,900,000				$ 10,900,000
Medical Aesthetics Business | Disposed of by Sale | Minimum
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Transition services agreement term		3 months
Medical Aesthetics Business | Disposed of by Sale | Maximum
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Transition services agreement term		15 months

Disposition - Schedule of Dispo

Disposition - Schedule of Disposition Related Income Statement Information (Details) - USD ($)	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Loss from operations	$ (46,500)	$ (781,200)

Business Segments and Geograp_3

Business Segments and Geographic Information - Additional Information (Detail)	12 Months Ended
	Sep. 25, 2021USD ($)Segment	Sep. 26, 2020USD ($)	Sep. 28, 2019USD ($)
Segment Reporting Disclosure [Line Items]
Revenues	$ 5,632,300,000	$ 3,776,400,000	$ 3,367,300,000
Intersegment
Segment Reporting Disclosure [Line Items]
Number of reportable segments | Segment	4
Revenues	$ 0	$ 0	$ 0

Business Segments and Geograp_4

Business Segments and Geographic Information - Segment Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Segment Reporting Information [Line Items]
Revenues	$ 5,632.3	$ 3,776.4	$ 3,367.3
Operating income	2,480.3	1,105	(123.8)
Depreciation and amortization	406.9	376	463.1
Capital expenditures	156.2	156.4	109.1
Identifiable assets	8,919.9	7,195.8	6,442.1
Corporate
Segment Reporting Information [Line Items]
Capital expenditures	1	3.8	7.7
Identifiable assets	2,935.6	2,355.9	1,522.5
Diagnostics
Segment Reporting Information [Line Items]
Revenues	3,695	2,102.1	1,205.5
Operating income	2,140.1	929.7	163.1
Depreciation and amortization	260.4	237.3	246.6
Capital expenditures	126.2	110.7	59.2
Identifiable assets	3,348.8	2,161.4	2,276.6
Breast Health
Segment Reporting Information [Line Items]
Revenues	1,352.3	1,151.9	1,314.2
Operating income	284.2	192.8	399.3
Depreciation and amortization	52.7	48.8	36.8
Capital expenditures	14.2	22.4	18.3
Identifiable assets	1,233.9	1,200.9	1,127.8
Gyn Surgical [Member]
Segment Reporting Information [Line Items]
Revenues	488.1	376.1	437.2
Operating income	58.9	42	99.2
Depreciation and amortization	93.1	85.1	87.7
Capital expenditures	14.5	17.9	15.7
Identifiable assets	1,369.7	1,438.7	1,328.6
Skeletal Health
Segment Reporting Information [Line Items]
Revenues	96.9	81	94.8
Operating income	(2.9)	(2.4)	(4.2)
Depreciation and amortization	0.7	0.7	0.6
Capital expenditures	0.3	0.2	1.2
Identifiable assets	31.9	38.9	27.3
Medical Aesthetics
Segment Reporting Information [Line Items]
Revenues	0	65.3	315.6
Operating income	0	(57.1)	(781.2)
Depreciation and amortization	0	4.1	91.4
Capital expenditures	0	1.4	7
Identifiable assets	$ 0	$ 0	$ 159.3

Business Segments and Geograp_5

Business Segments and Geographic Information - Revenues by Geography (Detail)	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Schedule Of Geographical Segments [Line Items]
Revenues	100.00%	100.00%	100.00%
United States
Schedule Of Geographical Segments [Line Items]
Revenues	69.30%	75.80%	75.30%
Europe
Schedule Of Geographical Segments [Line Items]
Revenues	21.30%	15.10%	11.80%
Asia-Pacific
Schedule Of Geographical Segments [Line Items]
Revenues	6.50%	6.00%	8.50%
Rest of world
Schedule Of Geographical Segments [Line Items]
Revenues	2.90%	3.10%	4.40%

Business Segments and Geograp_6

Business Segments and Geographic Information - Schedule of Geographically Located Property and Equipment, Net (Details) - USD ($) $ in Millions	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Geographic Information For Property Plant And Equipment [Line Items]
Property, plant and equipment, net	$ 564.7	$ 491.5	$ 470.9
United States
Geographic Information For Property Plant And Equipment [Line Items]
Property, plant and equipment, net	403.2	383	355.5
Europe
Geographic Information For Property Plant And Equipment [Line Items]
Property, plant and equipment, net	122.9	77.5	64.4
Costa Rica
Geographic Information For Property Plant And Equipment [Line Items]
Property, plant and equipment, net	26.9	20.8	33
Rest of world
Geographic Information For Property Plant And Equipment [Line Items]
Property, plant and equipment, net	$ 11.7	$ 10.2	$ 18

Accrued Expenses and Other Lo_3

Accrued Expenses and Other Long-Term Liabilities - Schedule of Accrued Expenses (Detail) - USD ($)	Sep. 25, 2021	Sep. 26, 2020
Accrued Expenses
Compensation and employee benefits	$ 297,200,000	$ 262,700,000
Income and other taxes	70,900,000	125,300,000
Contingent consideration	16,300,000	0
Operating lease liabilities (current)	26,800,000	23,500,000
Accrued interest	16,900,000	22,100,000
Other	168,100,000	114,000,000
Total	$ 596,200,000	$ 547,600,000

Accrued Expenses and Other Lo_4

Accrued Expenses and Other Long-Term Liabilities - Schedule of Other Long-Term Liabilities (Detail) - USD ($) $ in Millions	Sep. 25, 2021	Sep. 26, 2020
Other Long-Term Liabilities
Reserve for income tax uncertainties	$ 210	$ 103.7
Contingent consideration	58.8	81.8
Operating lease liabilities (non-current)	66.1	65.6
Interest rate swap	7.6	23
Pension liabilities	10	11.1
Other	16.2	18
Other long-term liabilities	$ 368.7	$ 303.2

Pension and Other Employee Be_3

Pension and Other Employee Benefits - Additional Information (Detail) - USD ($) $ in Millions	Sep. 25, 2021	Sep. 26, 2020
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined benefit pension plan, liabilities	$ (10.3)	$ (10.9)
Accumulated benefit obligation	(10.3)	(10.9)
Projected benefit obligation for long-term service awards	0.1	0.1
Pension Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Projected benefit obligation in excess of plan assets	$ (10.3)	$ (10.9)

Pension and Other Employee Be_4

Pension and Other Employee Benefits - Schedule of Reconciliation of Benefit Obligations, Plan Assets Funded Status (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Other Liabilities Disclosure [Abstract]
Benefit obligation at beginning of year	$ (10.9)	$ (10)	$ (9.7)
Service cost	0	0	0
Interest cost	(0.1)	(0.1)	(0.2)
Plan participants’ contributions	0	0	0
Actuarial gain (loss)	0.5	(0.5)	(1)
Foreign exchange gain	(0.1)	(0.7)	0.6
Benefits paid	0.3	0.4	0.3
Benefit obligation at end of year	(10.3)	(10.9)	(10)
Plan assets	0	0	0
Benefit obligation at end of year	$ (10.3)	$ (10.9)	$ (10)

Pension and Other Employee Be_5

Pension and Other Employee Benefits - Components of Net Periodic Benefit Cost and Related Actuarial Assumptions (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Other Liabilities Disclosure [Abstract]
Service cost	$ 0	$ 0	$ 0
Interest cost	0.1	0.1	0.2
Expected return on plan assets	0	0	0
Amortization of prior service cost	0	0	0
Recognized net actuarial gain	0.3	0.2	0.1
Net periodic benefit cost	$ 0.4	$ 0.3	$ 0.3

Pension and Other Employee Be_6

Pension and Other Employee Benefits - Schedule of Weighted-Average Net Periodic Benefit Cost Assumptions (Detail)	12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 28, 2019
Defined Benefit Plan, Assumptions Used in Calculations [Abstract]
Discount rate	1.00%	0.80%	1.10%
Expected return on plan assets	0.00%	0.00%	0.00%
Rate of compensation increase	0.00%	0.00%	0.00%

Pension and Other Employee Be_7

Pension and Other Employee Benefits - Schedule of Expected Pension Benefit (Detail) $ in Millions	Sep. 25, 2021USD ($)
Defined Benefit Plan, Expected Future Benefit Payment [Abstract]
2017	$ 0.4
2018	0.4
2019	0.4
2020	0.4
2021	0.4
2027 to 2031	$ 2.2